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SUMMARY 
Microtubules are a key cytoskeletal element within the axon, which provide structure, shape 
and polarity to the neuron. They are important in numerous cellular processes, as they provide 
the platform for intracellular transport; moving organelles and secretory vesicles to synaptic 
terminals and are a major constituent for cell division. Disruption to microtubules has been 
implicated in a number of neurodegenerative diseases including Alzheimer’s disease (AD), 
Parkinson’s disease and amyotrophic lateral sclerosis, which involve progressive loss of 
structure and function of neurons, leading to neuronal death in different regions of the nervous 
system. Although each of these diseases display different symptoms, some features may be 
shared across neurodegenerative diseases, such as axon degeneration, an active cellular 
process which can be initiated in pathological conditions resulting in synaptic impairment. 
Microtubule alterations have been implicated in mechanisms of axon degeneration. However, 
the alterations to microtubules in pathological conditions and the potential of modulating 
microtubules as a therapeutic target is currently unrealised. This thesis has examined the 
effect of microtubule stabilisation in a mouse model of AD and has investigated the changes 
to microtubules and microtubule-associated proteins within the axon following an excitotoxic 
insult, a pathological mechanism involved in several neurodegenerative diseases and injury. 
To examine microtubule alterations following excitotoxic insult, a compartmented primary 
mouse neuronal cell culture model was utilised and live imaging was used to monitor axon 
degeneration. Examination of alterations to microtubule associated proteins (MAPs) 
demonstrate that levels of tau and CRMP2 were significantly (p<0.05) increased after 
excitotoxic insult, but MAP1B levels were unchanged. Modifying the phosphorylation state 
of MAPs, using the PP2A inhibitor sodium selenate, which regulates their binding to 
microtubules, did not significantly affect the degeneration of axons. Examination of 
microtubule post-translational modifications demonstrated significantly (p<0.05) decreased 
 vii 
acetylated tubulin levels, specifically in axons, whereas tyrosinated tubulin levels were 
unchanged. Trichostatin A, an HDAC6 inhibitor, was used in vitro to determine whether 
preventing loss of acetylated tubulin protects against axon degeneration. Primary cortical 
neurons treated with trichostatin A had significantly (p<0.05) increased acetylated tubulin 
levels within axons. Furthermore, live imaging results confirmed that neurons treated with 
trichostatin A had significantly (p<0.05) decreased axon degeneration following an 
excitotoxic insult. Previous studies have demonstrated a positive effect of microtubule 
stabilisation in mouse models of tau pathology. However, AD involves deposition of amyloid 
plaques in addition to tau pathology and the effect of microtubule stabilisation on amyloid 
and axon pathology in AD models is unknown. Therefore, an AD mouse model of amyloid 
deposition, the APP/PS1 mouse model was treated with the microtubule stabilising agent, 
epothilone D to determine the effect on plaque deposition, dystrophic neurite pathology and 
synapse alterations. Behavioural testing demonstrated significant changes in tests associated 
with anxious activity in APP/PS1 mice following epothilone D treatment. Biochemical 
analysis demonstrated that epothilone D had effects on the cytoskeleton with a significant 
(p<0.05) decrease in levels of phosphorylated neurofilaments in both the neocortex and 
hippocampus. However, epothilone D did not alter amyloid deposition or neurite dystrophy 
within the mouse neocortex. Together these results suggest that microtubule instability may 
be a key factor in axon degeneration pathways, and pharmacological manipulation of 
microtubules is a promising therapeutic target to prevent axon degeneration.      
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1 LITERATURE REVIEW 
 
1.1  MICROTUBULES AS A THERAPEUTIC TARGET IN ALZHEIMER’S DISEASE 
AND NEURODEGENERATION 
1.1.1 Introduction 
Microtubules are part of the cytoskeleton and are vital to maintaining cellular function as they 
determine cell polarity, and are involved in gene expression and regulation, cell division and 
axon transport. They play an essential role in the development of the nervous system, where 
the dynamics of tubulin are fine-controlled by associated proteins. Alterations to microtubules 
have been documented in several neurodegenerative diseases and injury. In particular, their 
role in axon degeneration has been well-reported (Dubey et al., 2015; Tang-Schomer et al., 
2010), although the mechanisms of microtubule alterations are less clear. Recent evidence 
has suggested that microtubules may be an important therapeutic target in Alzheimer’s 
disease (AD) and other neurodegenerative conditions, particularly those involving axon 
degeneration (Eira et al., 2016; Pachima et al., 2016; Zhang et al., 2018). This thesis examines 
the potential of microtubules as a therapeutic target in AD and axon degeneration.  
 
 
1.2 TARGETING MICROTUBULES IN ALZHEIMER’S DISEASE 
1.2.1 Alzheimer’s disease 
Alzheimer’s disease is a progressive neurodegenerative disease with an increasing prevalence 
across the global population (Qiu et al., 2009). Alzheimer’s disease was first described in 
1907 and in the 100 years hence, little progress has been made in understanding the driving 
mechanisms of the disease. Familial AD accounts for <10% of AD cases, however, there is a 
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large genetic component to sporadic AD with the apolipoprotein E (APOE)-e4 allele being 
the strongest known genetic risk factor, and drives the early development of the disease (Liu 
et al., 2013). Other risk factors for developing sporadic AD frequently seen in people over 65 
years of age, are age-related alterations to the brain, such as atrophy (Habes et al., 2016), 
inflammation and reactive oxygen species (Kaur et al., 2015; Manoharan et al., 2016; Wyss-
Coray and Rogers, 2012). Brain injuries have also been proposed to increase AD risk (Lye 
and Shores, 2000).  
 
Alzheimer’s disease pathology, particularly neurofibrillary pathology, follows a specific 
pattern of development in brain regions, initiating in the transentorhinal region and 
distributing toward the hippocampus and the occipito-temporal region (Braak et al., 2006). It 
is unclear why particular regions are more vulnerable to pathology early in disease, whilst 
other regions are unaffected until very late in disease progression, although it is suggested 
that areas of high plasticity are more at risk (Arendt et al., 1998). On an anatomical level, AD 
is characterised by shrinkage of hippocampal and cerebral regions, especially posterior 
cortical areas (Serrano-Pozo et al., 2011). On a cellular level, AD is characterised by two 
major pathological hallmarks: amyloid plaque pathology and tau neurofibrillary tangles 
(Alzheimer, 1907).  
 
1.2.2 Pathology and treatment of Alzheimer’s disease 
The pathological hallmarks of AD mainly involve abnormal protein aggregation which 
disrupts normal function of the brain. Whilst the two main pathological hallmarks are amyloid 
beta (Ab) plaques and tau neurofibrillary tangles, other features also present, include 
dystrophic neurites, synapse loss, and gliosis (Serrano-Pozo et al., 2011; Spires-Jones and 
Hyman, 2014). There is considerable debate about what triggers the progression of these types 
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of pathology and how they are linked. Current hypotheses propose amyloid deposition and 
tau alterations as the drivers of neurodegeneration in AD and most therapeutic agents are 
based on targeting amyloid and tau pathology, although more work is needed to identify the 
events occurring in early stages of disease. Since the initiating events usually occur before 
clinical onset of symptoms, these early changes are difficult to define and may require use of 
biomarkers.  
 
Although numerous clinical trials targeting several different cellular mechanisms have been 
conducted, there are currently no disease modifying therapeutics for AD and the only US 
Food and Drug Administration (FDA)-approved drugs for AD provide symptom relief and 
include memantine and the cholinesterase inhibitors; tacrine, donepezil, rivastigmine, and 
galantamine (Anand et al., 2014; Folch et al., 2016). They act by modifying neurotransmitter 
levels, by decreasing acetylcholine breakdown, and therefore enhancing cholinergic 
neurotransmission.  
 
Amyloid pathology 
The amyloid cascade hypothesis, one of the most postulated theories of AD pathogenesis, 
proposes that amyloid deposition is the main driver of disease onset and progression (Hardy 
and Higgins, 1992). This hypothesis advocates that pathological changes associated with AD 
occur downstream of extracellular Ab accumulation. The hypothesis is supported by research 
which has focused on therapeutic strategies, which target amyloid pathology (Barage and 
Sonawane, 2015; Fernandez et al., 2014; Kim et al., 2007; Selkoe and Hardy, 2016) and 
familial genetics cases. The amyloid cascade hypothesis is also supported by the APOE risk 
genes, which is thought to play a role in clearance of Ab (Robert et al., 2017; Verghese et al., 
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2013). The presence of amyloid plaques is used to confirm diagnosis on post-mortem 
examination, making amyloid deposition a defining feature of AD.  
 
Amyloid plaque deposition is thought to result from altered cleavage of the transmembrane 
amyloid precursor protein (APP) by beta (BACE1) and gamma secretases. The normal role 
of APP is not completely known but it is thought to regulate synapse formation and play a 
role in neuroprotection and neuroplasticity (Plummer et al., 2016; Priller et al., 2006). Beta 
amyloid is the 40-42 kDa peptide cleavage product of APP, which is deposited into the 
extracellular space and aggregates to form Aβ plaques (Glenner and Wong, 1984). Mice 
deficient in BACE1 have a normal phenotype and abolished Aβ generation (Luo et al., 2001; 
Yan et al., 2014). Beta amyloid, in either of its soluble or insoluble forms is likely involved 
in toxicity or physical stress to neurons (Liu et al., 2004b; Zhang et al., 2012b). The cellular 
site of the cleavage of APP is unclear, although it is thought to occur at several sites within 
the cell. Secretase cleavage of APP occurs mostly within the Golgi complex or the plasma 
membrane, but the BACE1 cleavage may be localised mainly to endosomes (Koo and 
Squazzo, 1994; Lammich et al., 1999). It has been hypothesised that the time spent in specific 
cellular locations can affect APP processing into Aβ peptides, suggesting that alterations in 
cellular transport processes, including microtubule-dependent transport, can affect Aβ 
production (Gotz et al., 2006). Another potential cause of amyloid plaque deposition is 
reduced clearance of Aβ. The clearance of Aβ can be through non-enzymatic or enzymatic 
mechanisms (Yoon and Jo, 2012). Non-enzymatic pathways include microglial phagocytosis 
whereas enzymatic pathways, such as neprilysin, are directly involved in the clearance 
process (Yoon and Jo, 2012). 
 
Beta amyloid is also removed into the cerebrospinal fluid (CSF) through the glymphatic 
system, and normal levels of Aβ in CSF are 8.3% (Bateman et al., 2006). Although familial 
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AD is likely associated with altered Aβ production, it is hypothesised that sporadic AD results 
from reduced clearance rates (Lee and Landreth, 2010; Weller et al., 2000).  
  
Therapeutics targeting amyloid pathology 
Due to the amyloid cascade hypothesis, amyloid pathology is the most investigated 
therapeutic target for AD (Beyreuther and Masters, 1991; Hardy and Higgins, 1992; Selkoe, 
1991) with strategies targeting both the decreased production and increased clearance of Aβ 
from the brain. There have been a number of high profile immunotherapy trials in recent years 
using antibodies to enhance the clearance of Aβ including Aducanumab (Sevigny et al., 
2016), Solanezumab (Doody et al., 2014; Siemers et al., 2016) and Bapineuzumab (Ketter et 
al., 2017; Salloway et al., 2014; Vandenberghe et al., 2016). Each of these drugs target 
different forms or epitomes of Aβ. Although some efficacy for amyloid removal has been 
shown, to date, there is no convincing data demonstrating an effect on cognitive decline (Fiala 
et al., 2018; Mo et al., 2017). 
 
Beta-secretase inhibitors are another therapeutic strategy that have been proposed to block 
the abnormal cleavage pathway of APP, therefore decreasing Ab production and reducing 
disease progression (Menting and Claassen, 2014).  In mouse model studies of AD, BACE1 
inhibitors reduce Ab  pathology and rescue cognitive decline (Ghosh and Osswald, 2014), 
however in clinical trials for both AD patients and pre-symptomatic AD patients, concerns 
about the toxicity of b-secretase inhibitors due to links with cardio toxicity and inhibition of 
cytochrome enzymes have been raised (Vassar, 2014).  
 
It has also been proposed that therapeutic intervention could be provided to protect against 
the potential downstream effects of amyloid pathology (discussed below) including neuron, 
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synapse and axon loss. Microtubule manipulation is a possible target for this type of 
intervention. For example, microtubule stabilisation could protect against transport 
impairment and axon pathology (Varidaki et al., 2018). Similarly, microtubule stabilisation 
could be used to protect vulnerable synapses (Zajkowski et al., 2015). More specifically, tau-
dependent microtubule severing by TTLL6 and spastin induces synaptic damage by Ab 
oligomers (Zempel et al., 2013), suggesting that amyloid toxicity is able to cause alterations 
to microtubules, which can lead to synaptic damage. Dysregulation of microtubule stability 
also impairs connectivity in primary neuronal networks (Verstraelen et al., 2017). 
 
The lack of success in targeting Aβ in AD has led to the pursuit of other therapeutic targets 
such as tau pathology. The role of tau pathology in the amyloid cascade hypothesis is 
currently unclear.  
 
Tau pathology 
Tau, another key hallmark of AD, is a MAP, which promotes assembly and stability of 
microtubules (Kadavath et al., 2015; Prezel et al., 2018). In disease states, tau becomes 
hyperphosphorylated and can form intracellular accumulations known as neurofibrillary 
tangles. Several diseases/disorders result from different types of tauopathies, including Down 
syndrome, Pick’s disease, and frontotemporal dementia (Iqbal et al., 2010). Tau is encoded 
by the Mapt gene and can undergo alternative splicing to form numerous isoforms, which can 
either have a 3 or 4 microtubule binding domain (3-repeat and 4-repeat tau) in their C-
terminus. The 3-repeat and 4-repeat isoforms alter the capacity of tau to bind to microtubules. 
In disease, tau’s affinity for microtubules may be reduced by altered expression of the 3-
repeat isoform, or abnormal phosphorylation by cyclin-dependent kinase 5 (cdk5) and 
glycogen synthase kinase-3-beta (GSK-3β; Engmann and Giese, 2009; Sengupta et al., 2006). 
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Dissociated tau forms intracellular aggregates, potentially leading to microtubule 
depolymerisation or altered microtubule dynamics. Altered tau may lead to impaired 
intracellular transport and loss of synaptic function. Tau pathology is more closely associated 
with clinical cognitive decline in AD than amyloid pathology, justifying further analysis as a 
target for therapeutic intervention (Bi et al., 2011; Pedersen and Sigurdsson, 2015; 
Sigurdsson, 2016).   
 
Therapeutics targeting tau pathology  
Similar to amyloid-based therapeutics, some tau-based treatment strategies also focus on 
immunotherapy to promote clearance of aggregated tau from the brain. Currently, Phase I 
clinical trials are being performed, testing both active and passive forms of tau antibodies 
(Medina, 2018; West et al., 2017).  
 
Tau antibodies have been developed to interact with both extracellular and intracellular tau. 
Extracellular tau is more likely to be successfully cleared, but to prevent the secretion and 
further spread of tau, intracellular tau may be the most important target (Sigurdsson, 2016), 
thus the epitope target and charge of the antibody is of importance to gain entry into target 
cells. In animal tauopathy models, a passive immunisation approach targeting different 
epitopes of tau, showed success in reducing tau pathology (Ittner et al., 2015). Furthermore, 
some progress has been made in overcoming limitations of immunotherapy, such as 
hindrances of delivering larger-sized antibodies to the brain, using scanning ultrasound, 
which enhances the delivery of antibodies across the blood brain barrier (Nisbet et al., 2017). 
However, it is important to consider the potential toxicity of immunisation, as cytotoxic T-
cell responses have been enhanced through immunotherapy (Rosenmann et al., 2006).  
 
Chapter 1 – Introduction  
  9  
 
Other tau-based therapies include inhibition of tau phosphorylation (Castro and Martinez, 
2000), blocking tau aggregation (Wischik et al., 2014), and enhancing tau degradation (Lee 
et al., 2015). Alternatively, it has been proposed that the downstream effects of tau loss could 
be targeted through stabilising the microtubules themselves (Ballatore et al., 2010; Brunden 
et al., 2014).   
 
Other pathological alterations in AD  
In addition to the key pathological features of AD, there are a number of other pathological 
changes which are thought to be downstream effects of amyloid and tau pathology. A 
particular prominent pathology in AD is the presence of dystrophic neurites, which are 
swollen and distorted axons or dendrites present predominantly around fibrillar Aβ plaques 
(Dickson et al., 1999). In disease, it has been shown using an APP/PS1 mouse model, that 
neurons which contain neurofilament-triplet proteins are more vulnerable to dystrophic 
neurite pathology than other neuronal types (Mitew et al., 2013b). Neurochemically, 
dystrophic neurites have been suggested to predominantly contain either neurofilament, tau, 
or chromogranin A (Dickson et al., 1999). Similar pathology is also observed in other 
neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis 
(Vickers et al., 2009).  
 
Dystrophic neurites have been identified surrounding plaques, which are sites of microtubule 
disruption and increased BACE1 cleavage of APP and Aβ generation (Kandalepas et al., 
2013). Live cell imaging of primary neurons exposed to Aβ42 oligomers showed extensive 
microtubule disruption and inhibited anterograde and retrograde trafficking (Sadleir et al., 
2016), suggesting this could be a mechanism of dystrophic neurite formation and highlights 
the potential role for impaired axonal transport in exacerbation of amyloid pathology. Of note, 
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formation of dystrophic neurites is highly plastic, as a study using live two-photo imaging of 
two amyloidosis mouse models demonstrated a high turnover of dystrophic neurites around 
plaques (Blazquez-Llorca et al., 2017). 
 
Synapse loss is another pathological feature observed in both AD animal models and human 
AD cases. Synapse loss is thought to correlate more strongly with the loss of cognitive 
function than tau or amyloid pathology, and therefore is an important target for therapeutic 
intervention (Terry et al., 1991). Glutamatergic synapses are particularly vulnerable to loss 
with a relative sparing of GABAergic synapses in the disease (Mitew et al., 2013a). It is 
currently unclear whether the loss of synapses is associated with the presence of dystrophic 
neurites, which could cause a dying back of the distal axon terminals, or whether it is 
unrelated to axonal degeneration. The loss of neurites and synapses may be responsible for 
the loss of brain volume in disease (Baron et al., 2014; Crews and Masliah, 2010; Dickson et 
al., 1999; Heneka et al., 2010; Praprotnik et al., 1996; Terry et al., 1991; Wu et al., 2010).  
 
1.2.3 Pathological mechanisms in Alzheimer’s disease 
Alterations in neurotransmission 
Altered neurotransmission, particularly alterations to cholinergic and glutamatergic 
signalling, is thought to be a key driver of cognitive decline in AD. Acetylcholine is a 
neurotransmitter involved in memory and learning and is decreased in AD patients, along 
with a loss of cholinergic neurons (Francis, 2005). Excitatory glutamatergic synapses and 
inhibitory GABAergic synapses have also been studied in AD. Neuronal damage is thought 
to arise from overactivation of N-methyl-d-aspartate (NMDA) receptors by glutamate 
(Francis, 2005). Furthermore, expression of functional glutamate transporters and α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate-type glutamate receptors 
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were increased in AD mice (Peters et al., 2009). Kainate receptors mediate post-synaptic 
depolarisation and modulate the release of GABA and glutamate. Kainate receptors have 
many interactors, which interact with different specific sub-units of the receptor. For example, 
PSD95 interacts with GluK2 and GluK5 which alters receptor function by reducing 
desensitisation (Garcia et al., 1998). However, glutamatergic neurotransmission via kainate 
receptors have been implicate in several neurodegenerative diseases and brain disorders, such 
as epilepsy (Li et al., 2010; Falcón-Moya et al., 2018) and schizophrenia (Benes et al., 2001). 
Most of the excitatory transmission in the brain occurs via AMPA receptors, however in 
disease, AMPA receptor function is altered (Chang et al 2012). For example, altered AMPA 
receptors allow excessive calcium into neurons, causing cytotoxicity and neuron death in 
amyotrophic lateral sclerosis (Chang et al., 2012). However, decreased AMPA activation and 
synapse loss can lead to altered excitatory transmission and seizure activity, common in AD 
(Vossel et al., 2017). Recent research has shown that disrupted default neuronal networks 
may cause impaired memory (Li et al., 2014). GABAergic alterations may also be enhanced 
to negate excitotoxicity, and therefore disrupt overall neuronal network function (Li et al., 
2014). The post-synaptic membrane is dense with NMDA receptors, and in AD, excessive 
presynaptic glutamate release and decreased re-uptake may contribute to slow excitotoxicity, 
contrasting to that of rapid excitotoxicity associated with stroke or epilepsy.  
 
Therapeutics targeting neurotransmission alterations  
There are several therapeutic options available to modulate alterations in neurotransmission 
in AD. Acetylcholine inhibitors are currently the main effective treatment that are safe to use 
to reduce some of the cognitive symptoms exhibited in AD (Anand et al., 2014; Folch et al., 
2016). Although they do not alter the course of AD, the cholinesterase inhibitors tacrine, 
donepezil, rivastigmine, and galantamine, along with the NMDA receptor agonist, are the 
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only drugs approved by the FDA to treat AD symptoms (Anand et al., 2014; Folch et al., 
2016).  Several other strategies currently being investigated including other NMDA receptor 
antagonists (Olivares et al., 2012) and GABAergic modulation (Nava-Mesa et al., 2014). 
Other therapeutics for AD are reviewed (Chiang and Koo, 2014).  
 
 Inflammation 
Reactive glial cells are present in the brains of AD patients, leading to the proposal that the 
inflammatory response may relate to the development, progression or protection against AD 
pathology. Microglia, one of the main glial cells involved in AD inflammation (Dickson, 
1999; Heneka et al., 2010), can recruit astrocytes, which increases the neuroinflammatory 
response to Aβ (Heneka et al., 2010). 
 
Microglial cells are part of the innate immune system within the central nervous system 
(CNS) and act as the first line of defence against amyloid pathology (Ransohoff and Brown, 
2012; Solito and Sastre, 2012). In the early stage of AD progression, microglia are thought to 
play a protective role in promoting clearance of Aβ, however, in later stages of AD, microglia 
are no longer protective as they produce pro-inflammatory cytokines (Hickman et al., 2008). 
Microglia have been shown to react to Aβ plaques through the expression of cytokines and 
neurotoxins, which cause them to migrate around the Aβ plaques (Baron et al., 2014; El 
Khoury et al., 1996; Meda et al., 1995). Microglia also interact with the forms of Aβ in 
different ways, as soluble forms of Aβ are taken up by macropinocytosis, whereas fibrillar 
forms of Aβ interact with the cell surface innate immune receptor complex, stimulating 
phagocytosis (Lee and Landreth, 2010). As the inflammatory response influences the 
activation of microglia, it subsequently regulates the ability of microglia to degrade Aβ.  
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Microglia migration toward plaques has been shown occurs in both human AD and animal 
AD models (Baron et al., 2014; Dickson, 1999; Hickman et al., 2008; Perlmutter et al., 1990; 
Yoshiyama et al., 2007). In APP/PS1 mouse models, microglia have been demonstrated to 
move quickly to surround Aβ plaques and thereafter recruit more microglia if the plaque 
volume becomes greater (Bolmont et al., 2008). These processes are likely to be microtubule-
dependent and therefore could be affected by microtubule-stabilising drugs. However, the 
role of glial cells in AD has been debated and whether inflammation in AD is neuroprotective 
by creating a barrier between plaques and neurons, or harmful by contributing to neural 
damage, is currently unclear (Heneka et al., 2010). If neuroinflammation does contribute to 
the progression of AD pathology, it may become a potential therapeutic target, by the use of 
anti-inflammatory drugs (Heneka et al., 2010). Furthermore, in some animal model studies, 
microglial activation has been shown to precede amyloid plaques and tau neurofibrillary 
tangles formation (Griffin et al., 1989; Heneka et al., 2005), whilst clinical PET studies have 
shown inflammation changes in a third of mild cognitive impairment (MCI) cases (Cagnin et 
al., 2001; Okello et al., 2009), leading to a suggestion that inflammation may be an upstream 
driver of disease. 
  
 Effect of microtubule therapeutics on AD pathology 
It is currently unclear how altering microtubules could affect AD pathology. Changing 
microtubule dynamics could potentially affect amyloid plaque deposition, due to axonal 
transport impairment. If amyloid plaque deposition is altered via targeting microtubules, the 
downstream effects from amyloid pathology also have the potential to be altered. Microtubule 
stabilisation could also protect against neurite dystrophy formation and loss of synapses due 
to increased stability of the axon via stabilised microtubules.   
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1.3 TARGETING MICROTUBULES IN AXON DEGENERATION  
1.3.1 Mechanisms of axon degeneration  
Axon loss is present in several neurodegenerative diseases, including amyotrophic lateral 
sclerosis, Huntington’s disease and Parkinson’s disease (Lingor et al., 2012; Liu et al., 2012; 
Salvadores et al., 2017). Axonal and synaptic loss cause major circuitry dysfunction, which 
leads to significant clinical changes in people with neurodegenerative disease. Axonal and 
synaptic loss is promoted by axon degeneration, which occurs through specific pathways that 
are independent of cell death (Cusack et al., 2013; Geden and Deshmukh, 2016; Neukomm 
and Freeman, 2014; Wang et al., 2012). 
 
1.3.2 Normal function of axon degeneration  
Axon degeneration mechanisms, as well as being a consequence of neurodegeneration, can 
have normal biological functions within the nervous system that are associated with plasticity. 
For example, during development of the nervous system, neurons extend axons to more 
targets than are required for normal adulthood function. These excess projections are removed 
via programmed neurite removal, resulting in the programmed loss of synapses and processes 
(Yuan et al., 2003) to establish functional organisation of the circuitry (Low and Cheng, 
2006). This synaptic pruning includes both axons and dendrites and involves apoptotic 
pathways including caspase activation as well as removal of debris by nearby glial cells. 
 
To observe the molecular mechanisms of axon pruning, Drosophila has been used as a model 
(Yu and Schuldiner, 2014). In the Drosophila mushroom body, a brain structure implicated 
in learning and memory, there is considerable remodelling of axons and dendrites (Watts et 
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al., 2003) where microtubule and neurofilament degradation has been implicated in the initial 
stages of axon removal (Watts et al., 2004). Activation of caspases is also involved in 
developmental pruning (Cusack et al., 2013; Erturk et al., 2014; Simon et al., 2012). In 
addition to large-scale pruning of axonal processes, small-scale axon pruning can occur to 
fine-tune subsets of axonal terminals. This small-scale pruning does not involve removal of 
cellular debris, but rather a retraction of the axoplasm (Low and Cheng, 2006). This suggests 
that more than one axon removal process has evolved. A similar progression of events has 
been documented in Wallerian degeneration in vertebrates (Zhai et al., 2003). 
 
1.3.3 Wallerian degeneration  
A well-investigated alternative to development axonal pruning, frequently implicated in 
neuronal injury, is Wallerian degeneration (Conforti et al., 2014). Wallerian degeneration is 
the degeneration of the axon following a severing event, leading to disruption of the distal 
regions of the axon. Our understanding of Wallerian degeneration comes from the discovery 
of the mutant slow Wallerian degeneration (WldS) mouse, where severed axons, distal to the 
injury site, were observed to survive for several weeks, rather than the maximum of 48 hours 
that occurs in wildtype mice (Coleman and Freeman, 2010; Lunn et al., 1989). This led to the 
understanding that the axonal compartment can survive without the cell body. 
 
Wallerian degeneration is initiated by a cutting or a crushing of the axon, followed by 
disintegration and clearance of the axon distal to the injury site (Freeman, 2014). Within an 
hour of the sever, a calcium influx is localised to the severed ends of the axon, leading to 
retraction of both ends. Following a lag period of several hours, a second calcium influx 
occurs throughout the severed distal end of the axon, which initiates fragmentation and 
disintegration of the cytoskeleton and is followed by clean-up with glial cells (Wang et al., 
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2012). The amount of time for Wallerian degeneration to occur varies between neuron types 
and is slower in the CNS than in the peripheral nervous system (Mietto et al., 2015; Qin et 
al., 2012; Vargas and Barres, 2007). An important distinction between axonal pruning and 
Wallerian degeneration is the activation of caspases, which is absent in Wallerian 
degeneration.  
 
1.3.4 Axon degeneration in disease 
The mechanisms by which axon degeneration occurs in disease are currently unclear, 
although it is known that most diseases involving axon degeneration are not associated with 
frank axon severing. One way to investigate this is to examine the effects of specific 
pathological insults on the axon in order to determine targets for axon protection. One 
pathological insult that is implicated in a number of neurodegenerative diseases including AD 
(Hynd et al., 2004; Ong et al., 2013) and ALS (King et al., 2016; Van Den Bosch et al., 2006) 
is excitotoxicity. Excitotoxicity has been postulated to be one of the key pathological 
mechanisms of AD, potentially through alterations to calcium signalling (Fujiwara et al., 
2012). 
 
Excitotoxicity occurs through excessive stimulation of excitatory neurotransmitters (Carriedo 
et al., 1996), and can be modelled through application of agonists of glutamate receptors, such 
as kainic acid (agonist of kainate and AMPA receptors) and NMDA. Kainic acid has been 
shown to induce excitotoxicity in vitro (Hosie et al., 2012; King et al., 2013). Post-synaptic 
kainate receptors are excitatory, but pre-synaptic kainate receptors are inhibitory as they 
modulate the release of GABA (Cossart et al., 2001). Kainic acid has also been shown to 
increase production of reactive oxygen species, further causing oxidative damage (Layton 
and Pazdernik, 1999). 
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Excitotoxicity has been postulated as a potential cause of axon degeneration in disease and 
injury (Hynd et al., 2004). Although Wallerian degeneration does not activate the caspase 
pathway, models of excitotoxic-induced axon degeneration in vitro have been shown to 
activate axonal caspase 3 (King et al., 2013; Uribe et al., 2012), although it is not known if 
the intrinsic or extrinsic caspase pathway is involved. This suggests some differences between 
excitotoxin-induced axon degeneration and Wallerian degeneration. Excitotoxicity causes 
disruption of the cytoskeleton leading to axon fragmentation, axonal swelling and beading 
(Hosie et al., 2012; McCarran and Goldberg, 2007). Furthermore, stabilising microtubules 
with taxol has been shown to prevent axon fragmentation (King et al., 2013). It is currently 
unclear which changes to microtubules result in axon degeneration, such as that induced by 
excitotoxicity. 
 
 
1.4 MICROTUBULES AS A THERAPEUTIC TARGET  
In order to understand how to target microtubules therapeutically, a detailed understanding 
of their structure and function is needed.  
 
1.4.1 Structure of microtubules  
The cytoskeleton is a network of interlinking structures which provide and aid cells with 
shape, polarity, movement and cell division. Microtubules were first visualised by 
transmission electron microscopy (Fawcett and Porter, 1954; Manton and Clarke, 1952). 
Microtubules are a dynamic cytoskeletal element essential for normal cellular function. They 
are hollow cylinders of 25 nm diameter and are polarised molecules, composed of alpha- and 
beta-tubulin subunits, which were originally proposed as a homodimer model of alpha/alpha 
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and beta/beta tubulin (Mohri, 1968), but were later shown to be a heterodimer (Nogales et al., 
1998). This heterodimer structure is vital as it greatly increases the ability of tubulin to 
polymerise to form microtubules.  
 
1.4.2 Polymerisation and nucleation  
Polymerisation is the process where free tubulin subunits are integrated to form microtubule 
protofilaments which require guanosine triphosphate (GTP) binding. Nucleation is the 
process of microtubule polymerization de novo. Nucleation of microtubules only occurs at 
the centrosomes at the centre of the cell, which are capable of nucleating hundreds of 
microtubules (Job et al., 2002). The ‘plus’-ends of microtubules grow outwardly towards the 
periphery of the cell. The centrosome constantly sends out new microtubules, as microtubules 
are continually being depolymerised. Another type of tubulin, gamma tubulin ring complex, 
aids in nucleation by acting as a template for tubulin heterodimers, creating a 13 protofilament 
base for the growing microtubule (Dammermann et al., 2003). The gamma tubulin ring acts 
as a cap for the non-growing ‘minus’-end and provides stability (Moritz et al., 2000). After 
tubulin subunits have been polymerised, they are covalently linked together to form a rigid 
microtubule structure. Tubulin subunits are more likely to be added to the plus-end of 
microtubules, where polymerisation rates are higher (Brouhard and Rice, 2014).  
 
1.4.3 Dynamic instability and GTP hydrolysis 
Microtubule function heavily relies upon their ability to easily assemble and disassemble. The 
continuous process of microtubule growth and shrinkage is dynamic instability (Burbank and 
Mitchison, 2006). Dynamic instability is a tightly-regulated process dependent on GTP 
hydrolysis and interactions with MAPs (Bowne-Anderson et al., 2013). The rate of 
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microtubule polymerisation is proportional to free tubulin levels. Binding GTP and Mg2+ are 
essential for microtubule assembly and stability. When GTP binds to beta-tubulin, it binds to 
the exchangeable (E) site, is hydrolysed to guanosine diphosphate (GDP) and creates a change 
in confirmation causing instability of the microtubule (Nogales et al., 1998). The GTP binding 
site on alpha-tubulin is the non-exchangeable (N) site. The role of the Mg2+ cation is highly 
important for the structural integrity of microtubules (Menéndez et al., 1998). During GTP 
hydrolysis, Mg2+ binds to the same site on the heterodimer. Heterodimers will either bind 1 
or 2 Mg2+ cations, depending on the state of GTP hydrolysis. If the N-site of the alpha-tubulin 
binds GTP and the E-site of beta-tubulin binds GDP (after hydrolysis) then a Mg2+ cation will 
bind at the N-site (Alushin et al., 2014). However, if GTP is bound on both alpha- and beta-
tubulin subunits, then another Mg2+ cation will bind at the E-site. The Mg2+ at the N-site 
controls stability of the heterodimer, whereas the Mg2+ at the E-site controls the stability of 
the microtubule. When the polymerisation rate of microtubules is higher than the rate of GTP 
hydrolysis of beta-tubulin, it results in a GTP cap on the carboxyl-end of the microtubule. 
This causes a higher affinity between tubulin with GTP than GDP, therefore the GTP cap 
stimulates further microtubule growth. A GTP cap can stabilise a microtubule by preventing 
depolymerisation of that microtubule (Horio et al., 2014). The loss of a GTP cap results in 
rapid disassembly of the microtubule, due to GTP hydrolysis to GDP. Normally, GTP 
hydrolysis of tubulin allows microtubules to depolymerise as it breaks the bonds between the 
tubulin subunits. Delayed GTP hydrolysis after the tubulin polymerisation results in a GTP 
cap (Bowne-Anderson et al., 2013). When free tubulin levels fall below a critical 
concentration threshold, rapid shrinkage of the microtubule at the plus-end occurs, which has 
been proposed to be caused by the loss of the GTP cap (Bowne-Anderson et al., 2013). This 
is because dissociation of GTP bound to tubulin in turn exposes the GDP bound to tubulin, 
causing microtubule instability and shrinkage. When microtubule disassembly occurs rapidly, 
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protofilaments curve due to a conformational change of GDP bound to beta-tubulin (Horio et 
al., 2014). GDP-bound heterodimers form a ring shape, which differs to the straight shape of 
heterodimers with GTP bound, giving the protofilaments their straight shape. Most of the 
neuronal microtubules in axons are stabilised, however, many factors such as PTMs and 
MAPs influence microtubule stability (Kadavath et al., 2015; Song et al., 2013).   
 
 
1.5 POST-TRANSLATION MODIFICATIONS OF MICROTUBULES 
1.5.1 Post-translational modifications influence dynamics 
Microtubule stability is highly dependent on PTMs of its tubulin subunits, as they influence 
protein binding, as bound proteins can increase stability to aid in microtubule function. 
Tubulin can be modified in its soluble dimer form or polymerised as a microtubule. Most 
PTMs are acquired on the carboxyl-terminal of tubulin after polymerisation, except for 
acetylation of alpha-tubulin. Some PTMs are exclusive to one type of tubulin, such as 
acetylation, however, microtubule PTMs can also enhance binding of severing proteins (Song 
and Brady, 2015; Wloga and Gaertig, 2010), which have increased activity in 
neurodegenerative disease (Brunden et al., 2017; Sharp and Ross, 2012; Sudo and Baas, 
2011). Post-translational modifications can be altered by pharmacological intervention and 
therefore can be used as potential therapeutic targets. For a summary of PTMs refer to Table 
1.1. 
 
1.5.2 Acetylation of microtubules 
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Acetylation is currently the only known PTM which occurs inside the lumen of microtubules. 
Acetylation of alpha-tubulin is the only known acetylation process to occur on polymerised 
microtubules, suggesting it is marker of microtubule age as they are more stable and resistant  
  
Type of 
modification
Type of 
tubulin Enzymes Description Site
Acetylation
alpha,

assembled 
microtubules
Forward:

⍺TAT1

Reverse:

HDAC6

SIRT2
addition of acetyl 
group lysine 40 of ⍺-tubulin
Detyrosination /

Δ2 / Δ3 / 

Tyrosination
alpha, 
assembled 
microtubules, 
tyrosination on 
tubulin 
heterodimers
Forward:

CCP1,4,6

Reverse:

TTL
removal of C-terminal 
tyrosine

removal of penultimate 
glutamate from 
detyrosinated ⍺-tubulin
terminal tyrosine on 
CTT of ⍺-tubulin 
CTT of ⍺-tubulin
Glutamylation /  
Polyglutamylation
alpha

beta, 
assembled 
microtubules
Forward:

TTLL4,5,7

TTLL1,6,11,13

Reverse:

CCP5 
CCP1,4,6
addition of one or 
more glutamates as a 
side chain
multiple glutamates in 
the primary sequence 
of CTTs of ⍺- and β-
tubulin
Glycylation / 
Polyglycylation
alpha

beta, 
assembled 
microtubules
Forward:

TTLL3,8

TTLL10
addition of one or 
more glycine as a side 
chain
multiple glutamates in 
the primary sequence 
of CTTs of ⍺- and β-
tubulin
Phosphorylation
alpha

beta,

unpolymerised 
tubulin dimer
Forward:

Cdk1

PSK

Syk
addition of phosphate 
group serine 172 of β-tubulin
βΔ4 beta Unknown
removal of amino 
acids EDEA from the 
C-terminus
C-terminal of β-tubulin
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Table 1.1 Microtubule post-translational modifications  
 
A summary of the microtubule PTMs with a description of the type of tubulin and the 
enzymes and sites involved in each modification. 
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to turnover (Portran et al., 2017). However, it is unclear whether acetylated tubulin is the 
outcome of stabilised microtubules, or is a process required to stabilise microtubules. 
Acetylation is the transference of an acetyl group from acetyl Co-enzyme A to lysine 40 of 
alpha-tubulin by acetyltransferase 1 (αTAT1; Li and Yang, 2015). Deacetylation or removal 
of the acetyl group from lysine 40 is catalysed by histone deacetylase 6 (HDAC6) and sirtuin 
2 (SIRT2; Janke and Montagnac, 2017). It has been proposed that HDAC6 can inhibit 
microtubule growth because of its deacetylating activity (Asthana et al., 2013), but this is 
debated (Zilberman et al., 2009). However, acetylation has been proposed to induce 
microtubule severing as it enhances the binding of severing enzymes. Katanin, a severing 
enzyme, has been shown to have enhanced severing activity on acetylated-rich microtubules 
(Sudo and Baas, 2010). Supporting the view that acetylation is a result of microtubule 
stabilisation, αTAT1 has a higher rate of acetylation on assembled microtubules, rather than 
tubulin dimers (Kull and Sloboda, 2014). In contrast, αTAT1 has been shown to destabilise 
microtubules independently of its acetylating role (Kalebic et al., 2013), although there are 
no changes in the structural architecture of deacetylated and acetylated microtubules (Howes 
et al., 2014). Acetylated microtubules are also resistant to nocodazole, which alters 
microtubule polymerisation (Xie et al., 2010; Xu et al., 2017).  
 
1.5.3 Tyrosination of microtubules 
Tyrosination is another type of PTM which directly affects tubulin. Alpha-tubulin is 
tyrosinated and forms a heterodimer with beta-tubulin before being assembled into 
microtubules. After microtubule assembly, tyrosinated tubulin eventually becomes 
detyrosinated (Kumar and Flavin, 1981). Thus, detyrosination is a marker of microtubule 
stabilisation and microtubule age. Detyrosination is produced by cytosolic carboxypeptidase 
1 (CCP1) and the reverse process is generated by the enzyme tubulin tyrosine ligase (TTL). 
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Detyrosinated alpha-tubulin can undergo a second round of detyrosination, known as 2 (Vu 
et al., 2017). This process removes the terminal glutamic acid residue, however, as this 
process is not reversible, the tubulin heterodimers with this PTM are unable to be reused, 
making them another marker of microtubule age. 
 
In some forms of degeneration, microtubules are possibly converted back to a state of 
tyrosination and therefore more vulnerable to depolymerisation. The enzyme responsible for 
detyrosination, TTL is increased in injured axons and results in axon retraction (Song et al., 
2015). Microtubules, particularly in axons, have two major domains of varying degrees of 
stabilisation. The labile domain located at the plus-end of the microtubule is highly 
tyrosinated and acetylated, despite the connection with acetylation and stable microtubules. 
In mitosis, interphase microtubules which are detyrosinated (glutamylated tubulin) are more 
resistant to high concentrations of nocodazole than tyrosinated tubulin (Kreis, 1987). 
Detyrosination has also been demonstrated to stabilise microtubules (Peris et al., 2009). 
Detyrosination of alpha-tubulin is protective against depolymerisation of microtubules by 
kinesin-13 (a motor protein). Overall, the distal axon is mostly tyrosinated due to its role in 
outgrowth, whereas the proximal axon is mostly detyrosinated to stabilise the axon. When 
detyrosinated tubulin has a glutamate residue at the carboxyl-terminal, it becomes 
glutamylated tubulin. 
 
1.5.4 Glutamylation of microtubules 
Glutamylation is a PTM which enhances the severing activity of microtubules. In this case, 
severing activity is used for microtubule outgrowth, as glutamylation is the main regulator of 
the microtubule-severing enzyme, spastin (Valenstein and Roll-Mecak, 2016). Glutamylation 
is a polymodification as it has side chains branching from the glutamic acid residue from the 
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C-terminal tail. Glutamylation is catalysed by a similar enzyme to detyrosination, TTL-like 
proteins, whereas deglutamylation is catalysed by CCP5.   
 
Polyglutamylation increases MAPs binding to microtubules, including motor proteins, thus 
playing an important role in regulation of binding of proteins such as MAP1A, MAP1B, 
MAP2 and kinesin, but not tau (Bonnet et al., 2001). Polyglutamylation has been shown to 
occur on 50% of neuronal alpha-tubulin on glutamate 445 and can also be found on both 
tyrosinated and detyrosinated tubulin. Tau is closely linked to glutamylating enzymes, 
because in disease, mis-sorting of tau occurs, localising to the dendrites, which in turn induces 
mis-localisation of TTLL6 to the dendrites (Zempel and Mandelkow, 2015).  
 
1.5.5 Phosphorylation of microtubules 
Phosphorylation is thought to only occur on beta-tubulin by cdk1 kinase. Phosphorylation 
inhibits assembly of tubulin subunits into microtubules (Fourest-Lieuvin et al., 2006), 
however, alpha-tubulin phosphorylation on a tyrosine residue, has been demonstrated to 
prevent tubulin being incorporated into microtubules (Ley et al., 1994). In general, insight 
into phosphorylated microtubules is limited, especially in neurons. 
 
There are a variety of kinases which phosphorylate tubulin, including insulin receptor kinase 
(Kadowaki et al., 1985; Wilden and Kahn, 1994). Pharmacological manipulation can also 
influence tubulin phosphorylation, as taxol can promote phosphorylation, whereas 
nocodazole decreases tubulin phosphorylation (Fourest-Lieuvin et al., 2006; Song et al., 
2015).  
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1.6 MICROTUBULE-ASSOCIATED PROTEINS 
Microtubule-associated proteins bind to multiple sites on tubulin and stabilise microtubules 
by cross-bridging multiple tubulin subunits and promote stability by suppressing tubulin 
dissociation. As described above, most MAPs binding to microtubules are modulated by 
phosphorylation. For a summary of MAPs refer to Table 1.2. 
 
Tau is a neuronal MAP protein encoded by the Mapt gene on chromosome 17 and can undergo 
alternative splicing to form several different isoforms. During development, 3-repeat tau, is 
primarily expressed, while 4-repeat tau, is predominantly expressed in adulthood (D’Souza 
and Schellenberg, 2000; Malmanche et al., 2017). Tau is thought to promote microtubule 
stability, as the C-terminal of tau binds to tubulin subunits, with the 4-repeat tau isoform 
showing a higher affinity for microtubules than the 3-repeat tau (Goedert et al., 1989). 
Similarly, phosphorylation of tau also affects the capacity of tau to bind to microtubules. 
Phosphorylation at Ser262, Ser293, Ser324 and Ser365 decreases the capacity of tau to bind 
to microtubules (Drewes et al., 1995). 
 
 
Tau phosphorylation of Tyr18 has been suggested to have a role in regulation of axonal 
transport (Cox et al., 2016; Kanaan et al., 2012). Phosphorylation of these tyrosine sites of 
tau are also associated with tau’s capacity to aggregate. Importantly, tau is an inhibitor of 
HDAC6, therefore, it promotes microtubule stability (Perez et al., 2009). Phosphorylation of 
tau is regulated by various kinases, mainly by serine/threonine kinase. Like kinases, 
phosphatases, such as serine/threonine-specific protein phosphates 2A (PP2A), also play a 
role in tau regulation. Phosphorylation at sites serine 262 and 356, in turn activate other 
kinases GSK3β and cdk5, which have other roles in disease progression. 
  
Type of 
protein Isoforms
Molecular Weight 
(kDa) Function
MAP1 MAP1A
MAP1B
300

255
neural development; stabilisation of 
microtubules in axons and dendrites
MAP2
MAP2A

MAP2B

MAP2C

MAP2D
280

200

70

42
neural development; stabilisation of 
microtubules in dendrites; signal 
transduction; early neural development
MAP4 multiple 210 promotes microtubule assembly 
Tau
HMW-tau

tau 4R/2N

tau 4R/0N

tau 3R/0N
55-62 neural development; stabilisation of microtubules in axons; axonal transport
CRMP2 CRMP2A

CRMP2B
62 axon guidance; neuronal growth cone; cell 
migration
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Table 1.2 Proteins associated with microtubules 
 
A summary of the MAPs with a description of the known isoforms and their function when 
bound to microtubules. 
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MAP1A and MAP1B are structural MAPs, whose interaction with tubulin is modulated by 
polyglutamylation (Bonnet et al., 2001). MAP1A and MAP1B are expressed from different 
genes, from chromosomes 2 and 13 respectively (Halpain and Dehmelt, 2006). MAP2 does 
not compete with MAP1 binding to tubulin, suggesting they have different binding sites and 
function (Noble et al., 1989), although previous research has shown the opposite (Kuznetsov 
et al., 1984). MAP2, also a structural MAP, has three main isoforms expressed in neurons, 
MAP2A, MAP2B and MAP2C. Phosphorylation of MAP1B influences its microtubule-
binding capacity. MAP1B is highly expressed during development, perhaps due to its role in 
neurite outgrowth, which is also regulated by phosphorylation (Scales et al., 2009). In 
addition, MAP1B is also important for axonal plasticity (Bouquet et al., 2004). MAP2B is 
expressed in development and in adulthood, whereas MAP2C is expressed mainly during 
neuronal development and MAP2A expression levels are up-regulated during adulthood 
(Burgoyne and Cumming, 1984; Doll et al., 1993; Ferhat et al., 2009; Nunez, 1988). MAP2 
is located in the cell body and dendrites (Dehmelt and Halpain, 2005).  
 
In addition to structural MAPs, some MAPs are involved in promoting microtubule assembly. 
Collapsin response mediator proteins (CRMPs) are MAPs that bind to microtubules to 
promote assembly via their C-terminal (Fakata et al., 2002; Niwa et al., 2017). CRMPs are 
regulated by phosphorylation and are expressed from five genes, with many isoforms. 
Importantly, CRMP2 localises to the distal part of growing axons, where it mediates tubulin 
dimers to the ends of growing microtubules (Arimura et al., 2005). Phosphorylated CRMP2 
loses affinity for tubulin heterodimers resulting in reduced microtubule growth and increased 
axonal retraction. Therefore, CRMP2 binds and stabilises microtubule plus-ends and 
promotes axon growth (Niwa et al., 2017), along with CRMP4 (Khazaei et al., 2014; Tan et 
al., 2015). CRMP2 is observed in neurofibrillary tangles in AD (Soutar et al., 2009). CRMP2 
is also involved in transporting vesicles by acting as an adaptor for kinesin 1 motor protein 
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for anterograde transport vesicles (Encalada et al., 2011; Reis et al., 2012). It is hypothesised 
that it also acts in this way for retrograde transport vesicles for dynein motor proteins 
(Arimura et al., 2009). CRMP2 interacts with NMDA receptors and the Na+/Ca+ exchanger 
and regulates their functional activity (Brustovetsky et al., 2014). CRMP2 binding to 
microtubules is influenced by microtubule-stabilising drugs taxol and epothilone B as they 
displace CRMP2 (Lin et al., 2011).  
 
 Motor proteins 
Kinesins are microtubule motor proteins which transport cargo anterogradely along the axon, 
mainly transporting mitochondria and synaptic vesicles containing neurotransmitters 
(Encalada et al., 2011). Structurally, kinesin has light chains which mainly bind cargo, 
although some cargo may bind to the carboxyl terminal of the heavy chains. The globular unit 
of kinesin has a binding site for microtubules and one for binding adenosine triphosphate 
(ATP). Hydrolysis and release of adenosine diphosphate (ADP) makes a conformational 
change to microtubule-binding domains. When lysine 40 of alpha-tubulin is acetylated, 
kinesin-1 can bind to microtubules (Reed et al., 2006). Therefore, increased acetylation of 
microtubules results in increased requirement of kinesin-1 and another motor protein, dynein. 
 
 Microtubule severing enzymes 
Microtubule-severing enzymes, spastin and katanin are ATPases, although it is unknown how 
these severing enzymes bind to microtubules. Severing enzymes are required for normal cell 
function as they release newly polymerised microtubules to be transported to axons and 
dendrites for neurite outgrowth (Vemu et al., 2018). If severing occurs in a stable region of a 
microtubule, it results in two separate microtubules, however, if a severing event occurs in a 
labile region, it is more likely to result in depolymerisation. Katanin and spastin are the most 
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commonly known severing enzymes and preferably bind to stable regions of microtubules. 
Spastin is associated with enhanced axonal branching formation (Yu et al., 2008). A loss of 
spastin results in reduced axonal length and reduced formation of axonal branches. Differing 
from katanin, spastin accumulates more at the site of branching formation, however, in the 
absence of spastin, axonal branches continue to form. Polyglutamylated microtubules are also 
more susceptible to spastin severing (Lacroix et al., 2010). It is possible that spastin also 
influences other cytoskeletal elements such as actin filaments, because axonal branching 
requires actin filaments and microtubules. There are no microtubule modifications which are 
resistant to severing by spastin, however, axons with a lack of tau undergo more axonal 
branching independent of spastin being present (Yu et al., 2008). Spastin potentially has a 
role in nucleation of microtubules and it is hypothesised that spastin along with fidgetin 
releases microtubules from the centrosome. Fidgetin, another ATPase severing enzyme, 
severs microtubules particularly at the minus-end and promotes degeneration in dendrites 
after injury (Tao et al., 2016).  
 
The severing activity of katanin is highly influenced by tau, however, spastin severing activity 
is unchanged in the presence or absence of tau (Sudo and Baas, 2010). Generally, MAPs 
influence severing enzyme activity, whilst microtubule PTMs influence severing enzyme 
binding. MAP4 inhibits katanin severing activity, whilst tau activates katanin via the tau 
microtubule-binding domains, where it is phosphorylated to become activated (Sudo and 
Baas, 2011; Zempel and Mandelkow, 2015). Tau can therefore also inhibit katanin 
microtubule severing, since tau in disease enhances katanin microtubule severing as tau is no 
longer able to inhibit katanin through phosphorylation (Qiang et al., 2006). Katanin also 
enhances microtubule growth by severing the microtubule at the centrosome (Bailey et al., 
2015). Katanin is highly important for axonal outgrowth because if it or gamma-tubulin is 
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inhibited, no new microtubules are released from the centrosome and transported along the 
axon.  
 
 Mutations to MAPs in neurodegenerative disease 
Mutations of MAPs have been implicated in neurodegenerative disease. A mutated form of 
spastin has been found in hereditary spastic paraplegia (HSP; Errico et al., 2002; Yabe et al., 
2002). A spontaneous mouse mutation of MAP1A, mm2719, causes tremors, ataxia and loss 
of cerebellar Purkinje neurons due to abnormal focal swellings disrupting the axon initial 
segment morphology (Liu et al., 2015b). Tau mutations have been widely reported in several 
neurodegenerative diseases, including sporadic AD, Pick’s disease and progressive 
supranuclear palsy (as reviewed by Goedert and Jakes, 2005; Goedert and Spillantini, 2001; 
Wolfe, 2009). There are currently more than ten MAPT mutations that have been reported in 
familial cases of progressive supranuclear palsy, which are mainly located in exon 10 and its 
splicing region, which mainly produces 4-repeat tau (Rohrer et al., 2011; Stanford et al., 
2000). Mutations to tau have also been identified in frontotemporal dementia (FTD) cases, 
which result in hyperphosphorylation of tau and assembly into filaments, causing subsequent 
cell death (Rizzu et al., 1999). MAP11, whose function is currently unknown, has been shown 
to co-localise with alpha-tubulin during mitosis. Truncating mutations of MAP11 cause 
microcephaly in both humans and in zebrafish models (Perez et al., 2019). Mutations to 
microtubule motor proteins have also been identified. Kif5A is an isoform on kinesin-1, with 
23 separate mutations being identified in patients with HSP. These mutations have reduced 
catalytic and mechanical activities, with motility significantly reduced (Jennings et al., 2017). 
In Drosophila models, mutations in kinesin have been shown to cause motor neuron disease 
phenotypes by disrupting fast axonal transport (Kurd and Saxton, 1996). Mutations to 
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MAP1B cause extensive white matter deficits (Walters et al., 2018). Together this suggests 
that altered microtubule cytoskeleton can be a driver of neurodegenerative disease.  
 
1.6.1 Summary of post-translational modifications and microtubule-associated proteins 
interactions 
Microtubules are dynamic molecules, a property that is essential to fulfil their necessary 
function. This dynamic property is enabled through their PTMs and interactions with MAPs, 
either by promoting stability or instability. Furthermore, PTMs and MAPs also influence each 
other’s binding to microtubules and MAPs can also undergo their own PTMs, such as 
phosphorylation, which can prevent their binding to microtubules. Microtubules can be 
manipulated through pharmacological intervention. In disease, changes to the level of PTMs 
and dissociation of MAPs can occur, altering microtubule stability. There are several 
interactions between microtubules functions, such as axonal transport, and MAPs, which are 
implicated in AD pathology as well as other neurodegenerative diseases and injury.  
 
 
1.7 MICROTUBULE ALTERATIONS IN DISEASE AND INJURY 
1.7.1 Introduction 
Microtubule alterations have been reported in many diseases and injury conditions, including 
microtubule loss in AD (Cash et al., 2003; Jean and Baas, 2013). In stretch injury models, 
microtubules disassembly is one of the earliest events in axon degeneration (Tang-Schomer 
et al., 2010). Several studies have shown that microtubule alterations precede axon 
degeneration, although microtubule alterations in axon degeneration are relatively 
uncharacterised. Alterations to microtubules can be manipulated by microtubule-stabilising 
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drugs and have shown to be protective. However, changes to microtubules are currently 
unknown, but promoting microtubule stability has been shown to prevent axon loss by 
excitotoxic-induced axon degeneration (King et al., 2013).  
 
 Microtubule post-translational modifications in disease and injury 
Microtubule PTMs have been reported in several neurodegenerative disease models. 
Glutamylation is increased in the hippocampi of a model of kainic acid-induced epileptic 
seizures as well as in AD patients, particularly in the CA3 region (Vu et al., 2017), although 
other studies suggest a decrease (Zhang et al., 2015a). Excessive polyglutamylation of tubulin 
has been shown to cause neurodegeneration and impair neuronal transport (Magiera et al., 
2018). Likewise, tyrosination and detyrosination levels have been documented to be reduced 
in brains of AD patients. After injury, increased tyrosinated tubulin is required to promote 
axon regeneration, suggesting loss of tyrosination during injury (Song et al., 2015). Similarly, 
increased acetylated tubulin is required to rescue axonal transport in a model of Parkinson’s 
disease (Godena et al., 2014) and in a tauopathy mouse model (Mao et al., 2017), suggesting 
a loss of acetylation during neurodegenerative disease. 
 
1.7.2 MAPs in disease and injury 
Tau in neurodegenerative disease 
A number of alterations to tau in AD have been reported, including abnormal phosphorylation 
by cyclin-dependent kinase (cdk5) and glycogen synthase kinase-3-beta (GSK3β), as well as 
altered splicing in favour of the 3-repeat isoform, all of which are thought to reduce its affinity 
for microtubules and affect microtubule stability (Mietelska-Porowska et al., 2014). More 
recently, studies suggest that tau acetylation, which alters tau function, depending on which 
lysine is acetylated (Guo et al., 2017), may be altered in AD. Acetylation at Lys174 has been 
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shown to occur early in AD disease progression and results in cognitive deficits in vivo (Min 
et al., 2015), potentially through mis-localisation to the dendrites and disruption of AMPA 
receptors (Guo et al., 2017). Tau acetlyation may also be involved in FTD as lowering total 
levels of tau and acetylated tau at Lys174 in a PS19 FTD mouse model using a NSAID 
treatment, salsalate, rescued memory deficits and prevented hippocampal atrophy (Min et al., 
2015). However, other lysine sites when acetylated may be protetive by preventing tau 
phosphorylation and are reduced in AD brains (Cook et al., 2014; Mietelska-Porowska et al., 
2014). Ubiquitination of tau has also been suggested to be affected by acetylation of tau, as 
11 acetylation sites are also ubiquitination sites, which suggests that degradation of tau is 
affected by acetylation (Morris et al., 2015). In addition, GSK3β is known to phosphorylate 
tau and promote tangle-like morphology (Rankin et al., 2007). Tau and another MAP, 
CRMP2, have the same kinases which act upon them, suggesting that they are part of a similar 
pathway and may both be affected in disease conditions. In tau knockout mouse models, a 
lack of tau protected mice from kainic-acid induced seizures (Pallo et al., 2016), and tau has 
also been shown to exacerbate excitotoxic brain damage in a stroke mouse model (Bi et al., 
2017). However, the exact alterations that occur to tau during excitotoxicity are unknown. 
Aside from the changes to isoform expression, tau exon splicing, and tau to microtubule 
interactions, the alterations to tau remain unclear in neurodegenerative disease. 
 
MAP1 and MAP2 in neurodegenerative disease  
Like tau, MAP1B has been reported to be hyperphosphorylated in AD (Gong and Iqbal, 2008; 
Wang et al., 2001) and is present in sites of neurofibrillary degeneration in AD patients (Ulloa 
et al., 1994). Furthermore, MAP1A and MAP1B proteolysis was observed after Aβ-induced 
activation of caspase 3 and calpain (Fifre et al., 2006). Neuronal deficiency of MAP1B, 
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results in structural presynaptic deficiencies and altered presynaptic physiology (Bodaleo et 
al., 2016). 
 
In models of NMDA-induced excitotoxicity, loss of MAP2 from the apical dendrites was 
observed (Hoskison et al., 2007; Hoskison and Shuttleworth, 2006). Similarly, loss of MAP2 
immunoreactivity was reported prior to neuronal cell loss in rodent brain injury models (Huh 
et al., 2004), particularly in the hippocampus (Taft et al., 1992) and levels of MAP2 have 
been shown to fluctuate in a diffuse brain injury model immediately post-injury and up to 10 
days after (Papa et al., 2017).  
 
Collapsin response mediator proteins in neurodegenerative disease 
CRMP2 plays a major protective role in acute axon degeneration, as a calcium influx after a 
lesion activates calpain which then cleaves CRMP2, and impairs axon transport (Zhang and 
Koch, 2017). In models over-expressing CRMP2, proximal axons were protected in acute 
axon degeneration (Zhang and Koch, 2017). CRMP2 was also altered in models of 
excitotoxicity and over-expression of CRMP2 has also been shown to aggravate NMDA-
induced injury (Yin et al., 2013). CRMP2 has been proposed as a therapeutic target in 
neurodegenerative disease through its ability to regulate microtubule stability through a 
similar mechanism to tau (Hensley and Kursula, 2016). When CRMP2 is dephosphorylated, 
it facilitates axonogenesis (Voronkov et al., 2011).  
 
1.7.3 Phosphorylation of microtubule associated proteins 
Tau phosphorylation 
Phosphorylation of MAPs is involved in stability of microtubules. In disease, several MAPs 
become hyperphosphorylated, most notably tau, become hyperphosphorylated, which leads 
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to their pathological function (Ma et al., 2017). As such, targeting protein phosphorylation 
has become a proposed therapeutic in AD (Gong and Iqbal, 2008; Voronkov et al., 2011) and 
has led to reducing tau-based synaptic toxicity (Ma et al., 2017). In the current literature, 
sodium selenate has shown to mitigate tau pathology in AD models (van Eersel et al., 2010) 
via targeting the phosphatase PP2A.  
 
 Phosphorylation of other MAPs 
In addition to tau, other MAPs become phosphorylated and pathological in AD. Dendritic 
MAP2, is phosphorylated in disease and alters cytoskeletal function (Sánchez et al., 2000), 
as it has a role in nucleation and stabilisation of microtubules, neuronal processes outgrowth 
and synaptic plasticity. When MAP2 becomes hyperphosphorylated it dissociates from 
microtubules, increasing dynamic instability (Illenberger et al., 1996). Similarly, CRMP2 is 
hyperphosphorylated in AD, which is a feature not common to other neurodegenerative 
diseases (Williamson et al., 2011) and is one of the earliest events in AD progression in AD 
patients and in AD mouse models (Cole et al., 2007; Soutar et al., 2009). 
 
 Other microtubule modifications in neurodegenerative disease 
In addition to alterations to microtubule PTMs, other microtubule-associated changes are 
implicated in disease and injury. For example, mutations to presenilin have been shown to 
impair kinesin-based axonal transport (Gunawardena et al., 2013; Pigino et al., 2003). 
Acetylated microtubules are also more susceptible to katanin severing, particularly in the 
axon, where microtubules are more stable, due to their acetylation (Sudo and Baas, 2010). 
Tau bound to axonal microtubules, renders them less sensitive to katanin activity, thus the 
loss of microtubule-associated tau in neurodegenerative disease, makes them vulnerable to 
severing (Sudo and Baas, 2011).  
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1.8 PHARMACOLOGICAL MANIPULATION OF MICROTUBULES 
1.8.1 Microtubule stabilisation as a therapeutic 
Microtubule-stabilising drugs have been proposed as a therapy for AD and other 
neurodegenerative diseases with axonal transport impairments (Ballatore et al., 2012; 
Trojanowski et al., 2005). Reduced microtubule stability is an early pathological change in 
response to Aβ toxicity, likely a result of tau hyperphosphorylation. In addition, the 
destabilisation of microtubules is implicated in axon degeneration (Tang-Schomer et al., 
2010). There are a number of ways that microtubule stabilisation can be targeted. Firstly, 
there are microtubule-stabilising agents that bind directly to microtubules and can promote 
stability of microtubules and prevent them from depolymerising (Yu et al., 2013). Research 
into drugs that bind to the same site as tau, such as taxanes and epothilones, has demonstrated 
their effects in reducing pathology in tauopathy mouse models (Bakota and Brandt, 2016; 
Brunden et al., 2010; Erez et al., 2014; Zhang et al., 2012a). However, it is unknown whether 
binding by these agents cause a conformational change to microtubules which promotes 
stability. Alternatively, drugs that can target PTMs of tubulin such as acetylation and 
glutamylation, as well as MAPs such as tau, may promote stability and are also attractive 
targets for intervention. 
 
An important feature of any drug for neurodegenerative disease is that it must be able to cross 
the blood brain barrier. Many microtubule-stabilising drugs were first used to treat cancers 
by causing cell cycle arrest, so while they may have been developed for human use, their 
ability to access the CNS needs to be determined. Taxanes and epothilones are two of the two 
main classes of microtubule-stabilising agents, however their properties differ. Taxol has 
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poor permeability to the blood brain barrier, whereas epothilone B and D have been shown 
to cross the blood brain barrier and are a potential therapeutic for AD.  
 
1.8.2 Microtubule modifying drugs 
Taxol 
Taxol was first isolated from Taxus brevifolia in 1971 and was identified as an anti-leukemic 
and anti-tumour drug (Wani et al., 1971). It is now known that it enhances microtubule 
assembly and length, as well as stabilising microtubules (Parness and Horwitz, 1981; Schiff 
and Horwitz, 1981). Taxol has been found to assemble tubulin subunits of microtubules in 
the absence of GTP or MAPs, such as tau (Schiff and Horwitz, 1981). Without taxol, in in 
vitro preparations, tubulin is predominantly in the depolymerised state, however, with the 
addition of taxol, polymerisation increases, along with GTP hydrolysis (Hamel et al., 1981). 
When GTP is absent, tubulin still forms microtubule structures when taxol and MAPs are 
present (Hamel et al., 1981). Taxol binds to tubulin polymers between the ‘M-loop’ and the 
‘central helix’ of beta-tubulin (Amos and Lowe, 1999; Nogales et al., 1999). A number of 
studies have investigated the therapeutic potential of taxol in injury models to the brain, spinal 
cord and peripheral nerves. In a needle stick model of acute damage to the somatosensory 
cortex, taxol was an effective therapeutic agent to protect against neurodegeneration by 
reducing neurite loss via microtubule stabilisation of axons (Adlard et al., 2000). As taxol 
improves axonal elongation, the potential of taxol to improve axon regeneration of neurons 
following injury has also been investigated. In adult rats with a dorsal hemisection spinal cord 
injury, taxol treatment increased the number of axons regenerating, and increased axon 
outgrowth (Hellal et al., 2011). Moreover, when taxol was administered prior to axon stretch 
injury in vitro, it delayed axon degeneration was delayed compared to untreated injured axons 
(Tang-Schomer et al., 2010). Taxol restored facial nerve function after nerve crush injury in 
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Wistar rats, through the stabilisation of microtubules, which was evaluated through motor 
function and the degree of axonal branching (Grosheva et al., 2008). Furthermore, taxol 
administration to an optic nerve crush injury site, allowed axon regeneration past the lesion 
area because of microtubule stabilisation (Sengottuvel et al., 2011). At spinal cord lesions 
sites in rodents, microtubule stabilisation promoted axonal growth, and increased levels of 
detyrosinated and acetylated tubulin, at the lesion site of the spinal cord in rodents (Ruschel 
et al., 2015), suggesting that axon growth may have been due to the reduction of scar tissue, 
which contains axon growth-inhibitory factors (Ruschel et al., 2015), although astrogliosis 
was shown to be unaffected by microtubule stabilisation treatment. The effect of microtubule-
stabilising agents on glial cells has not been extensively investigated in disease models. The 
effects of taxol have also been studied in a T44 tau mouse model where fast axonal transport 
was improved, and microtubule density and detyrosinated tubulin levels increased (Zhang et 
al., 2005).  
 
 Epothilones 
Another family of microtubule-stabilising agents, epothilones, have similar characteristics 
and mechanisms to taxol, although they are able to cross the blood brain barrier (Bollag et 
al., 1995). Epothilone, originally an anti-tumour drug, is produced by the gram-negative 
bacteria Sorangium cellulosum, and has undergone both phases I and II clinical trials (Beer 
et al., 2007; Bollag et al., 1995; Konner et al., 2012). Taxol and epothilones have a similar 
structure and bind to beta-tubulin at a common site (Cheng et al., 2008). Like taxol, 
epothilone, has been shown to prevent microtubule disassembly when calcium is present. 
Taxol and epothilone also reduce the amount of tau bound to microtubules, suggesting that 
these drugs also compete with tau (Mukhtar et al., 2014; Ross et al., 2004). Due to their 
success in treating cancer, epothilones are being investigated as a treatment for 
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neurodegenerative diseases. As Parkinson’s disease shares some pathological features with 
AD, epothilone D was shown to reduce microtubule defects and increase detyrosinated 
microtubules in dopaminergic neurons in a mouse model of Parkinson’s disease (Cartelli et 
al., 2013). In a mouse model of schizophrenia, epothilone D was also shown to improve short-
term memory, suggesting that epothilone D may affect synapses in the hippocampus 
(Andrieux et al., 2006). Some research has suggested that the effectiveness of treatment with 
epothilone B depends on the type and age of the neuron (Jang et al., 2016). Many mouse 
models of varying neurodegenerative diseases have shown successful microtubule 
stabilisation, resulting in reduced pathology. For example, amyloid plaque pathology may be 
hindered by microtubule stabilisation, as APP is transported along microtubules in the same 
compartment as its cleaving enzymes (Kamal et al., 2001), and that loss of microtubules may 
cause altered processing of APP, leading to possible increased Ab production (Busciglio et 
al., 1995). Therefore, stabilisation of microtubules with taxanes or epothilones could 
potentially alter APP processing by preventing microtubule depolymerisation. Epothilone D 
has increased microtubule density in axons, decreased axonal dystrophy and reduced 
cognitive defects in a PS19 mouse model of frontotemporal lobar degeneration (Zhang et al., 
2012a). Tau acetylation leads to destabilisation of the axon initial segment cytoskeleton and 
leads to mis-localisation of tau to the somatodendritic compartment. The axon initial segment 
provides a barrier from the axon and the somatodendritic compartment and allows retention 
of axonal proteins. Cytoskeletal proteins Ankyrin G and βIV-spectrin, which are part of the 
axon initial segment, are reduced in AD and are associated with increased tau acetylation in 
tau transgenic mouse models. However, in primary neuronal cultures, epothilone D treatment 
restored the axon initial segment barrier function, preventing tau from being mis-localised 
(Sohn et al., 2016). Another type of microtubule-stabilising agent, NAPVSIPQ (Bassan et al., 
1999)  has been shown to reduce tau pathology and enhance cognitive function (Matsuoka et 
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al., 2008). Epothilones may also have an effect on mobility of glial cells, such as microglia, 
due to over-stabilisation of the cytoskeleton. One study demonstrated that epothilone B 
attenuated microglia activation through redistributing the cytoskeleton, causing 
morphological transition and suppressed expression of pro-inflammatory factors such as 
interleukin-1b and tumour necrosis factor-a (Yu et al., 2018). This suggests that epothilones 
may not alter mobility of microglia, but can have an effect on morphology. Epothilone D also 
had a similar effect in an in vitro model of multiple system atrophy. Epothilone D was shown 
to reduce microglial-mediated transport of alpha synuclein by inhibiting cytoskeletal 
dynamics (Valdinocci et al., 2018). 
 
 HDAC6 inhibitors 
Another microtubule-stabilising agent which has been postulated as a therapeutic is 
trichostatin A (Simões-Pires et al., 2013). Trichostatin A inhibits the de-acetylating enzyme 
HDAC6, responsible for deacetylation, therefore promoting acetylation (Liu et al., 2015a). 
Research has shown that HDAC6 inhibition by use of trichostatin A or tubastatin A in 
neurodegenerative mouse models, have rescued axonal transport and locomotor deficits 
(Benoy et al., 2018; Godena et al., 2014)  and neurite outgrowth (Hasan et al., 2013). Several 
HDAC6 inhibitors such as tubastatin A and tubacin have been used as a treatment in various 
diseases, including Japanese encephalitis virus (Lu et al., 2017), lymphoproliferative disease 
(Cosenza and Pozzi, 2018) and Charcot-Marie-Tooth disease (Benoy et al., 2018). Axonal 
transport has been shown to be restored after treatment with trichostatin A (Godena et al., 
2014). In an APP/PS1 mouse model, with a knock-out of HDAC6, Aβ-induced deficits in 
mitochondrial trafficking were rescued (Govindarajan et al., 2013).   
 
 PP2A agonists 
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Sodium selenate is an agonist to PP2A, enhancing phosphatase activity. Serine/threonine-
specific PP2A is a major phosphatase implicated in tau dephosphorylation and is reduced in 
protein and mRNA levels and activity in the AD brain (van Eersel et al., 2010; Vogelsberg-
Ragaglia et al., 2001). Altered expression of PP2A is also correlated with AD pathology 
(Sontag and Sontag, 2014). Sodium selenate acts upon the phosphatase, thereby stabilising 
the tau-PP2A complex, and reducing hyperphosphorylated tau (Shultz et al., 2015). In a 
tauopathy mouse model, mice treated with sodium selenate had reduced levels of both 
phosphorylated tau and total tau levels in both the hippocampus and amygdala compared with 
controls (Corcoran et al., 2010). The TAU441 mice also exhibited significantly improved 
spatial learning and memory. Sodium selenate is currently undergoing a Phase II clinical trial 
for mild-moderate AD (Malpas et al., 2016). More recently, sodium selenate has been used 
to treat hyperexcitability in mouse models of Lafora disease, where some motor and memory 
deficits were ameliorated and neurodegeneration and the glial response were reduced 
(Sánchez-Elexpuru et al., 2017). Other AD pathology has been reduced with sodium selenate 
treatment, where in a 3xTg-AD mouse model, sodium selenate repressed amyloid beta 
formation, via the Wnt/β-catenin signalling pathway (Jin et al., 2017). 
 
Developing microtubule-modifying drugs as therapeutics for neurodegenerative 
disease 
Microtubule stabilisation has been successful in treating many forms of cancer, as it causes 
cell cycle arrest at G2/M transition phase (Fanale et al., 2015; Rohrer Bley et al., 2013; Zhao 
et al., 2016). Microtubule stabilisation as a therapeutic has undergone many phase I and II 
clinical trials to treat solid tumours, lymphoma, malignancies, metastatic prostate cancer and 
advanced colorectal cancer. (Beer et al., 2007; Eng et al., 2004; Holen et al., 2004; Konner et 
al., 2012; Rubin et al., 2005; Spriggs et al., 2003).  
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Although these studies suggest that microtubule stabilisation with taxol, epothilone D or 
trichostatin A may be protective in a number of conditions, the use of taxol and epothilones 
as anti-cancer drugs has shown adverse side effects such as neutropenia, fatigue, nausea, 
dizziness as well as abdominal pain, when high doses of epothilone D were administered 
(Bedard et al., 2010; Holen et al., 2004). In addition, administration of these drugs can cause 
peripheral neuropathy. Most doses required to cause cell cycle arrest in cancer are 
approximately 100 mg/m2 weekly, however these doses are considered to be relatively high 
compared to only a low dose needed for neurodegenerative disease (Cartelli et al., 2013; 
Ruschel et al., 2015). A number of clinical studies using epothilone as a microtubule-
stabilising drug have demonstrated that these toxic effects are dose-dependent and when used 
at a lower dosage, the side effects are minimised (Fumoleau et al., 2007). Importantly, the 
concentrations of taxol or epothilone required to stabilise microtubules in axons or to promote 
axon regeneration are much lower than those required to prevent division of cancer cells 
(Brunden et al., 2012).  
 
 
1.9 PROJECT SUMMARY AND AIMS  
Microtubules are a key modifiable structural component of the neuron, essential to their many 
functions. Alteration to microtubules and associated proteins have been implicated in a 
number of neurodegenerative diseases and linked to neurodegeneration and neuronal 
dysfunction, particularly that relating to the axon. Modifying microtubules has been 
postulated as a therapeutic target, particularly in AD, which currently has no effective 
treatment. In this regard, clinical trials that reduced pathological features of AD such as 
amyloid deposition have been unable to reduce clinical symptoms. A key feature of many 
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neurodegenerative diseases is axon degeneration or the breakdown of axons following 
pathological insult such as excitotoxicity. Axonal transport impairment can lead to axon 
degeneration and previous research has shown that stabilising microtubules may protect 
against axon fragmentation following pathological insult, suggesting microtubules may be an 
important target for therapeutic intervention of axon degeneration. Furthermore, microtubule 
alterations, such as those occurring in AD through tau abnormalities, may lead to axonal loss 
and neurodegeneration (Roy et al., 2005; Stokin and Goldstein, 2006; Trojanowski et al., 
2005) and that axon transport failure may be a primary mechanism in AD (Stokin et al., 2005).  
Although microtubule alterations have been implicated in disease and postulated as a 
therapeutic target, limited research has focused on defining the alterations to microtubules 
that need to be targeted in disease. Furthermore, since modifying microtubules is likely to 
have downstream effects on cellular processes, it is important to determine their capacity to 
protect cellular structures but also to alter other pathological features of disease such as the 
amyloid plaques of AD. This thesis seeks to increase understanding of microtubule alterations 
following pathological insults, specifically excitotoxicity, and the effect of the microtubule-
stabilising drug epothilone D on the amyloid-related alterations in the AD brain.  
 
 
Aim 1:  To determine in vivo if the microtubule-stabilising agent epothilone D 
could be a viable therapy for AD 
 
The role of microtubules in AD has been previously explored, however, most microtubule-
based strategies have been limited to determining the effect in tauopathy mouse models. The 
effects on other AD-based pathology including amyloid plaques, dystrophic neurons and 
synapses has not been determined. Epothilone D is a microtubule-stabilising drug that crosses 
the blood brain barrier, increases microtubule density, and has been trialled in humans, 
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although the human AD trial was terminated. Therefore, the first aim was to explore the effect 
of epothilone D in an amyloid mouse model of AD to determine if microtubule stabilisation 
can affect AD pathology.  
 
 
Aim 2:  To determine alterations to microtubule PTMs in neurons and their axons 
following kainic acid-induced excitotoxicity in vitro and investigate 
whether inhibiting these alterations prevents axon degeneration 
 
Microtubule alterations have been described during axon degeneration, however the exact 
alterations to microtubules are relatively unknown. By modelling axon degeneration with an 
excitotoxic insult such as kainic acid, applied to primary cultured rodent neurons, microtubule 
alterations during excitotoxicity can be examined. Therefore, the second aim was to 
determine which PTMs are altered during kainic acid-induced axon degeneration in primary 
mouse cortical neurons. To determine microtubules alterations, specifically in axons, a 
compartmentalised microfluidic chamber was used to separate axons from the 
somatodendritic compartment and allow compartmented treatments and protein harvest. 
 
 
Aim 3:  To determine alterations to MAPs in neurons and their axons following 
kainic acid-induced excitotoxicity in vitro and investigate whether 
inhibiting MAP phosphorylation prevents axon degeneration  
 
MAPs which bind to microtubules can modify their function and alterations to MAPs have 
the capacity to promote axonal stability or destruction. MAP binding to microtubules can also 
be influenced by microtubule PTMs and microtubule-stabilising drugs. Therefore, the third 
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aim was to determine whether MAPs are altered during axon degeneration, or if 
dephosphorylation of MAPs prevents axon degeneration, potentially through stabilising the 
microtubule network. As in aims 2, primary cortical neuron cultures grown in compartmented 
microfluidic chambers were used to determine changes to MAPs.  
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2  METHODS 
2.1 MICE 
All experiments and procedures were approved by the University of Tasmania Animal Ethics 
Committee and were in accordance with the Australian Guidelines for the Care and Use of 
Animals for Scientific Purposes under the ethics A13471 and A16041 for the 12-month-old 
APP/PS1 mice cohort experiments, and ethics A12780, A15121 and A17530 for cell culture 
experiments. All experimental procedures utilised male (for APP/PS1 cohort experiments) or 
female (for cell culture experiments) mice. Male APPSWE/PS1dE9 (APP/PS1) on a C57BL/6 
background (Jankowsky et al., 2001) and wildtype littermates mice were used in the first 
study of this thesis. Differences between male and female mice on the B6 congenic line have 
been reported, as males have been shown to develop amyloid plaques more rapidly than 
females (Ordóñez-Gutiérrez et al., 2015), therefore only male mice were used in this study. 
Mice were housed in optiMICE cages with a minimum of 3 mice in a cage on a 12-hour light 
cycle and had access to food ad libitum. Mice were provided with minimal enrichment 
consisting of an igloo, tissue and a stick. 
 
 
2.2 IN VIVO EPOTHILONE D TREATMENT 
Epothilone D (AbCam, ab143616, Lot#APN14287-1-1) treatment was prepared in 100% 
DMSO (Sigma Aldrich, D4540, Lot#RNBF1056) to a stock of 10 mgmL-1 and vehicle was 
100% DMSO and diluted to a working stock of 1 mgmL-1. Twelve-month-old APPSWE/PS1dE9 
(Jankowsky et al., 2001) mice and wildtype littermates received weekly treatment of 2 mg/kg 
epothilone D (as previously shown by Brunden et al., 2010) of either epothilone D or vehicle 
(5% DMSO) delivered by intraperitoneal (IP) injection for 12 weeks. The maximum volume 
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delivered IP was 70 µL. Behavioural testing was performed post-treatment. Mice had weight 
monitored weekly to assess any detrimental health effects.  
 
 
2.3 BEHAVIOURAL TESTING 
Epothilone D used in cancer trials can have detrimental effects on health (Argyriou et al., 
2011; Konner et al., 2012). Therefore, mice were weighed weekly from 12 months old and 
behavioural testing was performed at 15-months of age to assess short-term memory, anxiety 
and movement of mice at 15-months of age. The following tests were used; open field, 
spontaneous Y-maze, Barnes maze and marble burying, with the distance and velocity 
travelled also being recorded (n = 9=10 mice per group). All tests except the marble burying 
test were analysed using EthoVision XT (Noldus). Each test was performed in the same 
position in the room with black opaque curtains surrounding the testing area for the duration 
of the test, under 200 lux lighting conditions. 
 
2.3.1 Habituation 
Habituation was performed a week prior to starting behavioural testing. Habituation involved 
placing mice in their home cages in the behaviour testing room for one hour in the same 
lighting conditions as testing conditions. Habituation was performed for five consecutive 
days. 
 
2.3.2 Marble burying 
The marble burying test was used to measure anxiety as mice should want to bury foreign 
objects. In this study, marble burying was examined as a behavioural measure as differences 
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in marble burying have been recorded in APP/PS1 mice (Kim et al., 2012; Koivisto et al., 
2016). Mice were placed in an OptiMICE cage with 5cm deep bedding and 6 evenly-spaced 
marbles. Mice were allowed to explore the cage for 30 minutes. After this time mice were 
removed and an image was acquired from above and from the side. From the images, the 
number of marbles that were at least 75% buried were recorded (Figure 2.1; (Angoa-pérez et 
al., 2013; Deacon, 2006). 
 
2.3.3 Open field  
An open field test is used to measure general movement and anxiety of mice, which aids in 
analysing performance on other behavioural and cognitive tests. Mice were allowed to 
explore a square box (30cm x 30cm) for 10 minutes and were recorded from a camera position 
above the box, under 200 lux lighting conditions. As mice have an aversion to open areas, the 
amount of time a mouse spends in the centre of the box relative to the outside of the box was 
calculated as a measure of anxiety (Figure 2.1; Brownlow et al., 2013; Ferguson et al., 2013). 
 
2.3.4 Spontaneous alternation Y maze 
Due to rodent’s natural instinct to explore new areas, the Y-maze was used to assess short-
term spatial memory in APP/PS1 and wildtype littermates. The Y-maze was situated in dim 
lighting conditions (200 lux) surrounded by black curtains to control for different spatial cues. 
The arms of the Y-maze measured 75 mm x 400 mm. Mice were placed in the centre and 
allowed explore the Y-maze for eight minutes, where mice rely on their ability to remember 
which arm they have explored immediately before and should therefore alternate exploring 
arms. Mice were recorded from above and the order of the arms that the mice entered were 
recorded and analysed (Figure 2.1; Miedel et al., 2017). The percentage of spontaneous 
alteration entries was calculated by:  
x1 trial 
30 mins
MARBLE BURYING
OPEN FIELD
30 cm
30
 c
m x1 trial 
10 mins
SPONTANEOUS Y MAZE
30 c
m
30
 c
m
30 cm
x1 trial 
8 mins
A
B
C
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Figure 2.1 Marble burying, open field and spontaneous alternation Y maze 
paradigms 
 
(A) The marble burying test was performed in OptiMICE cages with 5cm of fresh bedding in 
the bottom of the cage. Six marbles were placed evenly within the cage and the mice were 
places into the cage with the marbles. The cage was placed behind black opaque curtains 
which surrounded the cages, under 200 lux lighting conditions. The mice were left in the cage 
for 30 minutes. (B) The open field test arena is a 30cm x 30cm white box, with black opaque 
curtains surrounding the arena. The test was performed for 10 minutes in 200 lux lighting 
conditions. (C) The Y maze test arena was a 30cm long, 10cm wide, and 15cm deep white 
box in a Y shape. Each test was performed for 8 minutes behind black opaque curtains under 
200 lux lighting conditions. 
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Where, the number of triads = total entries -2, and the alternations are scored as a triad (set 
of three numbers) containing all three numbers (arm 1, arm 2 and arm 3).  
 
2.3.5 Barnes maze 
This test measures long-term memory over a period of five days. The Barnes maze arena was 
set up with curtains surrounding the testing area as described above. Images of a square, 
circle, arrow and triangle were attached to the curtains around the edge. The initial stages of 
this test are the training phases, which is followed by the testing phase. For training: on day 
one, mice were allowed three minutes on the Barnes Maze and shown the escape box at the 
end of the trial. On day two, mice had three trials on the Barnes Maze where they were 
allowed to explore the maze until they found the escape box or until three minutes had passed, 
at which stage the mice were showed the escape box. On day three, mice had two trials on 
the Barnes Maze. On day four, mice were not tested. For testing: day five was the test day 
where mice had one trial on the Barnes Maze for three minutes. The time until mice entered 
the escape box and the time spent in the quadrant of the escape box were measured (Figure 
2.2, 2.5; Pitts, 2018; Rosenfeld and Ferguson, 2014).  
 
 
2.4 TISSUE PREPARATION 
Following treatment, mice were terminally anaesthetised with sodium pentobarbitone (140 
mg/kg) and transcardially perfused with 4% paraformaldehyde (PFA) for histochemical  
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Figure 2.2 Barnes maze paradigm 
 
(A) Barnes maze set up: The Barnes maze test arena was a white 100cm diameter circular 
platform with X holes, one of which contained the escape hatch. The platform was placed 
behind black opaque curtains and maintained under 200 lux lighting conditions. Visual cues 
(arrow, triangle, circle and square) were printed on A4 paper and attached to the curtains 
every 90º around the Barnes maze. (B) Trial parameters used: The training phase was 
performed from day one to day three with a rest day was on day four of testing. Day five was 
the probe trial testing day, where only one trial was performed. Each trial lasted either for 
three minutes, or until the mouse had entered the escape box.  
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analysis or with 0.01 M PBS for Western blot analysis. Brains were post-fixed overnight in 
PFA at 4ºC for 24 hours and stored in PBS azide (0.02% sodium azide in 0.01 M PBS) for 
histological analysis or snap frozen in liquid nitrogen for biochemical analysis. For Western 
blot analysis, brains were immediately dissected into cortex, hippocampus, and rest of brain 
and were snap frozen in liquid nitrogen and stored at -80ºC prior to use. 
 
 Tissue preparation for histochemical analysis 
Prior to sectioning, brains were cryoprotected through sequential treatment in 18% sucrose 
and 30% sucrose (in 0.01 M PBS azide) for 24 hours each. For analysis, tissue was serially 
sectioned on a coronal plane at 40 µm at -15ºC on a cryostat from bregma 2 to -3 for analysis 
(Figure 2.3).  
 
Tissue preparation for biochemical analysis (details of protein extraction and 
measurement) 
Frozen brain tissue was transferred into 350 µL of RIPA buffer (Sigma Aldrich) containing 
protease (cOmpleteTM Mini Protease Inhibitor Cocktail tablets, Roche) and phosphatase 
inhibitors (Phosphatase Inhibitor Cocktail, A.G. Scientific) and homogenised using an 
UltraTurrax. Homogenates were mixed for 30 minutes at 4ºC followed by centrifugation at 
13,000 rpm for 20 minutes at 4ºC. The supernatant was transferred to a clean eppendorf tube 
and the pellet discarded. Protein concentration was determined using a Bradford assay as per 
the manufacturer’s protocol (BioRad Protein Assay, BioRad). Protein samples were stored at 
-80ºC.   
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Figure 2.3 Coronal sections used from bregma 1.18 to -2.06 
 
(A) Schematic to show coronal sections used for immunohistochemical analysis from bregma 
1.18 to -2.06. 
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2.5 IMMUNOHISTOCHEMISTRY 
2.5.1 Indirect fluorescent immunohistochemistry 
Brain sections were mounted onto slides, prior to being washed three times with tris-buffered 
saline (TBS-T; 0.3% Triton X, Sigma Aldrich) at 10-minute intervals at room temperature.  
Sections were blocked for 1 hour in 10% horse serum (Sigma Aldrich) in TBS-T, followed 
by overnight incubation with combinations of mouse monoclonal and rabbit polyclonal 
primary antibodies (See Table 2.1) diluted in 1% horse serum in TBS-T at 4ºC. Sections were 
washed in TBS-T and incubated with species and isotype specific fluorescent secondary 
antibodies (See Table 2.2) diluted at 1:500 in 1% horse serum in TBS-T for 2 hours. Sections 
were washed in TBS-T followed by DAPI (1:10,000) staining for 5 minutes to stain nuclei. 
Finally, the sections were washed in TBS before slides were coverslipped with immu-
mounting medium (Thermo Scientific).  
 
2.5.2 Thioflavin-S staining 
Thioflavin S (Sigma Aldrich) staining was used to determine Aβ plaque load, which labels 
fibrillar and dense-core plaques composed of Aβ with a β-pleated sheet confirmation. Brain 
sections were mounted onto slides prior to incubation in thioflavin S solution (0.125% 
thioflavin S in 60% absolute ethanol and 40% 0.01 M TBS) for 5 minutes at room 
temperature. Sections were then washed twice in 50%/50% absolute ethanol/0.01 M TBS for 
1 minute each followed by 3 10-minute washes in 0.01 M TBS. Immunohistochemistry was 
then performed as above.  
 
2.5.3 Confocal microscopy  
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Confocal images were taken on a spinning disk confocal Nikon TE- 2000 inverted microscope 
with a Yokagawa CSU-22 confocal scanning unit and a Hamamatsu C9100-02 EMCCD 
camera with a 40x objective using Velocity (PerkinElmer) software for image capture.  
 
2.5.4 Dystrophic neurite population quantitative analysis  
To quantitate the dystrophic neurite load surrounding individual plaques in APP/PS1 
epothilone D and vehicle-treated mice (n=7-8 per group), two coronal sections were 
immunolabelled with an antibody against phosphorylated neurofilament protein (SMI312), 
which labels distinct populations of dystrophic neurites, and stained with thioflavin S to label 
fibrillar plaques. Dystrophic neurites images were imaged using a spinning disk confocal 
microscope at 40x objective. Plaques were randomly selected between layers II – V in the 
cortex using the following criteria: between 10 µm – 30 µm in diameter, single plaques (not 
multilobed). A total of 10 isolated plaques per section were selected from layers 2, 3 or 4 of 
the cortex. Using Adobe Illustrator, 40 µm was measured from the edge of the plaque, to 
determine the region of interest, where the number, the average size and the dystrophic neurite 
load was measured (Figure 2.4 A). The dystrophic neurite load was determined by the 
following: 
 	
781&#,9ℎ+$	%";#+&"	*,'2 = 	 .&ℎ"	&,&'*	'#"'	,0	&ℎ"	281&#,9ℎ+$	%";#+&"1&ℎ"	&,&'*	'#"'	,0	&ℎ"	#"(+,%	,0	+%&"#"1& 3 	× 	100 
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Table 2.1  Primary antibodies 
Name Species 
Immunogen / 
Immunoreactivity 
Application Concentration Company 
Catalogue 
Number 
GAPDH M 
IgG1 
Glyceraldehyde-3-
phosphate dehydrogenase 
WB 1:5000 Millipore MAB374 
       
SMI312 M 
IgG1 
 
Phosphorylated 
neurofilament / axons 
 
IHC 
WB 
 
1:1000 
1:2000 
 
Covance SMI312R 
Synaptophysin R 
 
Synaptophysin / pre-
synaptic vesicle marker 
 
IHC 
WB 
1:200 
1:1000 
Millipore AB9272 
VGLUT1 M 
IgG1 
 
Anti-Vesicular Glutamate 
Transporter 1  
 
WB 1:1000 Millipore MAB5502 
Acetylated 
Tubulin 
M 
IgG2b 
 
 
Acetylated tubulin IHC 
WB 
ELISA 
1:1000 
1:1000 
1:1000 
Sigma 
Aldrich 
T7451 
Tyrosinated 
Tubulin 
 
R KLH-conjugated linear 
peptide corresponding to 
human tyrosinated alpha 
tubulin 
ELISA 
 
 
 
 
1:1000 Millipore ABT171 
       
MAP1B M 
IgG1 
Neuronal marker, MAP1B ELISA 1:1000 Abcam AB3095 
       
MAP2 M Clone AP20 ELISA 1:1000 Millipore MAB3418 
 IgG1  IHC 
WB 
1:500   
       
Iba1 R Ionised calcium binding 
adaptor molecule 1 / labels 
microglia 
IHC 1:1000 WAKO 019-19741 
       
 
M = mouse, R = rabbit, IHC = immunohistochemistry, WB = Western blotting 
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Table 2.2  Secondary antibodies for immunohistochemistry 
Emission 
(nm) 
Reactivity Species Concentration Company Catalogue Number 
Alexa 488 M 
IgG1 
 
G 
 
1:1000 Molecular 
Probes 
A-21121 
Alexa 594 M 
IgG 
 
G 
 
1:1000 Molecular 
Probes 
A-32742 
Alexa 488 R 
IgG 
 
G 1:1000 Molecular 
Probes 
A-11034 
Alexa 594 R 
IgG 
 
G 
 
1:1000 Molecular 
Probes 
A-11037 
M = mouse, R = rabbit, G = goat 
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2.5.5 Synapse quantitation 
Alterations in synaptic boutons were examined by immunolabelling coronal tissue sections 
from vehicle-treated APP/PS1 and wildtype mice with an antibody against synaptophysin, 
which is a presynaptic protein present at the majority of synapses and frequently used in 
synapse quantitation (Fernandez-Martos et al., 2015). Immunolabelling was performed in 
three coronal sections per mouse. To quantitate synaptic puncta, 10 random evenly-spaced 
areas were selected throughout the neocortex from the rhinal fissure to the midline, from 
layers 2-5. During imaging, the researcher was blinded to genotype of the tissue. From these 
images, synaptic bouton density and the number of synapses was measured. 
 
Previous studies suggest that synaptic puncta are reduced around plaques in APP/PS1 mice 
(Fernandez-Martos et al., 2015). Plaque-associated synaptic puncta were quantitated for 10 
plaques per section from 3 coronal sections per mouse. Plaques sized 10 µm – 30 µm were 
imaged throughout the neocortex to measure synaptic bouton density. A mask was made to 
determine the region of interest. The number of synapses per plaque, bouton size and density 
within 40 µm distance from the edge of the plaque was quantitated (Figure 2.4 B). 
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Figure 2.4 Analysis methods of dystrophic neurites, synapses and plaques 
 
Representative images to show analysis of (A) dystrophic neurites was performed from 
plaques sized 10 nm – 30 nm. Dystrophic neurites were assessed from the edge of the plaque 
to a 40 µm region from the edge. Analysis of (B) synapses was performed from the edge of 
the plaque to a 40 µm region from the edge. Analysis of (C) plaque load from the midline of 
the cortex to the rhinal fissure. Scale bar for (A, B) = 30 µm. Scale bar for (C) = 400 µm. 
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2.5.6 Plaque load quantitative analysis 
Plaque load analysis was performed in 5 evenly spaced (approximately 800 µm – 1000 µm 
apart) 40 µm cortical sections, taken from bregma 2 to -3 from each animal (n=7-8 per group). 
Whole cortices were imaged using a spinning disk confocal microscope at 20x objective. 
Plaques were assessed in a region of interest from the midline of the cortex to the rhinal 
fissure (Figure 2.4 C). Images were taken from the midline to the rhinal fissure, as this enables 
the same area to be consistently imaged throughout the brain sections selected. Plaque stain 
signal intensities were classified using ImageSURF (O’Mara et al., 2018). The Random 
Forest Segmenter removes human bias from thresholding positive immunohistochemical 
signal. Classified images were then analysed in Fiji using the analyse particles function to 
quantitate plaque load from the midline to the rhinal fissure of the cortex. The number of 
plaques, the average size and the plaque load were calculated and recorded. The plaque load 
was determined by the following: 
 
!*'<;"	*,'2 = 	 . &ℎ"	&,&'*	'#"'	,0	&ℎ"	9*'<;"1&ℎ"	&,&'*	'#"'	,0	&ℎ"	#"(+,%	,0	+%&"#"1&3 	× 	100 
 
2.5.7 Microglia qualitative analysis 
Microglia were qualitatively assessed between genotype and treatment to determine if the 
glial response is altered during amyloidosis pathology and with epothilone D treatment. 
Immunolabelling with Iba1 for microglia was performed in four coronal sections per mouse. 
Specific regions throughout the cortex where blindly qualitatively compared for any 
difference between groups. In particular, sections from bregma 0.22 were used for qualitative 
assessment. 
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2.5.8 Microglia quantitative analysis 
Microglia were quantitatively assessed between genotype and treatment to determine if the 
glial response is altered during amyloidosis pathology and with epothilone D treatment. 
Immunolabelling with Iba1 for microglia was performed in three coronal sections per mouse. 
A specific region from the midline of the cortex to the rhinal fissure was investigated to 
determine microglia cell density. Positive immunohistochemical signal from images 
classified using the ImageSURF plugin in Fiji then analysed in using the analyse particles 
function to quantitate microglia cell density. The microglia cell density was determined by 
the following: 
 
=+$#,(*+'	$"**	2"%1+&8 = 	 . &ℎ"	&,&'*	'#"'	,0	&ℎ"	>+$#,(*+'&ℎ"	&,&'*	'#"'	,0	&ℎ"	#"(+,%	,0	+%&"#"1&3 	× 	100 
 
 
2.6 WESTERN BLOT 
Semi-quantitatively Western blot analysis was performed to determine the level of proteins 
in APP/PS1 mice and wildtype littermates with either epothilone D or vehicle treatment.  
 
2.6.1 Gel electrophoresis and Western Blot 
Denatured protein samples (20µg for tissue and 25µg for cultured cells) were electrophoresed 
into Bolt® 4-12% Bis-Tris gels (Invitrogen), transferred to PVDF membrane (Bio-Rad). 
Membranes were probed overnight with primary antibodies (See Table 2.1) including anti-
synaptophysin (1:1000 rabbit, Millipore AB9272), anti-VGLUT (1:1000 mouse, Millipore 
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MAB5502) and anti-phosphorylated neurofilament protein (SMI312; 1:2000 mouse, 
Covance SMI312R). The corresponding anti-rabbit or anti-mouse horseradish peroxidase 
(HRP) conjugated secondary antibody (See Table 2.3; 1:7000, DAKO) was used as 
previously described (Fernandez-Martos et al., 2015). GAPDH (1:5000 mouse, Millipore 
MAB374) was used as a loading control. Bands were visualised with enhanced 
chemiluminescence (ECL) solution-Luminata Forte Western HRP substrate (Millipore) and 
images acquired with a Chemi-Smart 5000 Imaging System (Vilber Lourmat) equipped with 
Chemi-Capt 5000 software. Band intensity was measured as the integrated intensity using 
Fiji software. Each value was calculated as a percentage of the standard sample run between 
gels. Sample numbers were as documented in individual chapter results. 
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Table 2.3  Secondary antibodies for Western blotting 
Name Reactivity Species Concentration Company Catalogue Number 
Anti-Mouse 
Immunoglobulins/HRP 
M 
 
 
G 
 
1:7000 DAKO P044701-2 
Anti-Rabbit 
Immunoglobulins/HRP 
R 
 
 
G 
 
1:7000 DAKO  P044801-2 
M = mouse, R = rabbit, G = goat 
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2.7 CELL CULTURE 
2.7.1 Microfluidic chamber and culture tray preparation 
For experiments probing axons specifically, neurons were grown in compartmented 
microfluidic chambers (Figure 2.5; 450 µm long, 10 µm wide and 3 µm high barrier grooves, 
Xona Microfluidics), which allows fluidic isolation of cells from the axon (Taylor et al., 
2006). For other experiments, neurons were grown directly in 24-well culture trays. 
Microfluidic chambers were sterilised in 70% ethanol for 10 minutes and allowed to dry under 
sterile conditions. Chambers were attached to sterile 22mm2 coverslips. Culture wells and 
microfluidic chambers were treated with 5% poly-L-lysine (Sigma Aldrich) in Hank’s 
Balanced Salt Solution (HBSS) overnight. Poly-L-lysine was removed and replaced with an 
initial neuron plating media consisting of neurobasal medium (Gibco), 2% B27 supplement 
(Gibco), 10% fetal calf serum (Gibco), 0.5 mM glutamine, 25 mM glutamate and 1% 
antibiotic/antimycotic (Gibco). Chambers and culture trays were incubated at 37ºC prior to 
plating of the neurons. 
 
2.7.2 Cortical primary cell culture 
Mouse cortical neuron cultures were prepared as previously described (King et al., 2013). 
Neocortical tissue was dissected from C57Bl/6 embryonic day 15.5 (E15.5) mouse embryos. 
Heads were kept on ice during dissection to prevent tissue degradation. Cortices were 
removed using a dissecting microscope (Leica), dissociated from the meningeal layers and 
transferred to 5 mL Hanks Balanced Salt Solution (HBSS, Gibco). Tissue was incubated with  
  
Taxol
Trichostatin A
Sodium Selenate
Kainic Acid
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Figure 2.5 Compartmentalised treatment in microfluidic chamber  
 
(A) Schematic to show design of the microfluidic chambers used in this thesis. The two 
compartments (axonal and somal) are separated by microgrooves (450 µm long, 10 µm wide 
and 3 µm high, Xona Microfluidics), which allows fluidic isolation of cells from the axon. 
Treatments such as taxol, trichostatin A and sodium selenate were added to the axonal 
compartment, whereas kainic acid was added to the somatodendritic compartment, so the 
axon remains unexposed to the excitotoxin. 
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0.0125% trypsin in HBSS for 4 minutes at 37ºC followed by removal of HBSS and replaced 
with 1 mL of initial plating media (Neurobasal media (Gibco) containing 2% B27 
supplement, 0.5 mM glutamine, 25 µM glutamate, 10% fetal calf serum and 1% 
antibiotic/antimycotic. Cell viability and density was assessed using a trypan blue exclusion 
assay. For microfluidic chamber cultures, initial plating media was removed from the wells 
of chambers and 20 µL of cells (2x105 cells/mL) were plated onto one side of the microfluidic 
chamber. Cells were allowed to adhere to the coverslip surface for 30 minutes prior to filling 
chambers with initial plating media. For tray-only cultures, 2x105 cells/mL were loaded into 
wells with previously loaded initial plating media and gently shaken to evenly distribute cells. 
Cells were incubated at 37ºC overnight before removal of initial media and replacement with 
subsequent plating media, with no fetal calf serum and glutamate. Cells were grown for 10 
days in vitro (DIV) at 37ºC in 5% CO2, a timepoint which corresponds to dense axonal growth 
in the axon compartment of microfluidic chambers (Hosie et al., 2012; Millet and Gillette, 
2012). 
 
At 1-day in vitro initial plating media was removed and replaced with subsequent plating 
media, with no fetal calf serum and glutamate. Cells were grown for 10 days at 37ºC before 
being fixed with 4% paraformaldehyde in fume hood and agitated for 30 minutes at room 
temperature.  
 
2.7.3 Western blotting and ELISA protein extraction 
For Western blotting and ELISA analysis, cells were harvested from both microfluidic 
chambers and culture wells. Culture media was removed and cells were rinsed with cold 
HBSS. Cells were harvested using RIPA buffer with protease (cOmpleteTM Mini Protease 
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Inhibitor Cocktail tablets, Roche) and phosphatase inhibitors (Phosphatase Inhibitor Cocktail, 
A.G. Scientific). For culture wells, cells were collected using a cell scraper (Falcon) and 
transferred to an eppendorf tube. For chambers axons were harvested from the axon chamber 
by using RIPA buffer as stated above, where axons were pooled from 2-4 chambers per 
treatment. Once collected, tubes were mixed on a shaker for 30 minutes at 4ºC before being 
centrifuged at 4ºC for 15 minutes at 13,000 rpm. Supernatant was transferred to new 
eppendorf tube and stored at -80ºC until further use. 
 
 
2.8 IN VITRO MODEL OF EXCITOTOXICITY 
2.8.1 Pharmacological manipulation and excitotoxic modelling 
To model excitotoxicity in vitro neurons in either microfluidic chambers or growing in culture 
wells were with 0 µM, 10 µM, 25 µM, 35 µM, 50 µM and 100 µM of kainic acid (Sigma 
Aldrich, K0250, Lot#SLBD1491V) or vehicle (DMSO; Sigma Aldrich, Lot#RNBF1056) for 
0.5 hours, 1 hour, 3 hours, 6 hours and 18 hours. Kainic acid was added directly to the culture 
wells or to the somatodendritic side of the chambers. The microtubule-stabilising agent taxol 
(Calbiochem, 580556, Lot#B66835) was prepared in DMSO and used at 10 ngmL-1 and 100 
ngmL-1 and added to the axonal compartment of chambers. To alter microtubule acetylation, 
trichostatin A (TSA; Sigma Aldrich, T8552, Lot#026M4036V) was used to inhibit de-
acetylating enzyme HDAC6. TSA was diluted in DMSO and added to the axonal 
compartment of chambers or directly to the culture wells. To dephosphorylate microtubule-
associated proteins, sodium selenate was used at 100 µM (Sigma Aldrich, 288675, 
Lot#BCBT2170) dissolved in DMSO and was added to the axonal compartment of chambers.  
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2.8.2 Cell viability assay 
Cell viability was assessed using alamarBlue® viability assay (Bio-Rad), which is a 
resazurin-based solution which is a non-toxic, cell permeable compound. Living cells reduce 
resazuring to resorufin, which is red in colour and highly fluorescent, where changes are 
detected by either absorbance (detected at 570 and 600 nm) or fluorescence (using an 
excitation between 530–560 and an emission at 590 nm). Cells were incubated with 10% 
alamarBlue® in subsequent media for 2 hours in dark at 37ºC. 50 µL of alamarBlue® in 
subsequent media was removed and added to a 96-well flat-bottomed plate. Plate fluorescence 
was read at excitation 570 nm and emission at 585 nm. Viability was determined as a 
percentage of untreated control cells.  
 
2.8.3 Live-imaging of microfluidic chambers and quantification of axon degeneration in 
vitro 
To determine the amount of axon fragmentation and loss following treatments, microfluidic 
cultures were imaged on a Nikon TiE live cell microscope, with chambers maintained at 37ºC. 
Imaging was performed from the axon side of microfluidic chambers both prior to any 
treatment and 18h following treatment to allow analysis of axonal changes. Images were 
acquired using 40× objective lens over the axonal side of the chamber. A quantitative measure 
of axonal degeneration was obtained from five random regions of interest (200 × 200 μm) in 
the axonal chamber, at least 40 μm away from the microgrooves. Identical regions were 
imaged before and after treatment. Axons were scored as degenerating by a blinded observer 
(criteria used: axons must be able to be identified isolated from any bundles that are present 
and must display fragmenting with at least three sections missing along the axon and/or 
contain two or more swellings along the axon). Axon degeneration was calculated by 
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counting degenerated axons. A degeneration index (DI) was determined by the following 
equation.  
 
?@ = A BCDEFG	HIJIFIKCLIH	MINEKICDEFG	HIJIFIKCLIH	CNLIK OLELCP	FQRMIK	EN	CDEFGS × 	TUU 
 
The percentage degeneration refers to the percentage of axons the have degenerated after 
treatment, compared to the total number of axons before treatment.  Total numbers of axons 
in the images were also quantitated. The percentage degeneration refers to the percentage of 
axons the have degenerated after treatment, compared to the total number of axons before 
treatment. In these experiments, 35 µM, 50 µM, and 100 µM of kainic acid were also analysed 
in the cell culture using live-imaging, however the axons were too degenerated to be able to 
target therapeutically.  
   
2.8.4 ELISA to analyse cell culture samples 
Relative amounts of specific proteins were determined using ELISAs prepared in house. 
Extracted samples were centrifuged at 13,000 rpm for 1 minute. 50 µL of samples diluted at 
1:300 in coating buffer (approximately 4 µg of protein) were added to 96-well plate and 
incubated overnight at 4ºC in order to bind the protein to the well. For the standard curve, 
samples were serially diluted at 1:100, 1:200, 1:400, 1:800 and 1:1600 in coating buffer and 
50 µL was added to 96-well plate and incubated overnight at 4ºC. Plates were washed with 
washing buffer (0.05% tween-20, Sigma Aldrich; in 0.01 M PBS) 5 times and plates were 
dabbed onto paper towel in between each wash. 100 µL blocking buffer was added to each 
well and incubated at 37ºC for 30 minutes. Plates were washed 5 times with washing buffer. 
Detecting antibodies (See Table 2.1) were diluted in blocking buffer and 50 µL was added to 
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wells and incubated for 1 hour at room temperature. Plates were washed 5 times with washing 
buffer. 50 µL of species-specific HRP secondary antibody (See Table 2.3) was diluted in 
blocking buffer at 1:2000 and added to wells and incubated at room temperature for 45 
minutes. Plates were washed 5 times with washing buffer. 50 µL of room temperature 
tetramethylbenzidine (TMB) substrate was added to each well for 15 minutes. The reaction 
was stopped with 50 µL of 0.1 M H2SO4. Plate was read using a plate reader (SpectraMax 
Plus 384 Absorbance Reader, Molecular Devices) at 450 nm. Sample absorbance was 
averaged from each duplicate. A standard curve was produced from the serially diluted 
samples from the absorbance and protein concentration from a Bradford assay. Sample 
protein concentration was determined from the standard curve. An average from the control 
samples were obtained and expressed as 100% with samples expressed as a percentage of the 
control.  
 
2.8.5 Western blotting and ELISA protein extraction 
For Western blotting and ELISA analysis, cells were harvested from both microfluidic 
chambers and culture wells. Culture media was removed and cells were rinsed with cold 
HBSS. Cells were harvested using RIPA buffer with protease (cOmpleteTM Mini Protease 
Inhibitor Cocktail tablets, Roche) and phosphatase inhibitors (Phosphatase Inhibitor Cocktail, 
A.G. Scientific). For culture wells, cells were collected using a cell scraper (Falcon) and 
transferred to an eppendorf tube. For chambers axons were harvested from the axon chamber 
by using RIPA buffer as stated above, where axons were pooled from 2-4 chambers per 
treatment. Once collected, tubes were mixed on a shaker for 30 minutes at 4ºC before being 
centrifuged at 4ºC for 15 minutes at 13,000 rpm. Supernatant was transferred to new 
eppendorf tube and stored at -80ºC until further use. 
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2.8.6 Western blot to analyse cell culture sample 
Western blot was performed on cell culture samples as previously discussed in section 2.6.1. 
Briefly, membranes were incubated overnight with primary antibody acetylated tubulin 
(1:1000 mouse, Sigma Aldrich T7451). The corresponding goat anti-mouse HRP conjugated 
secondary antibody (1:7000, DAKO P0447) was used as previously described (King et al., 
2018). GAPDH (1:5000 mouse, Millipore MAB374) was used as a loading control.  
 
2.9 IMMUNOCYTOCHEMISTRY 
Cell cultures were fixed with 4% PFA for 30 minutes at room temperature. PFA was removed, 
cells rinsed with three washes of PBS and chambers were removed from coverslips. Fixed 
coverslips were incubated with PBS-T (0.3% triton-X100) diluent for 15 minutes with 
agitation. Primary antibodies were diluted in 0.01 M PBS and incubated overnight at 4ºC (See 
Table 2.1). Primary antibodies were removed and rinsed with three PBS washes. Secondary 
antibodies (See Table 2.2) were diluted in 0.01 M PBS for 2 hours at room temperature with 
agitation. Secondary antibodies were removed and rinsed with three PBS washes. Coverslips 
were mounted onto slides (Livingston International with mounting media; DAKO). 
 
2.10 STATISTICAL ANALYSIS 
Kolmogorov-Smirnov normality test was used to determine if the values from each group had 
a Gaussian distribution. Unpaired parametric t-tests were used to assess analysis between 
vehicle and epothilone D treated APP/PS1 tissue, and one-way ANOVAs using multiple 
comparison tests were used to compare treatment groups with the controls using GraphPad 
PRISM 6.0C. Differences for ELISA and axon degeneration counts were evaluated using 
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one-way ANOVA, with Tukey’s post-hoc test for multiple comparisons between groups. For 
kainic acid live-imaging experiments two coverslips from five separate culture days were 
analysed. For trichostatin A live-imaging experiments, 1-2 coverslips from four separate 
culture days were analysed. For whole cell kainic acid ELISAs, three coverslips per treatment 
from four separate culture days were used. For whole cell trichostatin A ELISAs, three 
coverslips per treatment from five separate culture days were used. For axon-only kainic acid 
ELISAs, cells were pooled from 2-3 chambers per treatment from four separate culture days. 
For axon-only trichostatin A ELISAs, cells were pooled from 2-3 chambers per treatment 
from five separate culture days. All statistical analysis and graphs were prepared in GraphPad 
Prism (v6.1). All analysis was performed with the researcher blinded to treatment and 
genotype. Values were reported as means ± standard error of the mean (SEM), with 
differences considered significant at p<0.05 Further details of statistical analysis are provided 
in results chapters. For details of n and statistical analysis for each result refer to Table 8.1, 
Table 8.2, Table 8.3. 
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3 THE EFFECT OF EPOTHILONE D ON AMYLOID AND AXONAL 
PATHOLOGY IN 12-15 MONTH-OLD APP/PS1 MICE 
3.1 INTRODUCTION 
3.1.1 Microtubules as a therapeutic target in AD 
Pathological alterations to the MAP tau are a key feature of AD and closely correlate with 
cognitive decline. Microtubules provide structural support to the axon and provide the tracks 
of axonal transport. Microtubule function relies heavily upon the dynamic ability to rapidly 
grow and shrink. It has been proposed that a loss of the normal function of tau, results in 
microtubule depolymerisation, impaired axonal transport and reduced axonal structural 
stability (Dubey et al., 2008; Mandelkow et al., 2003; Stamer et al., 2002). Thus, a potential 
strategy to maintain neuronal connectivity in AD is microtubule stabilisation through 
pharmacological manipulation (Trojanowski et al., 2005).  
 
3.1.2 Microtubule stabilisation drugs in neurodegenerative disease 
Microtubule-stabilising agents have been successfully used as a cancer treatments and many 
are FDA approved (Bollag et al., 1995; Fumoleau et al., 2007; Holen et al., 2004; Konner et 
al., 2012; Rubin et al., 2005). Microtubules have two major binding sites for drugs that 
stabilise microtubules; the taxol site and the laulimalide site (Zhao et al., 2016). Taxanes and 
epothilones are the two main classes of microtubule-stabilising drugs which bind to the taxane 
site (Nogales et al., 1995; Rao et al., 1999; Snyder et al., 2001). The blood brain barrier creates 
a major obstacle for treatment of neurodegenerative disease and must be considered in 
selecting therapeutics. Epothilone B and D in particular are known to cross the blood brain 
barrier (Brunden et al., 2010; Jang et al., 2016; Varidaki et al., 2018), suggesting that these 
stabilising agents have potential for treatment in neurodegenerative disease. Previous studies 
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have directly investigated the potential of  microtubule-stabilising drugs, including epothilone 
D, to reduce microtubule depolymerisation and rescue degeneration in tauopathy mouse 
models (Brunden et al., 2010; Cheng et al., 2008; Zhang et al., 2005, 2012a). Zhang and 
others found increased levels of acetylated tubulin, a marker of stable microtubules, after 
epothilone D administration in the PS19 tauopathy mouse model (Zhang et al., 2012a). 
Furthermore, they observed a significant decrease in axonal dystrophy and an increase in 
microtubule density in the optic nerve after epothilone D compared to vehicle treatment. 
These results also translated to improved cognitive performance in the Y maze and Barnes 
maze.  
 
In addition to tauopathy, microtubule stabilisation using taxanes or epothilones has been 
investigated as a therapeutic target in other disorders that involve axon degeneration. In 
particular, spinal cord injury is associated with several downstream neural mechanisms which 
ultimately lead to axon degeneration. Microtubule stabilisation has been shown to affect 
regeneration, axon degeneration, glial response after injury and dendritic spine plasticity 
(Dubey et al., 2015; Hellal et al., 2011; Ruschel et al., 2015; Sengottuvel and Fischer, 2011).   
 
3.1.3 Potential effects of microtubule stabilisation on AD pathology 
If microtubule stabilising drugs are to be investigated as a potential therapeutic in AD, we 
need to understand their effects on pathological disease processes. The link between Ab, the 
other key feature of AD, and microtubule stability has been established. According to the 
amyloid hypothesis, Ab alterations are proposed to drive alterations to microtubules, by tau-
independent (Pianu et al., 2014) and tau-dependent pathways (Gotz et al., 2001; King et al., 
2006; Lewis et al., 2001; Rapoport et al., 2002; Roberson et al., 2007). However, the effect 
of microtubule stabilisation on amyloid plaque deposition is unclear. Amyloid beta is derived 
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from the cleavage of APP, which is transported along microtubules in the same compartment 
as its cleaving enzymes (Kamal et al., 2001). It has been proposed that during axon 
degeneration and simultaneous microtubule breakdown that APP processing is altered, 
leading to possible increased Ab production (Busciglio et al., 1995). Therefore, stabilisation 
of microtubules with taxanes or epothilones could potentially alter APP processing by 
preventing microtubule depolymerisation.  
 
Dystrophic neurites have been identified at sites of microtubule disruption (Sadleir et al., 
2016). Microtubule stabilisation has potential to rescue dystrophic neurite pathology. 
Epothilone B has been shown to rescue neuritic dystrophy in MN9D cells after 6-hydroxyDA-
induced cytotoxicity in a culture model of Parkinson’s disease (Yu et al., 2018). In addition 
to amyloid and tau pathology, AD cases have substantial gliosis in the brain. In mouse models 
of amyloidosis, increased gliosis occurs by 6 months of age (Kamphuis et al., 2012). 
Microglia have also been observed to surround plaques, proposed as an attempt to block 
toxicity and clear plaques (Bolmont et al., 2008), however the interaction of astrocytes and 
plaques is still debated (Galea et al., 2015; Kraft et al., 2013; Lopez-Rodriguez et al., 2018; 
Perez-Nievas and Serrano-Pozo, 2018). The role of MAPs in glial activation and migration 
suggest that altering microtubules could affect these inflammatory processes (Hellal et al., 
2011).  
 
In summary, microtubule stabilisation has been investigated as a protective strategy against 
axon degeneration resulting from tau pathology, however, the effect of microtubule 
stabilisation on other pathological features of AD, such as amyloid deposition and glial 
activation, remain unclear. This is important to consider in investigating microtubule 
stabilisation as a therapeutic target for AD. In the current study, the effect of epothilone D, 
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used at concentrations shown in previous studies to affect axonal pathology, was investigated 
on AD pathology in a mouse model of amyloidosis. 
 
The mouse model used for this study was the APPSWE/PS1dE9 mouse model (Jankowsky et 
al., 2001). This model overexpresses humanised APP with the Swedish mutation, and PS1 
with a deletion in exon 9 of PS1 (both identified in familial AD cases), under the mouse prion 
protein promoter. This model develops amyloidosis, due to enhanced catalytic activity of APP 
by gamma secretase, which accelerates the deposition rate of Aβ, producing a higher ratio of 
Aβ-42 than the less toxic Aβ-40. By combining these mutations as a double transgenic mouse 
model, the pathology of AD is rapidly accelerated, allowing observation of changes to 
pathology within the mouse brain. The APPSWE/PS1dE9 mice used in this study develop 
amyloid plaques in the cortical and hippocampal regions of the brain from 4-6 months of age. 
Plaques are frequently surrounded by dystrophic neurites and a substantial glial response is 
present. Tau pathology is absent from this model allowing direct examination of the effect of 
amyloid on downstream pathological alterations. The effect of a weekly dose of 2 mg/kg 
epothilone D (Brunden et al., 2010) from 12-15 months of age, when substantial plaque 
pathology is present, was examined on amyloid plaques, as well as closely-related brain 
changes such as dystrophic neurites, astrocyte proliferation and cognition. This age group 
was chosen as it is representative of a treatment strategy occurring following diagnosis of 
AD.  
 
3.1.4 Study outline 
In the current study, an amyloidosis mouse model of AD, the APPSWE/PS1dE9 (Jankowsky et 
al., 2001), was used to examine the effect of a weekly dose of 2 mg/kg epothilone D at 12-
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months of age for 12 weeks. The effects of epothilone D on cognition, dystrophic neurites, 
synapse loss, amyloid deposition and inflammation were examined.  
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3.2 METHODS 
3.2.1 Ethics and mice 
Male APPSWE/PS1dE9 (APP/PS1) on a C57BL/6 background (Jankowsky et al., 2001) and 
wildtype littermates mice were used in this study (see section 2.1).  
 
3.2.2 Epothilone D treatment 
Epothilone D (AbCam Lot#APN14287-1-1) was dissolved in DMSO (Sigma Aldrich, 
Lot#RNBF1056) to a concentration of 100 mg/mL. Twelve-month old APP/PS1 and wildtype 
littermate controls received weekly treatment of either epothilone D or equivalent volume of 
DMSO vehicle treatment, intraperitoneally (IP) injected at 2 mg/kg dose (Brunden et al., 
2010) for 12 weeks (see section 2.2). 
 
3.2.3 Behavioural, cognitive and weight analysis 
Mice were weighed weekly from 12 months old and cognitive testing was performed at 15-
months of age. The following tests were used; open field, spontaneous Y-maze, Barnes maze 
and marble burying and were recorded using EthoVision XT (Noldus; see section 2.3).  
 
3.2.4 Tissue preparation 
Following epothilone D treatment, mice were terminally anaesthetised with sodium 
pentobarbitone (140 mg/kg) and were transcardially perfused with 0.1 M phosphate buffered 
saline (PBS) for Western blot analysis or with 4% paraformaldehyde (PFA) for histochemical 
analysis. Tissue was prepared for either molecular analysis or immunohistochemical analysis 
as outlined in Materials and Methods section 2.4. Amyloid plaque deposition, synaptic loss, 
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and dystrophic neurites were all analysed in cortical and hippocampal regions of brain tissue 
using methods outlined in section 2.5. 
   
3.2.5 Protein extraction for molecular analysis 
Protein extraction was performed as outlined in Material and Methods section 2.4. Briefly, 
snap-frozen cortical and hippocampal tissue were homogenised with an UltraTurrax using 
RIPA buffer with protease and phosphatase inhibitors. Protein concentration was determined 
using a Bradford assay as per the manufacturer’s protocol.  
 
3.2.6 Western blotting 
Methods are outlined in Materials and Methods section 2.6. Briefly, membranes were 
incubated overnight with primary antibodies, anti-synaptophysin (1:1000 rabbit, Millipore), 
anti-VGLUT (1:1000 mouse, Millipore) and anti-phosphorylated neurofilament protein 
(SMI312; 1:2000 mouse, Covance). Bands were visualised with enhanced 
chemiluminescence (ECL) solution-Luminata Forte Western horseradish peroxidase (HRP) 
substrate (Millipore) and images acquired with a Chemi-Smart 5000 Imaging System (Vilber 
Lourmat) equipped with Chemi-Capt 5000 software. Band intensity was measured as the 
integrated intensity using Fiji software. Each value was calculated as a percentage of the 
standard sample run between gels.  
 
3.2.7 Immunohistochemistry 
Immunohistochemical methods are outlined in Material and Methods section 2.5. For 
immunohistochemical analysis, sections were mounted on slides prior to washing with PBS 
and blocking with 10% horse serum. Tissue was incubated overnight with primary antibodies 
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(Table 2.1) in 0.3% triton-X100 followed by incubation with corresponding species-specific 
secondary antibodies (Table 2.2), in PBS for two hours in the dark. Slides were coverslipped 
with DAKO mounting media.  
 
3.2.8 Confocal microscopy  
Confocal images were taken on a spinning disk confocal Nikon TE- 2000 inverted microscope 
with a Yokagawa CSU-22 confocal scanning unit and a Hamamatsu C9100-02 EMCCD 
camera with a 40x objective using Velocity software for image capture.  
 
3.2.9 Plaque load quantitative analysis 
Whole cortices were imaged using a spinning disk confocal microscope at 20x objective. 
Plaque stain signal intensities were classified using ImageSURF (O’Mara et al., 2018). The 
number of plaques, the average size and the plaque load were calculated and recorded (see 
section 2.5.4). 
 
3.2.10 Dystrophic neurite quantitative analysis 
Dystrophic neurites images were captured using a spinning disk confocal microscope at 40x 
objective. Plaques were randomly selected between layers II – V in the cortex using the 
following criteria: between 10 µm – 30 µm in diameter, single plaques (not multilobed). The 
number, the average size and the dystrophic neurite load was measured (see section 2.5.5). 
 
3.2.11 Synapse quantitative analysis 
Alterations in synaptic boutons were examined by immunolabelling coronal tissue sections 
from vehicle-treated APP/PS1 and wildtype mice with an antibody against synaptophysin. 
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Immunolabelling was performed in three coronal sections per mouse. Synaptic bouton density 
and the number of synapses were measured. Synapses around plaques were also quantitated 
for the number of synapses per plaque, bouton size and density within 40 µm distance from 
the edge of the plaque (see section 2.5.6). 
 
3.2.12 Microglia qualitative analysis 
Microglia were qualitatively assessed between genotype and treatment to determine if the 
glial response is altered during amyloidosis pathology and with epothilone D treatment. 
Immunolabelling with Iba1 for microglia was performed in two coronal sections per mouse. 
Specific regions throughout the cortex where blindly qualitatively compared for any 
difference between groups, in particular, sections from bregma 0.22 were assessed (see 
section 2.5.7). 
 
3.2.13 Microglia quantitative analysis 
Microglia were quantitatively assessed between genotype and treatment to determine if the 
glial response is altered during amyloidosis pathology and with epothilone D treatment. 
Immunolabelling with Iba1 for microglia was performed in three coronal sections per mouse.  
A region of interest from the midline of the cortex to the rhinal fissure was quantitatively 
compared for any difference between groups (see section 2.5.8). 
 
3.2.14 Statistical analysis 
All statistical analyses were performed in GraphPad PRISM 6.0C. Kolmogorov-Smirnov 
normality test was used to confirm that the values from each group had a Gaussian 
distribution. All analyses were performed with the researcher blinded to treatment and 
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genotype and p<0.05 was considered significant. Values are expressed as means and standard 
error of the mean. For a list of all statistical analyses performed, see section 8.1. 
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3.3 RESULTS 
3.3.1 Epothilone D treatment did not produce any detrimental health effects 
To determine if APP/PS1 mice and wildtype littermates had any detrimental health effects 
following either epothilone D or vehicle treatment, mice were weighed weekly from the onset 
of treatment. During twelve weeks of treatment there were no significant difference in 
weights between genotype or treatment (Figure 3.1 A).  
 
3.3.2 Effect of epothilone on behavioural and cognitive measures 
At the end of the treatment period, mice underwent behavioural and cognitive testing to 
determine if genotype or treatment caused any difference in anxiety, short-term memory (one 
hour), and spatial memory (over a period of five days). During each test, distance and velocity 
were also measured to determine if epothilone D treatment affected motor performance as 
this would affect the outcome of the behaviour and cognitive testing.  
 
The marble burying test was performed to measure changes in behaviour. After spending 30 
minutes in an OptiMICE cage with 6 evenly spaced marbles (example image in Figure 3.2 
A), there was no difference in marble burying for either genotype or treatment (Figure 3.2 
A).  
 
Mice were then assessed in the open field test, which can be used to measure both movement 
and anxiety. In the 10 minutes that mice were placed in the arena, two-way ANOVA 
demonstrated a significant effect of genotype on velocity and distance. Tukey’s post hoc test 
demonstrated that while epothilone D had no effect on distance travelled and velocity relative 
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to vehicle treated mice of the same genotype, the epothilone D treated APP/PS1 mice 
travelled significantly further, and at a greater velocity than their wildtype counterparts.  
  
A
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Figure 3.1  The effect of epothilone D treatment on weight in APP/PS1 mice  
 
(A) Bar graph to show average weights of APP/PS1 (APP, red) and wildtype (WT, blue) mice 
prior to weekly treatment of 2 mg/kg epothilone D (EPO) or vehicle DMSO (VEH) for 12 
weeks. There were no significant differences in the weights of animals between groups. Data 
represented as mean ± SEM. 
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Figure 3.2  The effect of epothilone D treatment on behaviour and cognition in 
APP/PS1 mice  
 
APP/PS1 (APP) and wildtype (WT) epothilone D (EPO) and vehicle DMSO (VEH) treated 
mice were tested for anxiety, motor behaviour and cognition using the marble burying test 
(A), open field (B-D) and Y-maze (E-G).  
 
The number of marbles buried by mice did not depend on animal genotype or treatment (A). 
Picture representation of the marble burying task (right). APP/PS1 epothilone D treated mice 
moved at a faster velocity (B) and over a greater distance (C) in the open field arena than 
wildtype epothilone D treated mice. (D) The time spent in the centre of the arena did not 
differ between genotype or treatment groups. Picture representation of the open field task 
(right). APP/PS1 and wildtype mice had no difference in velocity (E), or distance travelled 
(F) in the Y-maze arena, regardless of treatment. There was no difference in the Y-maze 
spontaneous arm alternation between groups (G). Picture representation of the spontaneous 
alteration Y-maze task (right). Bar graph represents mean ± SEM *p < 0.05 relative to control.  
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There was no significant difference in the time the mice spent in the centre, regardless of 
genotype or treatment (Figure 3.2 B-D).  
 
Cognitive function was assessed using Barnes maze and spontaneous alternation in Y maze 
tests. There were no differences in velocity, distance or alternating entry in the Y maze 
(Figure 3.2 E-G). No cognitive differences were detected between genotypes, and short-term 
memory was not affected by epothilone D treatment in the Barnes maze (Figure 3.3 A-H).  
 
3.3.3 Epothilone D treatment had no effect on dystrophic neurites surrounding plaques  
Dystrophic neurites filled with neurofilaments, cellular organelles or lysosomes are a frequent 
finding surrounding amyloid plaques in AD (Figure 3.4 A, B). The cause of dystrophic neurite 
formation is unclear, but may result from an interaction of amyloid on the cytoskeleton. I 
investigated whether stabilising microtubules with epothilone D, affected neurofilament 
positive dystrophic neurite formation. Sections were immunolabelled with an antibody 
against phosphorylated neurofilament (SMI312). Dystrophic neurites were examined 
surrounding individual plaques (between 10 µm – 30 µm) and numbers and size were 
quantitated in an area of 40 µm distance from the edge of the plaque, according to our 
published protocols (Fernandez-Martos et al., 2015). There was no difference in the number 
or size of phosphorylated neurofilament-labelled dystrophic neurite particles around plaques 
(Figure 3.4 C, D). Similarly, there was no difference in the area occupied by dystrophic 
neurites (Figure 3.4 E).  
 
3.3.4 Epothilone D treatment reduced phosphorylated neurofilament in the mouse 
neocortex and hippocampus  
  
A B C
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Figure 3.3  The effect of epothilone D treatment on cognition in APP/PS1 mice  
 
APP/PS1 (APP) and wildtype (WT) epothilone D (EPO) and vehicle (VEH) treated mice 
were testing using the Barnes maze test. 
 
APP/PS1 and wildtype mice had no difference in (A) velocity or (B) distance travelled in the 
Barnes maze, regardless of treatment. The (C) latency of mice to find the escape hole and the 
(D) number of holes searched in error had no differences between groups on day five of 
testing (probe trial). Data from training days had no significant difference between treatment 
groups. Representative heatmap images to show areas of the Barnes maze explored over (E) 
day one, (F) day two, (G) day three and (H) day 5 (probe trial), with similar profiles for each 
group. Bar graph represents mean ± SEM *p < 0.05 relative to control.  
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Figure 3.4  Axonal pathology in epothilone D treated 15-month-old APP/PS1 mice 
 
Dystrophic neurites were assessed in APP/PS1 mice treated with vehicle DMSO or epothilone 
D. Representative images of thioflavin S (green) stained amyloid plaques surrounded by 
phosphorylated neurofilament immunolabelled dystrophic neurites (SMI312; red) in 
APP/PS1 mice cortices treated with either (A) vehicle or (B) epothilone D. White arrows 
indicate dystrophic neurite swellings. Graphs to show (C) the average number of dystrophic 
neurite particles surrounding a plaque, (D) the average size of the dystrophic neurite particles, 
and (E) the percentage area occupied by dystrophic neurites within a 40 µm radius of the 
plaque. There was no difference between treatment groups. Bar graph represents mean ± SEM 
*p < 0.05 relative to control. Scale bar = 14µm. 
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Since epothilone D binds to microtubules, I postulated that it may have an effect on the 
cytoskeleton of neurons or glial cells. The effect of epothilone D was examined on 
phosphorylated neurofilaments (SMI312 antibody) as well as acetylation of microtubules, in 
the neocortex and hippocampus through Western blotting. Previous studies have indicated 
that epothilone D may affect microtubule acetylation (Brunden et al., 2011). In the current 
study, Western blotting analysis demonstrated that in both wildtype and APP/PS1 mice, 
epothilone D treatment significantly decreased phosphorylated neurofilament compared to 
vehicle treated mice and this was consistent in the neocortical tissue as well as the 
hippocampus (Figure 3.5 A, B). Despite using a similar concentration of epothilone D that 
was used in previous studies, acetylation of microtubules was not affected by epothilone D 
treatment in either genotype (Figure 3.5 C).  
 
3.3.5 Epothilone D treatment did not affect numbers of synaptic puncta  
Microtubule stability is important for synapse and spine stability (Bodaleo et al., 2016; Maas 
et al., 2009; Merriam et al., 2013) therefore I examined the density of synaptophysin-labelled 
synaptic puncta in the neocortex in the mice cohort. Synaptic puncta were examined in 
plaque-free areas of APP/PS1 and wildtype mice neocortices (Figure 3.6 A) as well as 
surrounding individual plaques (40 µm from plaque edge; Figure 3.6 E) in APP/PS1 mice. 
There were no significant (p>0.05) differences found in the average number of synapses per 
micrometre, the average size of synaptic boutons or synaptic load between wildtype and 
APP/PS1 mice in plaque-free areas with or without treatment (Figure 3.6 B-D). There was no 
difference found in the average number of synapses per micrometre, the average size of the 
synaptic boutons, or synaptic load around plaques with epothilone D treatment relative to 
vehicle in APP/PS1 mice (Figure 3.6 F-H).  
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Figure 3.5  Effect of epothilone D on phosphorylated neurofilaments and acetylation 
of microtubules 
 
Western blot analysis of phosphorylated neurofilament (SMI312) levels in the (A) cortex and 
(B) hippocampus of APP/PS1 and wildtype (WT) mice treated with vehicle (VEH) or 
epothilone D (EPO). There were significant differences in epothilone D treated APP/PS1 and 
wildtype mice compared to vehicle treated mice in both the cortex and hippocampus. Western 
blot analysis of (C) acetylated tubulin in the cortex of APP/PS1 and wildtype mice treated 
with epothilone D and vehicle and showed no significant difference between groups. Images 
of representative blots incubated with SMI312 and GAPDH as a housekeeping control for 
(D) cortex and (E) hippocampus and (F) acetylated tubulin in the cortex. Bar graph represents 
mean ± SEM *p < 0.05 relative to control.  
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Figure 3.6  Synapse pathology in epothilone D treated 15-month-old APP/PS1 mice 
 
Synaptophysin immunolabelled tissue was used to quantitate synapses in the cortex of vehicle 
treated APP/PS1 and wildtype (WT) mice to determine if there were any baseline differences 
in synapses between genotypes. (A) Representative images of synaptophysin-labelled 
vehicle-treated mice cortices of wildtype and APP/PS1 mice.  Graphs to show the (B) number 
of synapses per µm2, (C) average size of synaptic boutons, and (D) synapse load (defined as 
the percentage area occupied by synaptic boutons) in wildtype and APP/PS1 mice. There 
were no differences in genotypes for any of the measures.  
Synapses were quantitated in APP/PS1 mice treated with vehicle and epothilone D to 
determine if epothilone D treatment affects synaptic density. (E) Representative images of 
synaptophysin-labelled synaptic boutons (arrows) around plaques in APP/PS1 mice cortices 
treated with either vehicle or epothilone D. Note the presence of synaptophysin labelled 
dystrophic neurites around plaques (arrow head) which were excluded from the analysis by 
size exclusion. Graphs to show (F) the number of synapses per µm2, (G) the average size of 
synaptic boutons, and (H) the synaptic load in APP/PS1 mice treated with vehicle or 
epothilone D. There were no differences between the treatment groups. Bar graph represents 
mean ± SEM *p < 0.05 relative to control. Scale bar = 14 µm. * = indicates presence of 
plaque. 
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Neocortical and hippocampal regions were also assessed for protein expression levels of pre-
synaptic markers synaptophysin and VGLUT1 using Western blotting as an indicator of 
synaptic alterations (Micheva et al., 2010). No differences were found between genotypes or 
treatment groups (Figure 3.7 A-H).   
 
3.3.6 Epothilone D treatment and amyloid pathology 
To determine whether epothilone D treatment affected plaque deposition, coronal sections (n 
= 5 sections per animal evenly spaced between bregma -2 and bregma 2) were stained with 
thioflavin S. Number and load (defined as the percentage of plaques per region of interest) of 
fibrillar plaques were quantitated in the neocortex from the midline to the rhinal fissure. 
Epothilone D treatment had no significant (p>0.05) effect on the average number of plaques 
per area, average plaque size, or amyloid plaque load in APP/PS1 mice (Figure 3.8 A-E).  
 
3.3.7 Epothilone D treatment and microglia 
To determine whether epothilone D treatment affected morphology of microglia in the 
neocortex, analysis was performed of Iba1 immunolabelled sections (on 2 sections per mouse 
at bregma 0.22). Qualitative analysis showed a presence of microglia throughout the cortex 
of all groups. Qualitatively, wildtype mice had more hyper-ramified and bushy microglia 
compared to APP/PS1 mice, which tended to have more amoeboid microglia present, 
suggestive of an activated phenotype (Figure 3.9 A-E). Qualitatively, epothilone D did not 
affect microglia morphology. Quantitative analysis showed no difference in the microglia cell 
density throughout the cortex of vehicle and epothilone D treated APP/PS1 mice (Figure 3.9 
F).  
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Figure 3.7  Western blot analysis of synapses in epothilone D treated 15-month-old 
APP/PS1 mice 
 
Graphs to show Western blot quantification of synaptophysin levels in (A) cortex and (B) 
hippocampus, relative to wildtype vehicle housekeeping GAPDH (at 100%). There was no 
difference between groups. Images of representative blots for synaptophysin and GAPDH for 
(C) cortex and (D) hippocampus. Graphs to show Western blot quantification of VGLUT1 
levels in (E) cortex and (F) hippocampus, relative to wildtype vehicle housekeeping GAPDH 
(at 100%). There was no difference between groups. Images of representative blots for 
synaptophysin and GAPDH for (G) cortex and (H) hippocampus. Synaptophysin and 
VGLUT1 were incubated on the same blot, where GAPDH was used as a housekeeping 
control for both synaptophysin and VGLUT1. Bar graph represents mean ± SEM.   
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Figure 3.8  Amyloid pathology in epothilone D and vehicle treated 15-month-old 
APP/PS1 and wildtype mice 
 
Graphs to show (A) the number of plaques per area, (B) the average plaque size and (C) the 
plaque load (defined as the area occupied by plaques) in the neocortex. There was no 
difference between treatment groups. Bar graphs represents mean ± SEM *p < 0.05 relative 
to control.  
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Figure 3.9  Microglia in epothilone D treated 15-month-old APP/PS1 and wildtype 
mice 
 
Microglia labelled with Iba1 were assessed qualitatively in APP/PS1 and wildtype mice 
treated with epothilone D or vehicle. Representative image to show (A) region of interest for 
qualitative assessment of microglia. Representative images of microglia in (B) wildtype 
vehicle treated mice (C) wildtype epothilone D treated mice (D) APP/PS1 vehicle treated 
mice and (D) APP/PS1 epothilone D treated mice. Arrows indicate hyper-ramified and bushy 
microglia with long and thin processes, and arrow heads indicate amoeboid microglia with 
short, thick processes. (F) Graph to show microglia cell density in the cortex of APP/PS1 
mice treated with either vehicle or epothilone D. Bar graphs represents mean ± SEM. Scale 
bar = 30µm. 
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3.4 DISCUSSION 
A primary aim of this study was to investigate the therapeutic potential of microtubule 
stabilisation with drugs such as epothilone D as a treatment for AD, by examining the effect 
on behavioural and cognitive outcomes, Aβ deposition, synaptic loss, and axonal dystrophy 
in the APP/PS1 mouse model of AD (Mitew et al., 2013a). Previous research has 
demonstrated that epothilone D reduces axon and tau pathology whilst increasing microtubule 
density in tauopathy mouse models (Brunden et al., 2010; Zhang et al., 2018). Following on 
from this research, this study aimed to determine whether epothilone D treatment has effects 
on other pathological alterations in AD such as amyloid deposition and dystrophic neurite 
formation in an amyloid mouse model; the APP/PS1 mouse. As epothilone D had the potential 
to alter behavioural and cognitive outcomes, memory and anxiety were also assessed using 
several cognitive tests. This study demonstrated that weight, short-term, spatial and long-term 
memory were not affected by epothilone D, however epothilone D did have an effect on some 
behavioural measures in APP/PS1 mice, compared to vehicle treatment, including velocity 
and distance travelled in the open field test. Furthermore, although epothilone D altered the 
composition of the cytoskeleton, with a decrease in phosphorylated neurofilament, it did not 
have any significant beneficial or adverse effects on the pathological features of AD measured 
in this study. 
 
3.4.1 Microtubule stabilisation with epothilone D affected mouse behaviour and cognition 
in APP/PS1 mice 
This thesis demonstrated that epothilone D did not have any effects on the weight of the mice 
suggesting no general detrimental effects on health. Similarly, memory function was 
unaltered by the treatment. In this study, no baseline differences were detected between the 
APP/PS1 mice and the wildtype mice with vehicle treatment as has been reported in previous 
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studies (Jankowsky and Zheng, 2017), meaning that there was no deficit to correct. However, 
this study still demonstrated that epothilone D did not adversely affect cognition supporting 
its use as a therapeutic. Marble burying is used to measure anxiety by many researchers (Bahi 
and Dreyer, 2012; Homma and Yamada, 2009; Kim et al., 2012; Taylor et al., 2017), although 
the interpretation of the results is of much debate (Lazic, 2015; Njung’e and Handley, 1991). 
Marble burying behaviour does not show habituation after repeated testing, indicating that it 
is not a learning process, and has also been reported that the behaviour does not differ by 
gender (Homma and Yamada, 2009). Some suggest that rodents have a tendency to bury 
harmful objects, although other studies have reported that if the objects make them more 
anxious, it is more likely that they will avoid the objects (Broekkamp et al., 1986; De Boer 
and Koolhaas, 2003; Nicolas et al., 2006; Thomas et al., 2009). This study showed no 
differences between genotype or treatment in marble burying activity. 
 
Overall, the results of the behavioural testing suggest that epothilone D may be having subtle 
effects in the APP/PS1 mice only, but further research would need to be done to determine 
the pathways effected. 
 
3.4.2 Epothilone D treatment altered the neuronal cytoskeleton 
Treatment with epothilone D significantly decreased phosphorylated neurofilament protein, 
immunolabelled with SMI312, in both wildtype and APP/PS1 mice.  A limitation of the 
current study is that it is currently unclear whether altered phosphorylated neurofilament 
protein is due to altered total neurofilament protein levels or to an altered phosphorylation 
state of neurofilaments as total neurofilament was not investigated and this will need to be 
performed in future studies. Aggregation of neurofilaments is a common marker of 
neurodegenerative disease (Liu et al., 2004a) and results from altered levels or 
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phosphorylation state of neurofilaments (Dale and Garcia, 2012; Yuan and Nixon, 2016). 
Previous research has examined the relationship between microtubules and neurofilaments in 
mice with a knockout of the neurofilament light protein (NFL), which is a core component of 
the neurofilament triplet protein and results in altered axonal expression of neurofilaments 
(Millecamps et al., 2007). It has been shown that neurofilament depletion increased 
microtubule density and improved microtubule dynamics (Yadav et al., 2016). Similar studies 
have shown that knockout of NFL in mouse cultured dorsal root ganglion neurons, depletes 
axonal neurofilaments and increases both fast axonal transport and mitochondria transport  
(Perrot and Julien, 2010), which are microtubule dependent processes. Furthermore, NFL 
depletion in mouse models of motor neuron disease have increased microtubule stability and 
delayed axon degeneration (Bömmel et al., 2002; Martin et al., 2002; Selvaraj et al., 2012; 
Yadav et al., 2016). As epothilone D was found to reduce phosphorylated neurofilament 
protein in this study, it provides proof of concept that epothilone D was having an effect on 
the cytoskeleton in this cohort, despite the lack of altered microtubule acetylation in this 
study, unlike the study by Brunden and colleagues (Brunden et al., 2011), which used the 
same concentration of the drug. The reason for the differences is unclear, but may be due to 
technological differences, such as the site of injections. Alternatively, as acetylated tubulin is 
a marker of long-lived microtubules, it may be that in these 15-month old animals, acetylated 
tubulin levels are already high and therefore less affected by epothilone D. This may suggest 
that new microtubules could be more vulnerable to dystrophic neurite pathology and it would 
be of interest to investigate dystrophic neurites in younger APP/PS1 mice. There is limited 
research about the interactions of epothilone D and phosphorylated neurofilament. Epothilone 
D could possibly affect phosphorylated neurofilament by increasing microtubule stability, 
thereby making neurofilaments redundant, however the mechanism by which microtubules 
and neurofilaments interact is not known. From the current study, the concentration of 
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epothilone D required to cause a change to prevent further axonal dystrophy, such as 
dystrophic neurite formation, may be much higher, and more in line with doses to treat 
cancers, which cause cell cycle arrest. 
 
3.4.3 Epothilone D did not alter neurofilament immunoreactive dystrophic neurite 
formation despite alterations to phosphorylated neurofilament 
Dystrophic neurites are damaged neural processes within the cortex of AD patients, and in 
AD mouse models, which frequently surround amyloid plaques. These plaques are termed 
neuritic plaques (Vickers et al., 1996). Neurofilament labelling with SMI312 antibody has 
previously been reported to visualise dystrophic neurites (Fernandez-Martos et al., 2015; 
Masliah et al., 1993). In the current study, neurofilament-labelled dystrophic neurites were 
assessed by immunohistochemical analysis. Dystrophic neurites were present surrounding 
amyloid plaques in this cohort, in line with other studies (Adlard et al., 2000; Spires-Jones 
and Hyman, 2014). However, immunohistochemical analysis showed no difference in 
number or size of dystrophic neurite particles labelled with SMI312. Since the current study 
administered epothilone D at a timepoint after formation of many dystrophic neurites, 
epothilone D may be unable to alter neurite dystrophy once formed. It is less clear whether 
epothilone D is able to prevent formation of new dystrophic neurites as the disease progresses 
and new amyloid plaques continue to grow. Further analysis of the timing of dystrophic 
neurite formation in this mouse model would aid in determining a timepoint for examining 
this. Previous work in this mouse model demonstrated that there is an increased plaque load 
between 12 and 15 months of age, however an analysis of dystrophic neurite formation over 
this timepoint has not been performed. It would be of interest in future studies to also examine 
the effect of epothilone D at earlier timepoints where plaque load increases and potentially 
dystrophic neurite formation are more dynamic.  
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The results of this thesis suggest that any strategy to reduce phosphorylated neurofilament is 
unlikely to rescue dystrophic neurites. A previous study has examined whether loss of 
neurofilament light protein (NFL), which reduces axonal neurofilament levels had an effect 
on dystrophic neurites (Fernandez-Martos et al., 2015). This study demonstrated that NFL 
deficiency significantly (p<0.05) increased neocortical dystrophic neurite pathology. Further 
examination of the changes to specific neurofilament triplet proteins and their 
phosphorylation state following epothilone D treatment would aid in an understanding of the 
mechanisms by which dystrophic neurite pathology is affected by neurofilament. It has 
previously been shown that the microtubule and neurofilament cytoskeleton are closely 
linked and alteration in one could result in compensation of the other (Liu et al., 2012).  
 
3.4.4 Epothilone D did not affect synapses 
In this study the effect of epothilone D on axons was further investigated by examining pre-
synaptic terminals in the neocortex. No difference in synaptic density or size was present in 
any treatment group or genotype. Since there was no difference in presynaptic puncta in 
plaque-free areas between vehicle treated wildtype and APP/PS1 mice, this suggests that there 
is no synapse loss in this model, in the age and cortical areas examined, as suggested by other 
studies (Hong et al., 2016; Wirths and Bayer, 2010). However, some researchers report 
synapse loss in the hippocampus of this mouse model (Alonso-Nanclares et al., 2013; Da 
Silva et al., 2016; Gengler et al., 2010; Salazar et al., 2017). One study has showed that 
oligomeric Aβ surrounding plaques does contribute to excitatory synapse loss in the APP/PS1 
mouse model, however the age range of these mice varied from 8-13 months (Koffie et al., 
2009). Other research is in line with the results of the current study, demonstrating that dense 
core plaques do not accentuate synapse loss in brains of AD patients (Masliah et al., 1990), 
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although results may be dependent on the specific markers analysed and the analysis 
technique. Overall the current study demonstrates that epothilone D at the levels used in this 
project does not damage synaptic connections. 
 
Previous reports have suggested that epothilone D does have the capacity to rescue synapse 
loss in other models that exhibit synaptic degeneration. For example, in a STOP-null mouse 
model of schizophrenia, epothilone D treatment increased synaptic vesicle pools and 
improved synaptic plasticity in glutamatergic neurons and improved cognition (Andrieux et 
al., 2006). However, consistent with the results from the current study, epothilone D has no 
effect on pre-synaptic terminal synapses at the neuromuscular junction (Clark et al., 2018; 
Dubey et al., 2015).   
 
3.4.5 Epothilone D did not affect fibrillar amyloid deposition 
A potential effect of microtubule stabilisation targeting tau pathology in AD is an effect on 
Aβ production. APP is transported via fast anterograde transport to the axon terminal. A link 
between APP transportation and amyloid processing has been suggested since APP, β-
secretase and presenilin 1 may be transported together via fast anterograde transport 
(Brunholz et al., 2012; Kamal et al., 2001; Lazarov et al., 2005; Rodrigues et al., 2012). The 
authors of this study demonstrated that processing of APP occurs within its compartment 
during transport along axons, resulting in production of the toxic Aβ peptide (Kamal et al., 
2001). This suggests that alterations in transport could drive APP processing along the 
amyloidogenic pathway, creating more amyloid deposits. To investigate potential effects of 
altered transport through microtubule stabilisation on amyloid processing, fibrillar plaque 
load was examined. The current data shows no difference in plaque load following epothilone 
D treatment, suggesting that microtubule stability may not affect amyloid deposition. While 
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epothilone B has been reported to exhibit both beneficial and detrimental effects in animal 
models, which is dependent on the drug concentration, the type of neuron, and the age of 
neurons (Jang et al., 2016), the data presented from the current study suggest that epothilone 
D is unlikely to have adverse effects on amyloid if used as a treatment strategy to protect 
against tau pathology.  
 
3.4.6 Epothilone D and microglia 
Microglia were qualitatively assessed to determine if genotype or epothilone D treatment 
affected morphology of microglia. Microglia were present throughout the cortex in all 
treatment groups. Wildtype mice treated with either vehicle or epothilone D had hyper-
ramified and bushy microglia. In APP/PS1 mice, amoeboid microglia were present regardless 
of vehicle or epothilone D treatment. An increase in microglia in an APP/PS1 mouse model 
has previously been reported (Holland et al., 2018; Manocha et al., 2016).  
 
There are a number of limitations which need to be considered in this study. One limitation 
is that the APP/PS1 model is limited to amyloidosis-driven pathology, and drives amyloid 
pathology through a specific pathway. Therefore, this model may not represent sporadic 
disease. Another limitation of is study is that the actual concentration of epothilone D in the 
brain is unknown, and as the acetylated tubulin results show, it suggests that there is less than 
in previous studies. One concentration and one timepoint was investigated in the current 
study, but future studies could investigate higher concentrations of epothilone D, such as 3 
mg/mL, and early timepoints could be examined, such as 6 months, when amyloid plaques 
are developing within the cortex and hippocampus. An unexpected outcome of this study was 
that synapses changes were not detected between genotypes in vehicle treated mice. Another 
limitation of this study is the use of male mice only. Future studies could also further 
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investigate astrocytes and microglia, by assessing morphology and density within the 
neocortex and hippocampus. 
 
3.4.7 Conclusion 
In conclusion, the results presented here provide evidence that epothilone D treatment does 
not further exacerbate APP/PS1 pathology, including amyloid plaques and neurite dystrophy. 
However, epothilone D treatment does significantly reduce phosphorylated neurofilament in 
both the neocortex and hippocampus. Although studies have shown changes to synapse loss 
around plaques, there were no changes detected in synapses in this mouse model at the age 
examined. Importantly, the low doses (2 mg/kg) of epothilone D appeared safe as weight and 
cognitive testing was unchanged to the vehicle-treated mice. 
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4 TARGETING MICROTUBULE POST-TRANSLATIONAL 
MODIFICATIONS IN EXCITOTOXIN-INDUCED AXON 
DEGENERATION 
4.1 INTRODUCTION 
4.1.1 Introduction 
The previous chapter demonstrated that epothilone D treatment caused some alterations to 
the cytoskeleton and had minor effects on behaviour but did not affect the key pathological 
features of the APP/PS1 mouse model. Previous studies suggest that epothilone D can protect 
against tau pathology. Together these results suggest that targeting microtubules to stabilise 
their structure could be an effective intervention to prevent axon degeneration without 
adverse effects on other types of pathology in neurodegenerative disease. Axon degeneration 
and microtubule breakdown are reported in several neurodegenerative diseases, however the 
relationship between microtubule depolymerisation and axon degeneration, particularly as it 
relates to neurodegenerative disease, is not clearly understood.  
 
Axon degeneration is reported, not only in several neurodegenerative diseases, but also in 
acquired forms of brain injury, and can occur independently of cell death (Lingor et al., 2012). 
The best described mechanisms of axon degeneration are axonal pruning, which occurs 
during development and Wallerian degeneration, which occurs following axon severing 
(Coleman, 2005; Coleman and Freeman, 2010). In contrast, the cellular process underlying 
axon degeneration in a range of neurodegenerative diseases and following brain injury are 
less understood and are unlikely to be linked to direct axonal severing, but rather to a gradual 
series of biochemical changes following specific disease-associated pathological insults.  
 
4.1.2 Excitotoxin-induced axon degeneration 
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One such pathological insult, excitotoxicity, is a result of excessive stimulation by the 
excitatory neurotransmitter glutamate, leading to increased intracellular calcium and a 
cascade of harmful calcium-dependent events (Dong et al., 2009). Excitotoxic mechanisms 
have been implicated in AD, traumatic brain injury, stroke, and amyotrophic lateral sclerosis, 
which all undergo some form of axon degeneration (as reviewed by Gibson and Bromberg, 
2012; Lai et al., 2014; Lewerenz and Maher, 2015). Previous studies in compartmentalised 
cultured cortical neurons have shown that excitotoxic insult directed to the neuronal soma 
results in fragmentation of the unexposed axon (Hosie et al., 2012). This was significantly 
attenuated by treatment of the axons with the microtubule stabilising drug, taxol, implicating 
microtubule disruption in the breakdown of the axon (King et al., 2013).  
  
4.1.3 Microtubule post-translational modifications 
As described in section 1.4, microtubule are highly dynamic polymers of alpha- and beta-
tubulin. Their ability to undergo rapid changes in polymerisation state (termed dynamic 
instability) is essential for their function and is controlled by the binding of MAPs as well as 
by their PTMs (Horio et al., 2014). The microtubule disruption that occurs following 
excitotoxin exposure and leads to axon degeneration could result from depolymerisation, 
potentially relating to changes to PTM or from altered MAP binding. However, microtubule 
PTMs and MAP binding are not independent, as the binding capacity of some MAPs can be 
influenced by microtubule PTMs (Howes et al., 2014). Understanding the specific changes 
that occur to microtubules following an excitotoxic insult could help in directing therapeutics 
to protect axons and maintain nerve cell connectivity in neurodegenerative disease. In this 
chapter I focus on examining alterations to microtubule PTMs following an excitotoxic insult. 
PTMs of microtubules include glutamylation, tyrosination and acetylation. Acetylation, 
glutamylation and detyrosination are associated with stable microtubules, whereas 
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tyrosination is associated with unstable and more dynamic areas of microtubules (Uchida and 
Shumyatsky, 2016). Thus, microtubule PTMs may be a potential target for therapeutic 
intervention. In this regard, drugs targeting acetylation such as histone deacetylase 6 
(HDAC6) inhibitors have been investigated for the treatment of depression, cancer, stroke, 
environmental stress and Huntington’s disease (Brindisi et al., 2016, 2018; Ceccacci and 
Minucci, 2016; Dompierre et al., 2007; Jochems et al., 2014; Lazo-Gómez et al., 2013; Rao 
et al., 2017; Simões-Pires et al., 2013; Wang et al., 2016). 
 
4.1.4 Microfluidic chambers as a model to study excitotoxin-induced axon degeneration 
Microtubules are present in all cell types and there may be cell-type specific responses to 
excitotoxin exposure. Therefore, in order to investigate microtubule alterations in neurons 
and more specifically in axons, it is necessary to be able to separate out these specific 
compartments and an appropriate model is needed. Primary neuron cultures derived from 
rodents can be grown in isolation of other cell types and can be grown in compartmented 
microfluidic chambers. These multicompartment culture chambers allow for fluidic isolation 
of neuronal processes from their cell bodies, thereby allowing for pharmacological 
manipulation on isolated parts of the neuron (Taylor et al., 2006). Therefore, microfluidic 
chambers are ideal to investigate axon degeneration and the associated mechanisms.  
 
Axonal growth within the microgrooves of microfluidic chambers is well-documented 
(Taylor et al., 2005), whereby at 7 DIV, axons have extended into the axonal compartment of 
the chamber, while dendrites remain isolated to the somal compartment, even up to 14 DIV, 
a timepoint between 10-14 DIV also corresponds to an established mature glutamate receptor 
phenotype (Taylor et al., 2005). Therefore, in the current study, axons were grown to 10 DIV 
to allow for both axonal growth and mature receptor phenotype. Furthermore, excitotoxicity 
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by continuous stimulation of NMDA and AMPA/kainite stimulation has been implicated in 
several neurodegenerative diseases, including AD, Huntington’s disease, Parkinson’s disease 
and amyotrophic lateral sclerosis (as reviewed in (Dong et al., 2009; Van Den Bosch et al., 
2006). NMDA receptors have high Ca2+ permeability and conductance properties and 
continuous stimulation leads to a cascade of events resulting in caspase activation and cellular 
toxicity (Fan and Raymond, 2007; Ikonomidou et al., 2000; Jung et al., 2009; Ndountse and 
Chan, 2009). AMPA-type glutamate receptors have been implicated in excitotoxicity and are 
also highly permeable to Ca2+. Stimulation of NMDA and AMPA receptors has been 
implicated in excitotoxin-induced axon degeneration (Wang et al., 2006, 2008). However, 
mechanisms of toxicity may differ between disease and little is known about how each 
contributes to axon degeneration. In this thesis, kainic acid toxicity through modulating 
AMPA/kainite receptors was investigated. This model has been well-characterised (King et 
al., 2013; Wang et al., 2005; Zhu et al., 2011). Although glutamate receptors are present 
throughout the neuron (Hosie et al., 2012), the majority are present on the somatodendritic 
compartment, therefore, using microfluidic chambers allows for targeted exposure to the 
somatodendritic compartment, while changes to the unexposed axon are observed.   
 
4.1.5 Study outline 
In this study, alterations of microtubule PTMs were examined after excitotoxic-induced axon 
degeneration. Microtubule breakdown occurs in axon degeneration, although mechanisms of 
microtubule alterations are unknown. Kainic acid has been previously used in vitro to induce 
excitotoxicity, resulting in axon degeneration. In this model, primary cortical cultures at 10 
DIV, grown either on coverslips or in microfluidic chambers, were treated with kainic acid. 
Microtubule PTMs were examined using ELISA and immunocytochemical techniques. Live-
imaging techniques were utilised to measure the degree of axon degeneration in cells treated 
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with kainic acid. After microtubule alterations were characterised, the potential of 
microtubule stabilising agents was investigated to determine if they prevent axon 
degeneration.   
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4.2 METHODS 
4.2.1 Ethics and mice 
All experiments and procedures were approved by the University of Tasmania Animal Ethics 
Committee (A12780, A15121 and A17530) and were in accordance with the Australian 
Guidelines for the Care and Use of Animals for Scientific Purposes. C57Bl/6 mice were used 
for cell culture experiments (see section 2.1).  
 
4.2.2 Primary cortical cell culture 
Mouse cortical neuron cultures were prepared as previously described (King et al., 2013). 
Cortical neurons were prepared from embryonic day 15.5 (E15.5) C57Bl/6 mice. Cortices 
were and transferred to 5 mL Hanks Balanced Salt Solution (HBSS, Gibco). Trypsin 
(0.0125%) was added for 5 minutes at 37ºC, followed by removal of HBSS and replaced with 
1 mL of initial plating media and mechanically triturated with a 1 mL pipette. Cells were 
plated either into the soma compartment of microfluidic chambers or directly into the wells 
of poly-L-lysine coated culture plates. Cells were allowed to adhere to the coverslip 
(Livingstone) at 37ºC for 30 minutes prior to adding initial plating media to the chambers. 
Cells were incubated at 37ºC overnight before initial media was replaced with subsequent 
media with no fetal calf serum and glutamate. Cells were grown to 10 days in vitro (DIV) at 
37ºC in 5% CO2 (see section 2.7.1, 2.7.2). 
 
4.2.3 Pharmacological manipulation 
Cells were treated with 0 µM, 10 µM, or 25 µM of kainic acid (Sigma Aldrich, 
Lot#SLBD1491V) in DMSO (Sigma Aldrich, Lot#RNBF1056) at 10 DIV. Cells grown in 
12-well plates or the soma compartment of microfluidic chambers were exposed to kainic 
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acid for 1 hour, 6 hours and 18 hours. For a set of experiments cells were treated with 
trichostatin A. Cells at 10 DIV in 12-well plates or axonal compartment of microfluidic 
chambers were treated with 10 nM or 100 nM trichostatin A (Sigma Aldrich, 
Lot#026M4036V) for 2 hours before 6 hours of kainic acid exposure. The health of cells was 
determined using an alamarBlue® assay. For a set of experiments cells were treated with 
taxol (Calbiochem, Lot#B66835). For all pharmacological manipulations, vehicle controls 
were performed and are reported. No significant difference was found in any measure for 
vehicles to untreated cells (see section 2.8.1, 2.8.2). 
 
4.2.4 Live cell imaging and quantitation of axonal degeneration 
Microfluidic cultures were imaged on a Nikon TiE live cell microscope, with chambers 
maintained at 37ºC. Imaging was performed prior to treatment and 18 hours following 
treatment. Axonal side of the microfluidic chambers were imaged using 40x objective lens in 
identical regions before and after treatment. Axon degeneration was calculated by counting 
degenerated axons (see section 2.8.3). 
 
4.2.5 ELISA analysis of microtubule post-translational modifications 
Cells were harvested with RIPA buffer with protease and phosphatase inhibitors. Samples 
were diluted at 1:300 in 50 µL bicarbonate/carbonate coating buffer (AbCam), added to 96-
well plate and incubated overnight at 4ºC. For the standard curve, protein samples were 
serially diluted at 1:100, 1:200, 1:400, and 1:800. A blank and no primary control were 
included to correct for ELISA results. ELISA plates were incubated with detecting antibodies 
(acetylated tubulin 1:500 mouse, Sigma Aldrich; tyrosinated tubulin 1:500 rabbit, Millipore; 
see section 2.8.4). 
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4.2.6 Western blot analysis of microtubule post-translational modifications 
Axons were harvested with RIPA buffer with protease (cOmpleteTM Mini Protease Inhibitor 
Cocktail tablets, Roche) and phosphatase inhibitors (Phosphatase Inhibitor Cocktail, A.G. 
Scientific), with protein pooled from 2-4 chambers per treatment group. Membranes were 
incubated overnight with primary antibody acetylated tubulin (1:1000 mouse, Sigma 
Aldrich). Bands were visualised with enhanced chemiluminescence (ECL) solution-Luminata 
Forte Western horseradish peroxidase (HRP) substrate (Millipore) and images acquired with 
a Chemi-Smart 5000 Imaging System (Vilber Lourmat) equipped with Chemi-Capt 5000 
software (see section 2.8.5).  
 
4.2.7 Immunocytochemistry 
Immunocytochemistry was performed as previously described in section 2.9. After fixation 
cultures were blocked in diluent and incubated with primary antibody acetylated tubulin 
(1:1000 mouse, Sigma Aldrich). 
 
4.2.8 Statistical analysis 
Differences for ELISA and axon degeneration counts were evaluated using one-way 
ANOVA, with Tukey’s post-hoc test for multiple comparisons between groups. For kainic 
acid live-imaging experiments two coverslips on five separate culture days were analysed. 
For trichostatin A live-imaging experiments, 1-2 coverslips from four separate culture days 
were analysed. For whole cell kainic acid ELISAs, three coverslips per treatment from four 
separate culture days were used. For whole cell trichostatin A ELISAs, three coverslips per 
treatment from five separate culture days were used. For axon-only kainic acid ELISAs, cells 
were pooled from 2-3 chambers per treatment from four separate culture days. For axon-only 
trichostatin A and taxol ELISAs, cells were pooled from 2-3 chambers per treatment from 
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five separate culture days. All statistical analysis and graphs were prepared in GraphPad 
Prism (v6.1). Values were reported as means ± standard error of the mean (SEM), with 
differences considered significant at p<0.05. For a list of all statistical analyses performed, 
see section 8.2. 
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4.3 RESULTS 
4.3.1 Model of excitotoxin-induced axon degeneration 
To establish an acute model of excitotoxin-induced axon degeneration, mouse cortical 
neurons were grown to 10 DIV either on poly-L-lysine coated culture trays or in microfluidic 
chambers. At this timepoint, there is robust growth of axons in the axon compartment of 
microfluidic chambers and the neurons are mature enough to express glutamate receptors and 
respond to an excitotoxic insult with a calcium influx (unpublished data by Dr Nan Tian). 
Previous research in our laboratory has used a relatively high concentration of kainic acid to 
induce axon degeneration. Therefore, I first determined whether axon degeneration occurred 
at lower concentrations of kainic acid. Microfluidic chambers allow compartmentalised 
separation of axons from the somatodendritic compartment, which permits treatment to be 
applied to the somatodendritic compartment and the effects examined on the axons. Neurons 
were exposed to 0 µM, 10 µM and 25 µM kainic acid in the somatodendritic compartment 
for 18 hours. Live-imaging of axons was performed immediately prior to and post-treatment 
to determine a degeneration index (detailed in section 2.8). Axon loss was significantly 
increased (p<0.05) at 25 µM kainic acid compared to control (Figure 4.1 A). Axonal 
degeneration at both 10 µM and 25 µM kainic acid was significantly increased (p<0.05) 
compared to control (Figure 4.1 B). A time-course of axon degeneration was established over 
18 hours (Figure 4.1 C, D).  
 
4.3.2 Microtubule alterations after excitotoxin-induced axon degeneration 
The previous experiment determined that axon degeneration and axon loss were present at 18 
hours post exposure to excitotoxin. To look at early changes to microtubules that could 
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contribute to axon degeneration, changes to microtubule PTMs were next determined 
following 25 µM kainic acid exposure at 1 and 6 hours. Primary mouse cortical neurons were   
A B C
D
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Figure 4.1 Axon degeneration and loss in microfluidic chambers after kainic acid 
treatment 
 
Live-imaging of the axonal compartment of microfluidic chambers. For analysis images were 
taken of identical areas before and after treatment. Quantitation was performed for (A) axon 
loss and (B) axon degeneration index 18 hours after treatment with 10 µM or 25 µM kainic 
acid. Axon loss was significantly increased (p<0.05) relative to control following exposure 
to 25 µM kainic acid, but not 10 µM kainic acid. The axon degeneration index was 
significantly increased (p<0.05) relative to control following either 10 µM or 25 µM doses of 
kainic acid. (C) Representative images to show axons at 0 hours and 18 hours after treatment 
with 25 µM kainic acid. (D) Representative axon image showing a timeline of changes to 
axons from 1 hour to 18 hours following exposure to 25 µM kainic acid. Bar graph represents 
mean ± SEM *p < 0.05 relative to control. Scale bar = 50 µm.  
  
Chapter 4 – Results  
  138  
 
grown on 12-well culture trays to 10 DIV and were exposed to 25 µM kainic acid for up to 6 
hours. Protein was harvested from the cells at 1 and 6 hours. ELISA analysis of neurons 
demonstrated that, at 1 hour after 25 µM kainic acid treatment, acetylated and tyrosinated 
tubulin levels were unchanged, compared to vehicle control (Figure 4.2 A, B). At 6 hours 
after 25 µM kainic acid treatment acetylated tubulin levels were significantly (p<0.05) 
decreased (Figure 4.2 A), while tyrosinated tubulin levels were unchanged (Figure 4.2 B). To 
confirm that these changes were present in axon, primary neurons were grown in 
compartmented chambers to 10 DIV and the somatodendritic compartment exposed to 25 µM 
kainic acid and protein harvested from the axon compartment at 6 hours post exposure. 
ELISA analysis confirmed the results found in whole neurons with a significant decreased 
(p<0.05) in axonal acetylated tubulin at 6 hours post kainic acid (Figure 4.2 C) with no change 
in tyrosinated tubulin (Figure 4.2 D). Western blot analysis of acetylated tubulin levels in 
axons confirmed this was also significantly (p<0.05) decreased (Figure 4.2 E).  
 
As acetylated tubulin was significantly decreased after kainic acid treatment, analysis of 
acetylated tubulin was performed using immunocytochemical labelling after 0, 1 or 6 hours 
of 100 µM kainic acid. Qualitative analysis demonstrated that initially without kainic acid, 
acetylated tubulin labelling is bright with no fragmentation present, demonstrating that the 
axon is still intact (Figure 4.2 F). However, after 1 hour, immunolabelling is less intense, and 
fragmentation and beading is observed in the acetylated tubulin labelling (Figure 4.2 G). At 
6 hours, intensity of immunohistochemistry appears further decreased and more 
fragmentation is observed (Figure 4.2 H). Overall, qualitative analysis suggests that 100 µM 
kainic acid reduced intensity of acetylated tubulin immunoreactivity.  
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Figure 4.2  Changes to microtubule PTMs after kainic acid treatment  
 
Changes to microtubule PTMs were investigated in whole cultured cortical neurons as well 
as isolated axons in microfluidic chambers after treatment with 25 µM kainic acid. ELISA 
analysis of neurons at 1 and 6 hours after 25 µM kainic acid treatment showed (A) a 
significant decrease (p<0.05) in acetylated tubulin levels after 6 hours whereas (B) tyrosinated 
tubulin levels were unchanged compared to control. ELISA analysis of isolated axons at 6 
hours post treatment with 25 µM kainic acid demonstrated (C) significantly decreased 
(p<0.05) levels of acetylated tubulin, at this timepoint relative to control. Axonal levels of 
(D) tyrosinated tubulin were unchanged compared to control. To confirm the effect of 25 µM 
kainic acid on acetylated tubulin in axons Western blot analysis was performed (E) 
demonstrating a significant decrease (p<0.05). Representative images of axons grown in 
microfluidic chambers immunolabelled with acetylated tubulin after (F) 0 hours, (G) 1 hour 
and (H) 6 hours of 100 µM kainic acid treatment. Bar graph represents mean ± SEM *p < 
0.05 relative to control. Scale bar = 50 µm, scale bar for panel F = 30 µm. 
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4.3.3 The effect of trichostatin A on microtubules 
Since the data showed significantly reduced acetylated tubulin levels in the axon after 25 µM  
kainic acid treatment (Figure 4.2), it was hypothesised that promoting microtubule acetylation 
could rescue these changes and prevent axon degeneration. To promote microtubule 
acetylation, the drug trichostatin A was used to inhibit the de-acetylating enzyme HDAC6.  
 
Firstly, the concentration of trichostatin A required to promote acetylation in primary mouse 
cortical cultures was determined. Primary cortical neurons were grown to 10 DIV in 12-well 
trays and treated with 2 concentrations of trichostatin A which were selected based on 
published literature (Moreira et al., 2003; Rahman et al., 2003; Williams et al., 2011). Protein 
was harvested at 2 hours post-treatment. ELISA analysis demonstrated that acetylated tubulin 
levels after 10 nM and 100 nM trichostatin A were significantly (p<0.05) increased compared 
to vehicle control at 2 hours post-treatment (Figure 4.3 A). There was no significant 
difference in the levels of acetylated tubulin between the two concentrations of trichostatin 
A, suggesting a threshold effect. To determine whether trichostatin A had any detrimental 
effects on the neurons, cell viability was tested using an alamarBlue® cell viability assay, 
which measures cell proliferation. This demonstrated that 10 nM and 100 nM trichostatin A 
did not significantly affect cell health different compared to vehicle treated cultures. 
However, cells treated with higher doses (250 nM and 500 nM) of trichostatin A had 
significantly reduced (p<0.05) cell health compared to vehicle control (Figure 4.3 B). Cell 
viability was also tested after treatment with trichostatin A (10 nM and 100 nM) in the 
presence of kainic acid and there was no significant difference compared to the vehicle 
control for any treatment concentration (Figure 4.3 C). 
 
  
A B
C
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Figure 4.3 Effect of trichostatin A on microtubule acetylation following kainic acid 
treatment 
 
(A) Levels of acetylated tubulin were examined after treatment of whole neurons with the 
HDAC6 inhibitor trichostatin A. ELISA analysis to show significantly (p<0.05) increased 
acetylated tubulin after both 10 nM and 100 nM trichostatin A treatment in neurons. (B) Cell 
viability in neurons was determined using an alamarBlue® assay after treatment with varying 
concentrations of trichostatin A for two hours. 10 nM and 100 nM trichostatin A resulted in 
no loss in cell viability compared to control, however cell viability was significantly (p<0.05) 
decreased after both 250 nM and 500 nM trichostatin A, compared to control. (C) Cell 
viability of neurons was determined after treatment with kainic acid for 6 hours in the 
presence of trichostatin A. Trichostatin A (10 nM or 100 nM) was applied 2 hours before 
kainic acid treatment. There was no difference in cell viability compared to control (untreated 
cells), for any of the treatments.  
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4.3.4 Trichostatin A and microtubule alterations after excitotoxicity 
It was next determined whether HDAC6 inhibition by trichostatin A, at non-toxic doses, could 
rescue acetylated tubulin following excitotoxin exposure. Neuronal cells grown on 12-well 
trays and the axonal compartment of microfluidic chambers were pre-treated with low (10 
nM) trichostatin A for 2 hours prior to exposure to 25 µM kainic acid for 6 hours, after which 
time protein was harvested from the neurons. ELISA analysis demonstrated that 10 nM 
trichostatin A restored acetylated tubulin levels after kainic acid exposure, as compared to 
vehicle control (Figure 4.4 A). To confirm these changes in axons, neurons were grown in 
microfluidic chambers and the axons were pre-treated with 10 nM trichostatin A for 2 hours 
prior to exposure of the somatodendritic compartment to 25 µM kainic acid for 6 hours. 
ELISA analysis was performed on harvested axons and demonstrated that axonal acetylated 
tubulin levels were significantly decreased, after kainic acid exposure (similar to previous 
results) and significantly increased after trichostatin A. After combined treatment acetylated 
tubulin levels were unchanged from vehicle control (Figure 4.4 B). Western blot analysis of 
harvested axons also demonstrated that 10 nM trichostatin A restored acetylated tubulin levels 
after excitotoxicity in axons (Figure 4.4 C, D), confirming the ELISA analysis. Tyrosinated 
tubulin levels in both the neurons (Figure 4.5 A) and axons (Figure 4.5 B) were unchanged 
after combined trichostatin A and kainic acid treatment, when compared to control levels. 
 
4.3.5 Effect of trichostatin A on axon degeneration 
After demonstrating acetylated tubulin levels in axons following excitotoxic injury are 
restored by treatment with trichostatin A, it was next determined if trichostatin A treatment 
following excitotoxin exposure was also protective against axonal degeneration at 18 hours 
post treatment. Neurons were grown in microfluidic chambers and axons exposed to 10 nM 
and 100 nM trichostatin A for 2 hours prior to somatodendritic treatment with 25 µM kainic  
A B C
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Figure 4.4 Effect of trichostatin A on microtubule acetylation following kainic acid 
treatment 
 
(A) Levels of acetylated tubulin were quantitated in whole neurons following six hours of 
kainic acid treatment in the presence of trichostatin A (applied two hours prior to kainic acid). 
ELISA analysis demonstrated a significant decrease (p<0.05) in acetylated tubulin levels after 
6 hours of kainic acid treatment, a significant increase (p<0.05) in acetylated tubulin after 2 
hours of 10 nM trichostatin A. Acetylated tubulin levels in neurons treated with kainic acid 
in the presence of trichostatin A were not significantly different from control. (B) Levels of 
acetylated tubulin were quantitated in axons following six hours of kainic acid treatment 
applied to the somatodendritic compartment of microfluidic chambers in the presence of 
trichostatin A (applied to axons two hours prior to kainic acid). ELISA analysis demonstrated 
a significant increase (p<0.05) in acetylated tubulin after 2 hours of 10 nM trichostatin A. 
Acetylated tubulin levels in neurons treated with kainic acid in the presence of trichostatin A 
were not significantly different from control. (C) To confirm the effect of 10 nM trichostatin 
A on acetylated tubulin in axons, Western blot analysis was performed demonstrating a 
significant increase in axonal acetylated tubulin following 10 nM trichostatin A and no 
significant difference in combined trichostatin A and kainic acid compared to control 
(p<0.05). (D) Representative Western blot used for quantitation of (C). Bar graph represents 
mean ± SEM *p < 0.05 relative to control.  
A B
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Figure 4.5 Effect of trichostatin A on microtubule tyrosination following kainic acid 
treatment  
 
(A) Levels of tyrosinated tubulin were examined after treatment of whole neurons with the 
HDAC6 inhibitor trichostatin A. ELISA analysis demonstrated no difference in tyrosinated 
tubulin after 10 nM trichostatin A treatment for 2 hours or 25 µM kainic acid for 6 hours. (B) 
Levels of tyrosinated tubulin were examined after treatment of isolated axons with 
trichostatin A. ELISA analysis demonstrated that tyrosinated tubulin levels were unchanged 
in any treatment group, relative to control. Bar graph represents mean ± SEM *p < 0.05 
relative to control. TSA; trichostatin A, KA; kainic acid.  
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acid. Axon degeneration was quantitated from images acquired from identical regions of the 
coverslip, before and 18 hours after kainic acid treatment. In the presence of 10 nM and 100 
nM trichostatin A, axon loss (Figure 4.6 A) and axon degeneration (Figure 4.6 B) were 
significantly reduced (p<0.05) after exposure to 25 µM kainic acid. Live-imaging 
demonstrated that trichostatin A prevented axons from degenerating following kainic acid 
treatment (Figure 4.6 D-G). 
 
4.3.6 Taxol and microtubule post translational modifications after excitotoxicity 
The above results demonstrated the microtubule acetylating agent, trichostatin A altered 
microtubule PTMs, and protected axons from degenerating. Previous studies have also 
demonstrated an axonal protective effect of the microtubule stabilising agent, taxol following 
kainic acid exposure in a similar model (King et al., 2013). Thus, in this thesis I further 
investigated the effect of taxol on microtubule PTMs following kainic acid exposure. Primary 
mouse cortical neurons were grown in microfluid chambers to 10 DIV and the axonal 
compartment of microfluidic chambers was pre-treated with 10ng taxol for 2 hours prior to 
exposure of the somatodendritic compartment to 25 µM kainic acid, followed by harvest of 
the axonal proteins at 6 hours. ELISA analysis demonstrated that both 10ng taxol alone and 
combined taxol and kainic acid treatment restored acetylated tubulin levels in axons after 
kainic acid exposure, as compared to vehicle control in axons (Figure 4.7 A). However, 10ng 
of taxol also significantly decreased (p<0.05) tyrosinated tubulin levels in axons, compared 
to vehicle, both in the presence and absence of kainic acid (Figure 4.7 B).  
 
 
 
  

Chapter 4 – Results  
  151  
 
Figure 4.6 Axon degeneration and axon loss after kainic acid treatment in the 
presence of trichostatin A 
 
Degenerating and lost axons were quantitated from live images of the axonal compartments 
of microfluidic chambers following 25 µM kainic acid treatment in the presence of axonal 
trichostatin A (10 nM or 100 nM). Both (A) axon loss and (B) axon degeneration were 
significantly increased (p<0.05) with 25 µM kainic acid treatment, however, these effects 
were rescued by treatment with either concentration of trichostatin A. In the presence of 
trichostatin A, axonal loss and degeneration were not significantly different from controls. 
(C) Schematic showing where each treatment was applied to the microfluidic chambers. 
Representative images of axons for (D) control, (E) 25 µM kainic acid, (F) 10 nM trichostatin 
A + 25 µM kainic acid and (G) 100 nM trichostatin A + 25 µM kainic acid. Bar graph 
represents mean ± SEM *p < 0.05 relative to control. Scale bar = 50 µm. TSA; trichostatin 
A, KA; kainic acid. 
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Figure 4.7 The effect of taxol on microtubule PTMs 
 
Changes to microtubule PTMs were investigated in isolated axons after treatment with 10ng 
taxol in the presence or absence of 25 µM kainic acid. ELISA analysis of axons showed (A) 
significantly decreased (p<0.05) acetylated tubulin after 6 hours of 25 µM kainic acid 
exposure. After taxol and combined taxol with kainic acid treatment, acetylated tubulin was 
significantly increased (p<0.05) compared to control levels. ELISA analysis of axons showed 
(B) unchanged levels of tyrosinated tubulin after 6 hours of 25 µM kainic acid exposure. 
However, after 10ng taxol, and combined taxol and kainic acid treatment, tyrosinated tubulin 
was significantly decreased (p<0.05) compared to control levels. Bar graph represents mean 
± SEM *p < 0.05 relative to control. 
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4.4 DISCUSSION 
Understanding the mechanisms underlying the relationship between microtubule alterations 
and axon degeneration can potentially lead to a better understanding of neurodegenerative 
changes linked to excitotoxicity. The current study investigated whether excitotoxin-induced 
axon degeneration caused alterations in the PTMs of microtubules and whether inhibition of 
these biochemical changes to the cytoskeleton can protect axons.  
 
The main finding of this study was that, following excitotoxin exposure, there were 
significant decreases to acetylated tubulin by six hours after treatment, both in the whole 
neuron and more specifically within the axon. It is currently unclear whether loss of tubulin 
acetylation in the current project results from increased deacetylation or from decreased 
acetylation. Furthermore, downstream processes following kainic acid exposure that result in 
loss of acetylation are currently not known but will be the subject of future investigations. In 
the current study, treatment with trichostatin A prevented decreases in acetylated tubulin 
levels after kainic acid exposure, consequently reducing axonal fragmentation and axon loss, 
suggesting that tubulin deacetylation is a key event in excitotoxin induced axon degeneration.  
 
There are three key enzymes involved in microtubule acetylation levels. The major enzyme 
involved in tubulin acetylation state in mammals is alpha-tubulin acetyltransferase 1 (αTAT1; 
Coombes et al., 2016). There are two enzymes involved in deacetylation, histone deacetylase 
6 (HDAC6) and sirtuin 2 (SIRT2; Seto and Yoshida, 2014). In this study, I chose to 
therapeutically target HDAC6 inhibition using the drug, trichostatin A, which has previously 
been investigated in motor neuron degeneration (Lazo-Gómez et al., 2013; Yoo and Ko, 
2011) and used to treat retinal degenerative diseases (reviewed in Zhang et al., 2015b). 
HDAC6 is one of a family of histone deacetylases. There are 18 HDAC enzymes, divided 
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into 4 classes in humans that use either zinc or NAD+ dependent mechanisms to deacetylate 
the lysine substrate. HDACs are substrate-specific and are subject to a range of controlling 
mechanisms, including PTMs and protein to protein interactions (Seto and Yoshida, 2014). 
Trichostatin A is a non-specific HDAC6 inhibitor, which inhibits class I and class II HDACs. 
However, since the current study tested its use in the axonal compartment, I was able to test 
its effect on HDAC6, which is the only HDAC expressed in this compartment. Besides its 
effect on acetylation, it is possible that trichostatin A could have other effects on axon 
degeneration. For example, trichostatin A has been shown to suppress TNF-α expression and 
signalling in a rat model of ischemic injury in the retina (Crosson et al., 2010). Trichostatin 
A can regulate the levels of interleukin-6 and TNF- α and thereby improve neurological 
performance in a rat model of permanent middle cerebral artery occlusion of stroke (Hyeon 
et al., 2007). In future in vivo studies, it would be useful to test other more specific HDAC6 
inhibitors such as, MS-275, which also crosses the blood brain barrier, to determine if these 
would be suitable drugs for further therapeutic development (Yang et al., 2017a; Zhang and 
Schluesener, 2013).   
 
The importance of acetylation in microtubule stability has been widely reported (Howes et 
al., 2014; Portran et al., 2017). It is known that acetylated tubulin protects microtubules 
against mechanical ageing and is also a marker of long-lived microtubules (Portran et al., 
2017). Increasing microtubule acetylation using trichostatin A, has been shown to restore 
axonal transport in rat cortical neurons, following exposure to mutant leucine-rich repeat 
kinase (LRRK2; Godena et al., 2014). The same study showed that in vivo, trichostatin A 
treatment or knockdown of HDAC6 and Sir2-related protein (Sirt2), rescued axonal transport 
in a Drosophila model of mutant LRRK2. In cultured mouse cerebellar granule cells, levels 
of acetylation were compared between Wallerian degeneration slow (WldS) mice, which have 
a mutation that slows Wallerian degeneration (Lunn et al., 1989) and wildtype mice (Suzuki 
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and Koike, 2007). The authors found that base levels of acetylation were increased in WldS 
cells compared to wildtype. Furthermore, the authors showed that the deacetylating enzyme 
SIRT2 plays a key role in resistance of WldS cells to axon degeneration, whereby they found 
decreased SIRT2 in WldS granule cell cytoplasm. Additionally, SIRT2 knockdown enhanced 
microtubule acetylation and reduced axon degeneration in wildtype granule cells. These 
findings also highlight the importance of microtubule acetylation in axon degeneration.  
 
This study also showed that tyrosinated tubulin is unchanged following kainic acid exposure. 
In contrast to acetylation, which is associated with long-lived microtubules, tyrosination is 
present in highly dynamic microtubules at the proximal end of the axon (Witte et al., 2008), 
and has been reported as a destabilising microtubule PTM (Khawaja et al., 1988; Kreis, 1987). 
This suggests that destabilising microtubules through tyrosination is not a key factor in 
driving excitotoxin-induced axon degeneration. In contrast to this, the absence of tubulin 
tyrosine ligase, which promoted tubulin tyrosination, has been shown to severely reduce axon 
regeneration (Song et al., 2015), suggesting that tubulin tyrosination may be more important 
for regeneration rather than degeneration. However, PTMs have also been described 
following developmental axon pruning, which can be modelled in vitro by trophic factor 
withdrawal (reviewed in Saxena and Caroni, 2007). Developmental axon pruning has been 
shown to involve decreases in both acetylation and tyrosination, with an accompanying 
increase in detyrosinated tubulin (Unsain et al., 2018). 
 
In the current study, the influence of taxol, which has been investigated in a number of 
experimental axon degeneration paradigms (as review by Fukuda et al., 2017), and has been 
shown to protect against kainic acid-induced axon degeneration (King et al., 2013) was 
investigated on both acetylated tubulin and tyrosinated tubulin. Acetylated tubulin levels were 
significantly increased after taxol treatment, suggesting that the protective effect of taxol may 
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be through preventing deacetylation. Previous research in a mouse kidney ischemia model 
demonstrated that taxol treatment increased αTAT1 levels in the kidney, but did not change 
HDAC6 expression (Han et al., 2016). The acetylating enzyme, αTAT1 is still able to 
acetylate microtubules, even when stabilised by taxol (Howes et al., 2014), suggesting an 
overall promotion of acetylation in the presence of taxol. However, this thesis also showed 
that taxol decreased tubulin tyrosination. The down-stream effects of this modification on 
axonal health are unclear. 
 
In addition to excitotoxic injury, alterations to microtubules have been demonstrated in other 
forms of axonal injury. For example, dynamic stretch injury of neuronal cultured cells 
induced axon degeneration, which was inhibited by taxol (Tang-Schomer et al., 2010). This 
is in line with earlier research in this area, suggesting that cytoskeletal changes begin as early 
as five minutes post fluid percussive injury (Povlishock and Pettus, 1996), indicating that 
changes to microtubules could be one of the earliest events to occur after initiating axonal 
injury and degeneration. Another study which investigated alpha-tubulin levels after optic 
nerve stretch injury found decreased alpha-tubulin levels between 0.5-4 hours post-injury, 
and a secondary decline after 72 hours post-injury (Serbest et al., 2007). This also suggests 
that microtubules may have an initial role after injury and another role in a secondary event 
post-injury. 
 
One of the limitations of this study is that PTMs were investigated at 1 and 6 hours after 
kainic acid-induced axon degeneration. Future studies could investigate earlier timepoints, 
such as 0.5 hours, however, to target PTMs therapeutically, changes that occur at later 
timepoints, may not be effective targets. Future studies could also investigate the PTM 
glutamylation to identify any changes that may occur to glutamylation during excitotoxicity. 
As tyrosination was unchanged, drugs targeting tyrosination were not investigated in this 
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study, however, future studies could target tyrosination to determine if it affects the process 
of axon degeneration. Furthermore, it will be important to confirm these changes in animal 
models.  
 
4.4.1 Conclusion 
Together the data presented in this thesis, indicate that alterations to microtubule may be an 
early and modifiable event in several forms of axon degeneration. The key finding from this 
study was a significant decrease in acetylated tubulin following excitotoxin exposure, which 
was then targeted by the HDAC6 inhibitor, trichostatin A. With trichostatin A treatment to 
promote acetylation, axon degeneration was significantly reduced. Tyrosinated tubulin was 
unchanged suggesting axon degeneration pathways are not affected by changes to tyrosinated 
tubulin. Together these results demonstrate that altering microtubule acetylation can help 
prevent axon degeneration following excitotoxin exposure. Further deciphering microtubule 
PTMs and their interaction with degenerating pathways will be important in providing 
therapeutic treatment in several neurodegenerative diseases.  
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5 TARGETING MICROTUBULE-ASSOCIATED PROTEINS IN 
EXCITOTOXIN-INDUCED AXON DEGENERATION 
5.1 INTRODUCTION 
5.1.1 Microtubule-associated proteins 
The previous chapter demonstrated that microtubule PTMs played an important role in the 
progression of axon degeneration. By altering the stabilising microtubule PTM, acetylated 
tubulin, axon degeneration was reduced to almost control levels. This suggests that 
microtubules may play a more integral role in axon degeneration pathways than previously 
hypothesised. To further investigate the role of microtubules in excitotoxin-induced axon 
degeneration, this chapter focuses on the potential role of MAPs. Microtubule PTMs 
influence the binding of MAPs (Magiera and Janke, 2014), therefore a loss of binding may 
escalate axon degeneration.  
 
Dissociation of MAPs may be an early event in pathological conditions and may occur 
through altered PTMs or through altered phosphorylation. Dissociation of MAPs can drive 
microtubule instability, leading to degeneration (Baas et al., 2016). In addition, MAPs could 
also be involved in other pathways and may drive other events to cause degeneration, such as 
neuronal signalling and transport (Mietelska-Porowska et al., 2014). 
 
Due to its role in AD and other neurodegenerative diseases, previous research has focussed 
on the MAP tau during axon degeneration (Dawson et al., 2010; Kneynsberg et al., 2017). 
Tau is located in the axonal compartment of a neuron, but in axon degeneration it migrates to 
the somatodendritic compartment. Research has shown that this may be due to initial damage 
to the axon initial segment (Yoshimura and Rasband, 2014), which normally keeps these 
regions separate and may suggest a general disruption to the normal localisation of proteins 
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in the neurons. Another MAP, which has an important role in regulating microtubule stability 
and has been implicated in neurodegenerative disease is collapsin response mediator 2 
(CRMP2; Cole et al., 2007; Gu and Ihara, 2000; Hensley and Kursula, 2016; Isono et al., 
2013; Soutar et al., 2009). CRMP2 has been proposed as a therapeutic target for AD due to it 
being phosphorylated by cdk5 and GSK3β (Yang et al., 2017b) and CRMP2 protects 
microtubules against depolymerisation with nocodazole (Hensley and Kursula, 2016). 
Previous research has shown that CRMP2 binding to microtubules is displaced when exposed 
to taxol or epothilone B, and suggests that it has a similar microtubule binding site to tau (Lin 
et al., 2011).  
 
Another MAP of interest in neurodegeneration is MAP2, which is usually located in the 
dendrites. In disease, and particularly in excitotoxic conditions, MAP2 has been shown to be 
lost from the dendritic compartment (Hoskison et al., 2007). For example, there was an 
irreversible loss of MAP2 from the dendritic compartment in hippocampal slices when 
exposed to excessive NMDA (Hoskison et al., 2007), where MAP2 especially accumulated 
in CA1 hippocampal somata. Similarly, after excitotoxic neuronal damage via a glutamate 
transport inhibitor there was a loss of dendritic MAP2 immunoreactivity and the effects were 
restricted to the CA1 region (Arias et al., 1997). This suggests that MAP2 disruption may be 
a marker of excitotoxicity.  
 
Activation of caspase-3 causes proteolysis of MAP1B and is also degraded by calpain, but 
degradation of MAP1B is prevented by antioxidants, suggesting that reactive oxygen species 
perturbs the microtubule network (Fifre et al., 2006). MAP1B is also widely distributed in 
both dendrites and axons. Although its role in axon regeneration is well-documented 
(Bouquet et al., 2004; Leibinger et al., 2017; Yang et al., 2012), its role in axon degeneration 
is currently unknown.  
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5.1.2 Phosphorylation of microtubule-associated proteins 
Phosphorylation of MAPs is one of the key factors that determines how they bind to 
microtubules (Brugg and Matus, 1991) and it has been proposed that abnormal 
phosphorylation could be potentially a driver of neurodegenerative disease. In this regard, 
hyperphosphorylation of tau and CRMP2 have been reported as an early event in AD (Cole 
et al., 2007; Mondragón-Rodríguez et al., 2014; Rissman et al., 2004). Phosphorylation state 
is controlled by balance of kinase action to add phosphate groups and phosphatase action to 
remove phosphate groups. While there are a number of kinases implicated in 
neurodegenerative disease, which act specifically on the different MAPs, phosphatase activity 
is primarily performed by protein phosphatase PP2A, which removes phosphate groups from 
MAPs (Li et al., 2002; Van Kanegan and Strack, 2009). Protein phosphatase 2A specifically 
binds to tau and MAP2, which are both associated with microtubule stability (Sontag et al., 
2012). This makes activating PP2A an attractive target for investigating MAP 
phosphorylation using drugs such as sodium selenate, which activates PP2A and removes 
phosphate groups (Corcoran et al., 2010). Pharmacological manipulation using sodium 
selenate has been shown to alter microtubule assembly in both in vitro and in vivo models 
(Shi et al., 2013). Therefore, determining whether MAPs are altered following an excitotoxic 
insult and whether altering their phosphorylation affects the degeneration process may lead 
to mechanistic insight in the role of microtubules in excitotoxin-induced axon degeneration. 
 
5.1.3 Study outline 
This study investigated the role of MAPs in an excitotoxin-induced model of axon 
degeneration. To investigate the potential changes to these MAPs, mouse cortical primary 
cell cultures were grown to 10 DIV in culture trays or in microfluidic chambers (as described 
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in section 2.7). To induce excitotoxicity, cultures were treated with kainic acid. Western 
blotting, ELISA and immunocytochemistry were used to determine alterations.  
 
Firstly, the expression levels of some of the major axonally localised MAPs were 
investigated, including: MAP1B, CRMP2, and tau. The dendritic MAP, MAP2 was also 
investigated to determine if location is altered during degeneration. To examine the role of 
MAP phosphorylation, the PP2A activator sodium selenate was used to promote 
dephosphorylation of MAPs. Determining if MAP phosphorylation is an early event of axon 
degeneration can aid our understanding of degenerative mechanisms. Finally, since this 
research has demonstrated an effect of microtubule drugs taxol and trichostatin A on axon 
degeneration, I investigated the effect of these drugs on the expression levels of MAPs to 
determine whether these agents may be driving alterations in MAPs that could affect the 
microtubule cytoskeleton. 
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5.2 METHODS 
5.2.1 Ethics and mice 
All experiments and procedures were approved by the University of Tasmania Animal Ethics 
Committee (A12780 and A15121) and were in accordance with the Australian Guidelines for 
the Care and Use of Animals for Scientific Purposes. C57Bl/6 mice were used in cell culture 
experiments (see section 2.1).  
 
5.2.2 Primary cortical culture 
Mouse cortical neuron cultures were prepared as previously described (King et al., 2013). 
Cortical neurons were prepared from embryonic day 15.5 (E15.5) C57Bl/6 mice. Cortices 
were removed and transferred to 5 mL Hanks Balanced Salt Solution (HBSS, Gibco). Trypsin 
(0.0125%) was added for four minutes at 37ºC, followed by removal of HBSS and replaced 
with 1 mL of initial plating media (Neurobasal media (Gibco) v/v 2% B27 supplement, 0.5 
mM glutamine, 25 µM glutamate, 10% v/v fetal calf serum and 1% v/v 
antibiotic/antimycotic) and mechanically triturated with a 1 mL pipette. Cells were plated 
either into the soma compartment of microfluidic chambers or directly into the wells of poly-
L-lysine coated culture plates. Cells were allowed to adhere to the coverslip (Livingstone) at 
37ºC for 30 minutes prior to adding initial plating media to the chambers. Cells were 
incubated at 37ºC overnight before initial media was replaced with subsequent plating media 
with no fetal calf serum and glutamate. Cells were grown to 10 days in vitro (DIV) at 37ºC 
in 5% CO2 (see section 2.7.1, 2.7.2). 
 
5.2.3 Pharmacological manipulation  
Cells were treated with 0 µM, 10 µM or 25 µM of kainic acid (Sigma Aldrich, 
Lot#SLBD1491V) in DMSO (Sigma Aldrich, Lot#RNBF1056) at 10 DIV. Cells in 12-well 
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plates or the soma compartment of microfluidic chambers were exposed to kainic acid for 6 
and 18 hours. For a set of experiments cells were treated with taxol (Calbiochem, 
Lot#B66835). Cells at 10 DIV in 12-well plates or axonal compartment of microfluidic 
chambers were treated with 10 nM or 100 nM trichostatin A (Sigma Aldrich, 
Lot#026M4036V) for 2 hours before 6 hours of kainic acid. For a subset of experiments cells 
were treated with sodium selenate. Cells at 10 DIV in axonal compartment of microfluidic 
chambers were treated with 100 µM of sodium selenate (Sigma Aldrich, Lot#BCBT2170) for 
1 hour prior to 18 hours of kainic acid exposure (see section 2.8.1).  
 
5.2.4 Live cell imaging and quantification of axonal degeneration 
Microfluidic cultures were imaged on a Nikon TiE live cell microscope, with chambers 
maintained at 37ºC. Imaging was performed prior to treatment and 18 hours following 
treatment. Axonal side of the microfluidic chambers were imaged using 40x objective lens in 
identical regions before and after treatment. Axon degeneration was calculated by counting 
degenerated axons.  
 
5.2.5 ELISA analysis of microtubule post-translational modifications and associated 
proteins 
Cells were harvested with RIPA buffer with protease (cOmpleteTM Mini Protease Inhibitor 
Cocktail tablets, Roche) and phosphatase inhibitors (Phosphatase Inhibitor Cocktail, A.G. 
Scientific). Samples were diluted at 1:300 in 50 µL bicarbonate/carbonate coating buffer 
(AbCam), added to 96-well plate and incubated overnight at 4ºC. For the standard curve, 
protein samples were serially diluted at 1:100, 1:200, 1:400, and 1:800. A blank and no 
primary control were included to correct for ELISA results. Plate was washed with washing 
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buffer (0.01 M PBS with 0.05% v/v tween-20) prior to blocking with blocking buffer (0.01 
M PBS with 5% v/v fetal bovine serum) and incubated at 37ºC for 30 minutes. Plates were 
incubated with detecting antibodies (tau 1:1000 rabbit, DAKO; CRMP2 1:1000 rabbit, Sigma 
Aldrich; MAP1B 1:500 mouse, AbCam) diluted in blocking buffer for 1 hour at room 
temperature (see section 2.8.4). 
 
5.2.6 Immunocytochemistry 
Immunocytochemistry was performed as previously described in section 2.9. After fixation 
cultures were blocked in diluent and incubated with primary antibody MAP2 (1:500, 
Millipore, MAB3418).  
 
5.2.7 Statistical analysis 
Differences for ELISA and axon degeneration counts were evaluated using one-way 
ANOVA, with Tukey’s post-hoc test for multiple comparisons between groups. For kainic 
acid live-imaging experiments two coverslips on five separate culture days were analysed. 
For sodium selenate live-imaging experiments, 1-2 coverslips from four separate culture days 
were analysed. For whole cell kainic acid ELISAs, three coverslips per treatment from four 
separate culture days were used. For whole cell trichostatin A ELISAs, three coverslips per 
treatment from five separate culture days were used. For axon-only kainic acid ELISAs, cells 
were pooled from 2-3 chambers per treatment from four separate culture days. For axon-only 
trichostatin A and taxol ELISAs, cells were pooled from 2-3 chambers per treatment from 
five separate culture days. All statistical analysis and graphs were prepared in GraphPad 
Prism (v6.1). Values were reported as means ± standard error of the mean (SEM), with 
differences considered significant at p<0.05. For a list of all statistical analyses performed, 
see section 8.3.  
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5.3 RESULTS 
5.3.1 The effect of kainic acid on axonal MAPs 
The previous chapter showed kainic acid affected the microtubule PTM, acetylated tubulin. 
This chapter investigated the effect of kainic acid on MAPs. Neuronal cells were grown on 
12-well trays to 10 DIV and were exposed to 25 µM kainic acid for 6 hours, followed by 
protein harvests. Firstly, the MAP tau was investigated. ELISA analysis demonstrated that 
treatment with 25 µM kainic acid significantly (p<0.05) increased tau levels after 6 hours 
(Figure 5.1 A). To further investigate the time-course of altered tau expression, the 
experiment was repeated and protein was harvested at one hour. Tau was also significantly 
(p<0.05) increased at 1-hour after 25 µM kainic acid treatment (Figure 5.1 B). Next CRMP2 
and MAP1B levels were examined using ELISA in neurons following 6 hours kainic acid. 
Like tau, CRMP2 levels were significantly (p<0.05) increased following excitotoxicity 
(Figure 5.1 C). To further examine whether these changes were present specifically in axons, 
neurons were grown in microfluidic chambers, the somatodendritic compartment treated with 
25 µM kainic acid and protein harvested from axons at 6 hours. Similar to the findings in 
whole neurons, axonal tau and CRMP2 were significantly (p<0.05) increased (Figure 5.1 D). 
ELISA analysis demonstrated neuronal MAP1B levels were unchanged (Figure 5.1 E), and 
MAP1B levels in axons were not altered (Figure 5.1 F). Together these data suggest that 
following an excitotoxic insult, expression levels of MAPs tau and CRMP2 are increased in 
the axon from as early as 1-hour post exposure. 
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Figure 5.1 The effect of kainic acid on MAPs 
 
Levels of MAPs were quantitated by ELISA analysis in neurons and axons after 25 µM kainic 
acid treatment for 1 or 6 hours. Quantitation demonstrated that (A) tau was significantly 
increased (p<0.05) after 1 and 6 hours 25 µM kainic acid treatment in whole neurons. (B) 
Analysis of isolated axons from neurons grown in microfluidic chambers confirmed that 25 
µM kainic acid treatment for 6 hours in the somatodendritic compartment significantly 
increased (p<0.05) axonal tau. CRMP2 levels in (C) neurons and (D) axons were significantly 
increased (p<0.05) relative to control following 6 hours kainic acid treatment. MAP1B levels 
in (E) neurons and (F) axons were unchanged compared to control after 25 µM kainic acid 
treatment for 6 hours. Bar graph represents mean ± SEM *p < 0.05 relative to control. 
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5.3.2 The effect of kainic acid treatment on MAP2 
I next examined whether levels of the dendritic MAP, MAP2, were altered following 
excitotoxicity. Using an identical protocol as in section 5.3.1, I demonstrated using Western 
blotting that MAP2 levels in axons were significantly increased (p<0.05) at 1, 3 and 6 hours 
kainic acid exposure, compared to control (Figure 5.2 A). As MAP2 is a dendritic marker and 
levels were detected in the axon after kainic acid treatment with Western analysis, 
immunocytochemical labelling with an antibody against MAP2 was performed to confirm 
whether there was immunoreactivity in the axonal compartment. Cortical neurons grown in 
microfluidic chambers were treated in the somatodendritic compartment with kainic acid for 
1, 3 and 6 hours with 100 µM kainic acid. Qualitative analysis demonstrated that while MAP2 
was not detected in the axonal compartment at 0 hours, at 1-hour post kainic acid treatment, 
MAP2 immunoreactivity was present in the axonal compartment of the chamber (Figure 5.2 
B). After 3 hours, MAP2 was still present, although the labelling was fragmented (Figure 5.2 
C), potentially due to fragmentation of the axons with the higher concentration of kainic acid. 
After 6 hours, MAP2 immunolabelling was less intense relative to the 1 and 3-hour timepoints 
(Figure 5.2 D). These data suggest that excitotoxicity alters the localisation of MAP2 protein 
to the axon. Future studies will determine whether MAP2 mis-localisation is also present 
following lower concentrations of excitotoxin. 
 
5.3.3 The effect of sodium selenate on excitotoxin-induced axon degeneration 
Microfluidic chambers allow compartmentalised separation of axons from the 
somatodendritic compartment, which permits treatment to be applied exclusively to either 
compartment of the chamber. In the previous chapter, trichostatin A applied to axons 
protected them from kainic acid-induced axon loss and axon degeneration. In this study, I 
determined whether treatment of sodium selenate, which acts to increase activity of PP2A,   
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Figure 5.2 Changes to MAP2 after excitotoxin exposure 
 
MAP2 levels were quantitated in neurons following 100 µM kainic acid exposure (A) 
Western blot analysis demonstrated a significant (p<0.05) increase in neuronal MAP2 levels 
after 1, 3 and 6 hours kainic acid treatment relative to control. Representative images to show 
(B) control labelling with beta III tubulin after 6 hours of 100 µM kainic acid treatment. 
MAP2 labelling in the axon compartment of microfluidic chambers after (C) 1 hour, (D) 3 
hours and (E) 6 hours of 100 µM kainic acid treatment. Bar graph represents mean ± SEM *p 
< 0.05 relative to control. Scale bar = 40 µm. 
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thus reducing phosphorylation of MAPs and promoting binding to microtubules, protected 
against axon degeneration. Mouse cortical neurons grown in microfluidic chambers to 10 
DIV were exposed to 100 µM sodium selenate, which has previously been shown to activate 
PP2A in primary neuron culture (Alturkmani et al., 2012; van Eersel et al., 2010), in the 
axonal compartment of microfluidic chambers for 1 hour prior to treatment with 25 µm kainic 
acid in the somatodendritic compartment for 18 hours. Live-imaging of axons was performed 
immediately prior to and post-treatment to determine a degeneration index. Axon loss was 
significantly increased (p<0.05) at 25 µM kainic acid compared to vehicle control (Figure 5.3 
A). However, addition of sodium selenate to the axonal compartment did not significantly 
alter kainic acid-induced axon loss and the combined treatment was still significantly 
(p<0.05) increased compared to vehicle control (Figure 5.3 A). Similarly, axonal sodium 
selenate did not have a protective effect on axon degeneration (Figure 5.3 B). Example live 
images showing axon loss and degeneration after 18 hours of all treatments (Figure 5.3 C-E). 
 
5.3.4 The effect of trichostatin A on axonal MAPs following excitotoxin-induced axon 
degeneration 
As the results show that tau and CRMP2 levels were increased by kainic acid, and I had 
previously shown that trichostatin A protects against kainic acid-induced axon degeneration, 
the effect of trichostatin A on these MAPs was investigated. Neurons were grown in 12-well 
culture trays and treated with trichostatin A for 2 hours followed by kainic acid treatment for 
6 hours, prior to protein harvesting. ELISA analysis of neurons demonstrated that 10 nM 
trichostatin A treatment restored tau to control levels in the presence of kainic acid (Figure 
5.4 A). To determine whether this effect was also present in axons, cortical neurons were 
grown in microfluidic chambers and the same treatment course was added as above before 
protein was harvested from axons.  Similarly, 10 nM trichostatin A restored axonal tau levels   
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Figure 5.3 Axon degeneration and loss after sodium selenate treatment after kainic 
acid treatment  
 
Live-imaging of the axonal compartment of microfluidic chambers were analysed for (A) 
axon loss and (B) axon degeneration index after treatment with 25 µM kainic acid 
(somatodendritic compartment) and 100 µM sodium selenate (axon compartment). Axon loss 
was significantly (p<0.05) increased after treatment with kainic acid. Combined treatment of 
sodium selenate and kainic acid, relative to control did not significantly alter kainic acid-
induced axon loss and degeneration. Representative images of axonal compartment of (C) 
control, (D) kainic acid treatment, and (E) combined treatment of sodium selenate and kainic 
acid. Bar graph represents mean ± SEM *p < 0.05 relative to control. Scale bar is 50 µm.    
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Figure 5.4 Changes to MAPs following kainic acid treatment in the presence of 
trichostatin A  
 
Changes to MAPs were investigated in neurons and isolated axons after treatment with 10 
nM trichostatin A for 2 hours and 25 µM kainic acid for 6 hours. (A) ELISA analysis of tau 
in whole neurons demonstrated significantly increased levels (p<0.05) after kainic acid. In 
trichostatin A treated neurons levels of tau were not different from control. Levels of tau in 
kainic acid and trichostatin A treated neurons were not significantly different from control. 
(B) ELISA analysis of tau in isolated axons demonstrated significantly increased levels 
(p<0.05) after kainic acid treatment. In trichostatin A treated axons, levels of tau were not 
different from control. Levels of axonal tau in kainic acid treated neurons with trichostatin A 
were not significantly different from control. Levels of (C) CRMP2 were significantly 
increased (p<0.05) by either kainic acid or trichostatin A in neurons. Treatment of neurons 
with kainic acid in the presence of trichostatin A also resulted in significantly (p<0.05) 
increased CRMP2. Levels of (D) MAP1B in neurons were unchanged after kainic acid 
treatment but were significantly (p<0.05) increased after trichostatin A treatment and 
combined trichostatin A and kainic acid treatment, compared to control. Bar graph represents 
mean ± SEM *p < 0.05 relative to control.   
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following kainic acid treatments and they were no longer significantly different from vehicle 
control (Figure 5.4 B). However, 10 nM trichostatin A had no effect on neuronal CRMP2 
levels, which remained significantly (p<0.05) higher following kainic acid in the presence of 
10 nM trichostatin A (Figure 5.4 C). Neuronal MAP1B levels were unaffected by kainic acid 
and these were also unchanged at 10 nM trichostatin A treatment (Figure 5.4 D). 
 
5.3.5 The effect of taxol on axonal MAPs following excitotoxin-induced axon degeneration 
As it has been shown that taxol protects against kainic acid-induced axon degeneration, I next 
determined the effect of taxol on MAPs following kainic acid treatment. Neurons were grown 
in microfluidic chambers to 10 DIV and treated with taxol for 2 hours in the axonal 
compartment prior to 6 hours of kainic acid treatment in the somatodendritic compartment 
before axonal protein was harvested. As described previously, tau levels were significantly 
increased (p<0.05) after kainic acid treatment compared to vehicle control. When combined 
with treatment with axonal taxol, tau levels continued to be significantly increased (p<0.05) 
compared to vehicle control following kainic acid treatment, and did not differ from kainic 
acid treatment alone (Figure 5.5 A). As previously demonstrated, CRMP2 levels were 
significantly increased (p<0.05) after kainic acid treatment, and continued to be significantly 
increased (p<0.05) after taxol treatment and combined taxol and kainic acid treatment, 
compared to vehicle control (Figure 5.5 B). As demonstrated in previous results, MAP1B 
levels were not significantly increased after kainic acid treatment, compared to vehicle 
control. However, after taxol treatment alone and combined taxol and kainic acid treatment, 
MAP1B levels were significantly increased (p<0.05) compared to vehicle control (Figure 5.5 
C). 
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Figure 5.5  Changes to MAPs following kainic acid treatment in the presence of taxol 
 
Changes to MAPs were investigated in isolated axons after treatment with 10ng taxol for 2 
hours and 25 µM kainic acid for 6 hours. (A) Tau was significantly increased in axons 
(p<0.05) in all treatment groups. (B) CRMP2 and (C) MAP1B levels were significantly 
increased in axons (p<0.05) after taxol treatment and combined taxol and kainic acid 
treatment in axons. (D) MAP2 levels were significantly (p<0.05) increased in axons 
compared to control after kainic acid treatment. MAP2 levels were unchanged by axonal taxol 
treatment with axonal taxol and somatodendritic kainic acid, MAP2 levels in axons were 
significantly (p<0.05) increased relative to control. MAP2 control levels of the axon were 
very low, and are expressed as 100%. Bar graph represents mean ± SEM *p < 0.05 relative 
to control.   
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5.3.6 The effect of taxol on MAP2 following excitotoxin-induced axon degeneration 
As this thesis demonstrated the altered localisation of MAP2 following kainic acid treatment, 
the effect of taxol on axonal MAP2 was examined. MAP2 levels in untreated axons of cortical 
neurons grown in microfluidic chambers were very low, however, for data interpretation this 
was defined as 100%. ELISA analysis demonstrated that after 25 µM kainic acid treatment, 
axonal MAP2 levels were significantly increased (p<0.05) compared to vehicle control. Taxol 
alone applied to the axonal compartment did not significantly affect MAP2 levels. 
Furthermore, taxol did not significantly affect the increased axonal levels of MAP2 induced 
by kainic acid treatment and levels remained significantly increased (p<0.05) compared to 
vehicle control and taxol alone treatment (Figure 5.5 D). 
 
Together these results suggest that targeting acetylation by trichostatin A can alter MAPs and 
prevent axon degeneration, suggesting that targeting microtubule PTMs which are altered 
during excitotoxicity, could be a potential therapeutic target in several neurodegenerative 
diseases.  
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5.4 DISCUSSION 
The current study investigated the potential of targeting MAPs to protect against excitotoxin 
induced axon degeneration. Firstly, the expression levels of key axonal and somatodendritic 
MAPs were investigated. Microtubule-associated proteins play an important role in 
stabilising microtubules, so early changes to these proteins could enhance degeneration. 
Secondly, the effect of promoting MAP dephosphorylation through increasing activity of 
PP2A on axon degeneration was determined. I also determined how treatment with 
microtubule targeting drugs, which have been shown to protect axons following 
excitotoxicity, affected expression of MAPs following excitotoxicity. As microtubule 
alterations do not occur in isolation it is important to understand the downstream effects of 
any microtubule targeting drug. This study had a number of key findings that have increased 
our understanding of the role of MAPs following excitotoxicity. Firstly, following an 
excitotoxic insult there are changes in expression levels as well as a localisation of MAPs. 
Furthermore, treatment with trichostatin A or taxol has the capacity to prevent some of these 
changes to MAPs. I also showed that promoting dephosphorylation via PP2A is unlikely to 
protect against excitotoxin-induced axon degeneration. 
 
In this study, I showed that excitotoxicity induced a significant increase in the expression of 
both tau and CRMP2. In the current study tau was shown to be increased as early as one hour 
after kainic acid treatment. It is currently unclear whether this increase in tau is through 
altered translation or reduced clearance of the protein. Kainic acid induced-excitotoxicity in 
a mouse model caused initial dephosphorylation of tau, followed by sustained 
hyperphosphorylation, possibly due to activation of cdk5 and down-regulation of PP2A 
(Liang et al., 2009). Overexpression of tau, induced by NMDA receptors, has been shown to 
mediate neuronal death by suppressing ERK phosphorylation (Sun et al., 2016). Since tau’s 
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function is to stabilise microtubules, increased tau levels could be a compensatory 
mechanism, potentially to increase microtubule stability. However, research has increasingly 
investigated tau secretion into the extracellular space, increased tau expression could lead to 
increased release of tau, potentially leading to the spread of tau pathology and an increase in 
Ab production (Dubal, 2018; Yamada, 2017). Levels of soluble and insoluble tau reflect the 
phosphorylation status of tau in vivo (Hirata-Fukae et al., 2009) and soluble tau has been 
shown to decrease the structural plasticity of hippocampal neurons (Bolós et al., 2017).  
 
The effects of altered tau expression are currently debated. Tau knockdown results in learning 
and memory deficits in mouse models (Velazquez et al., 2018), whereas overexpression of 
tau results in increased phosphorylated tau, which has shown to protect against oxidative 
stress (Castellani et al., 2008), but is also implicated in neurodegenerative disease (Kadavath 
et al., 2015; Sontag et al., 1996). Furthermore, the phosphorylation state of tau, which was 
not investigated in the current study, is an important indicator of tau binding to microtubules, 
which is reported to inhibit axonal transport (Cox et al., 2016; Dubey et al., 2008), which can 
be rescued by changing tau’s phosphorylation status (Kanaan et al., 2012). Interestingly, it 
has been shown that tau inhibits HDAC6 function (Perez et al., 2009), further supporting a 
protective role for the increased tau expression. However, it is currently unclear whether 
increased tau following excitotoxicity plays a protective or detrimental role. 
 
The changes in tau prompted examination of expression levels of other MAPs and 
demonstrated that like tau, CRMP2 was significantly increased following excitotoxin 
exposure. The dysregulation and hyperphosphorylation of CRMP2 has been observed in AD 
(Hensley and Kursula, 2016; Williamson et al., 2011) and does not occur in other 
neurodegenerative diseases (Cole et al., 2007; Soutar et al., 2009; Williamson et al., 2011). 
CRMP2 is a MAP with a number of similarities to tau as it regulates microtubule stability, is 
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regulated by the same kinases as tau (Cole et al., 2008) and PTMs of CRMP2 may also 
contribute to disease (Hensley and Kursula, 2016). However, to date neuropathic mutations 
in CRMPs have not been reported. CRMP2 has been studied in an axon degeneration model 
of the optic nerve where CRMP2 is a downstream target of calpain, which cleaves CRMP2, 
leading to axon degeneration (Zhang et al., 2016). When calpain is inhibited and CRMP2 is 
overexpressed, it protects axons against acute axon degeneration (Zhang and Koch, 2017), 
suggesting that increased expression of CRMP2 may be a neuroprotective strategy in our 
model. Although CRMP2 phosphorylation was not investigated in the current study, previous 
research has shown that in contrast to our kainic acid induced excitotoxicity model, 
excitotoxicity through NMDA exposure reduces phosphorylation of CRMP2 and promotes 
CRMP2 cleavage after 6 hours (Yin et al., 2013). MAP1B levels, which are associated with 
microtubule stability (Riederer, 2007) were unchanged in this study, suggesting excitotoxin-
induced axon degeneration does not affect microtubule stability thorough MAP1B alterations.  
 
Phosphorylated MAP expression was not examined in the current study, although the effect 
of promoting MAP phosphorylation with sodium selenate was examined. In particular, PP2A, 
the target of sodium selenate, has been shown to bind to tau and MAP2 (Sontag et al., 2012). 
In this study, treatment with sodium selenate had no effect on axon loss or axon degeneration 
after kainic acid treatment.  
 
Phosphorylation states of cytoskeletal proteins are regulated via protein kinase and 
phosphatase activity. Transduction of cellular signalling propagates through MAPK cascades 
and is mainly controlled by phosphorylation events (Nguyen et al., 2013). For example, 
neuronal MAP2 can regulate organelle transport within the axons and dendrites and the 
regulation of protein kinases for signal transduction (Sánchez et al., 2000). Other kinases such 
as MAP kinase kinases (MKK) can also activate kinases which regulate MAP 
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phosphorylation. For example, phosphorylation of tau by isoforms of MAPK p38, promotes 
microtubule assembly (Zarubin et al., 2005). Upstream signals by either extracellular stimuli 
such as inflammatory cytokines like TNF-a, or growth factors like CSF-1, can activate MAP 
kinases (Zarubin et al., 2005). Thus, phosphorylation in the microtubule-binding domain of 
MAPs by protein kinase p110 can regulate microtubule dynamics within neurons (Illenberger 
et al., 1996). 
 
To more fully understand the role of MAP phosphorylation in excitotoxin-induced axon 
degeneration, further studies should examine the phosphorylation state of MAPs after kainic 
acid exposure, both with and without sodium selenate. 
 
An unexpected finding of interest in the current study was the mis-localisation of MAP2 to 
the axon following excitotoxicity. It has been reported that during axon degeneration, axonal 
tau enters the dendritic compartment (Li et al., 2011), however, alterations to MAP2 
localisation have not previously been reported. Previous research has shown that dendritic 
MAP2 is lost from the apical dendrites after NMDA-induced dendritic injury in hippocampal 
slices (Hoskison et al., 2007) and in a rat model of glutamate-induced excitotoxicity, 
immunoreactivity of MAP2 in the dendrites was reduced (Irving et al., 1996). Increased levels 
in MAP2 in aged wildtype mice have been associated with cognitive decline (Benice et al., 
2006). In the current study, ELISA analysis demonstrated that MAP2 levels in axons were 
significantly increased after 25 µM kainic acid treatment. This was also confirmed with 
MAP2 immunolabelling in the axonal chamber after 100 µM kainic acid treatment. This 
supports the hypothesis that there may be breakdown of the axon initial segment, which 
separates MAPs to their respect compartments, after excitotoxicity (Clark et al., 2017; Evans 
et al., 2015; Leterrier, 2018). 
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This thesis investigated the downstream effects of microtubule-modifying drugs on MAPs. 
After promoting acetylation with trichostatin A, tau was unchanged compared to control, 
suggesting that increasing the PTM acetylation does not influence tau. However, trichostatin 
A increased CRMP2, which may promote microtubule stability through binding to tubulin 
heterodimers (Fukata et al., 2002). The relationship between acetylated tubulin and CRMP2 
is currently not understood. Taxol treatment also increased CRMP2, and in an in vivo model 
taxol has been shown to abolish microtubule association of CRMPs (Lin et al., 2011). 
Inhibition of the tau phosphate kinase GSK3b has shown to improve CRMP’s ability to 
promote microtubule polymerisation (Lin et al., 2011). This suggests that taxol could be 
potentially promoting microtubule stability via increasing CRMP2 expression. MAP1B was 
unchanged after trichostatin A treatment, which suggests that acetylation does not influence 
MAP1B expression, however, taxol does increase MAP1B expression. MAP1B has been 
shown to bind to taxol-stabilised microtubules (Ma et al., 2000; Pedrotti and Islam, 1996).  
 
Taxol treatment increased tau expression, which could be due to competitive binding at the 
tau binding site, leading to tau dissociation from microtubules, and increasing tau secretion. 
Taxol has no effect on MAP2 expression, although taxol-induced flexibility of microtubules 
is decreased after the addition of MAP2 or tau (Dye et al., 1993).  
 
This study has a number of limitations that could be addressed in future studies. Firstly, MAPs 
were investigated at six hours after kainic acid-induced excitotoxicity, and it would be of 
interest to examine earlier timepoints in future studies. Furthermore, it would be of interest 
to investigate the mechanism of MAP altered expression either through increased synthesis 
or decreased breakdown. Inhibiting phosphorylation of MAPs via sodium selenate treatment 
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was shown to not prevent axon degeneration, but the phosphorylation of specific MAPs was 
not investigated in the current study, and should be investigated in the future.  
 
5.4.1 Conclusion 
Together these data demonstrate that changes to the expression and localisation of MAPs are 
an early event in axon degeneration and that these can be modulated by a number of 
microtubule-targeting drugs, suggesting a complex interplay between microtubule modifying 
agents which needs to be considered in any therapeutic intervention. There has been much 
focus in neurodegenerative disease research around altered phosphorylation of MAPs. 
Although this data suggests that reducing phosphorylation of MAPs does not protect against 
degeneration, examining MAP phosphorylation as well as how proteins investigated in this 
study are altered by excitotoxic treatment, will be of interest in future studies.  
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6 FINAL DISCUSSION 
 
 
This thesis sought to investigate the potential of microtubules as a therapeutic target in AD 
and to identify other more specific targets through understanding the mechanisms of axon 
degeneration. The pathological processes that occur in axons leading to their degeneration are 
under intense investigation. This thesis focussed on cellular and axonal changes following an 
excitotoxic insult, as this is implicated in many neurodegenerative diseases and injury. 
Specifically, the alterations to microtubules and associated proteins was investigated as well 
as the downstream consequences of these changes and how they can be target therapeutically 
to prevent axon degeneration. In addition, the effect of microtubule stabilisation on the 
pathological features of an AD model of amyloidosis was investigated. The data presented in 
chapters four and five demonstrate that following an excitotoxic insult the microtubule 
cytoskeleton undergoes a number of changes, some of which are directly related to axon 
degeneration. The data presented in this thesis also highlights the significant interplay 
between microtubule modifications, in that one modification cannot be targeted without 
causing changes to other parts of the cytoskeleton. 
 
One of the major outcomes of this thesis, is the characterisation of microtubule alterations 
that occur after excitotoxin-induced axon degeneration in a primary cell culture model. The 
PTM, acetylation was significantly decreased, whereas the MAPs, tau and CRMP2 were 
significantly increased after excitotoxin-induced axon degeneration. Furthermore, targeting 
the PTM acetylation with an HDAC6 inhibitor, trichostatin A, not only promoted acetylation 
following excitotoxic insult, but also prevented axons from degenerating. This finding 
endorses microtubules as a therapeutic target in axon degeneration.  
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Hyperphosphorylation of MAPs, particularly tau, has been identified in AD. This thesis 
investigated whether phosphorylation of MAPs through the activation of the phosphatase 
PP2A can drive axon degeneration. In this in vitro study, activating PP2A via application of 
sodium selenate did not prevent axon degeneration or axon loss in a model of excitotoxin-
induced axon degeneration. This suggests that phosphorylation status of MAPs may not have 
a driving role in excitotoxin-induced axon degeneration.  
 
Finally, a number of microtubule-associated alterations were documented in the presence of 
microtubule-modulating drugs in this thesis. Of note, the microtubule-stabilising agent 
epothilone D significantly decreased phosphorylated neurofilament levels in the cortex and 
hippocampus of APP/PS1 and wildtype mice at 15-months of age. This finding highlights a 
potential compensatory mechanism within the cytoskeleton, whereby increased levels of 
stabilised microtubules, promotes decreased phosphorylated neurofilament levels. This result 
is also in accordance with previous research (Liu et al., 2012), which showed decreased 
neurofilament after promoting microtubule levels. Despite this effect on the cytoskeleton, 
there were no alterations in the number of dystrophic neurites surrounding plaques and no 
alteration in amyloid pathology, supporting safety of this drug for reduction of tau pathology 
in AD. 
 
Can microtubule changes drive degeneration of the axon? 
A hypothesis of this thesis was that microtubules undergo alterations during excitotoxin-
induced axon degeneration, which can drive the fragmentation and loss of the axon. To 
determine potential changes to microtubule modifications and associated proteins, a model of 
axon degeneration was utilised. In this model, cultured neurons were grown in a 
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compartmentalised microfluidic chamber and changes to axons were determined following 
application of the excitotoxin kainic acid.  
 
After kainic acid-induced axon degeneration, acetylated tubulin was significantly decreased 
in the axon. It was hypothesised that this reduction could drive axon degeneration as 
acetylated tubulin is associated with microtubule stability (Howes et al., 2014; Janke et al., 
2017). To test this hypothesis, trichostatin A treatment was used to inhibit the activity of the 
de-acetylase HDAC6, and therefore promote acetylation. Treatment of axons with trichostatin 
A resulted in protection of the axon following excitotoxicity, demonstrating a key role for 
microtubule changes in axon fragmentation and loss following kainic acid. This result is in 
line with previous experiments suggesting that acetylated tubulin levels are affected before 
microtubule breakdown during axon degeneration (Neumann and Hilliard, 2014). This 
suggests that the PTM acetylation has a major role in preventing axon degeneration and that 
microtubule changes may drive degeneration of the axon. However, the role of acetylated 
tubulin in microtubule stability is not simple. For example, it has been documented that 
acetylated tubulin promotes the binding activity of the microtubule severing enzyme, katanin, 
which would potentially increase microtubule breakdown rather than decreasing it (Sudo and 
Baas, 2010). This suggests that other microtubule alterations promote microtubule breakdown 
in axon degeneration and it is not through enhanced severing by katanin. However, it would 
be of interest to rule out increased katanin binding and microtubule severing as a protective 
effect of acetylation in future studies. 
 
Previous research has shown that the microtubule-stabilising drug taxol protects against 
kainic acid-induced axon degeneration (King et al., 2013). This prompted investigation into 
whether taxol also promotes microtubule acetylation. This thesis demonstrated that acetylated 
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tubulin was significantly increased in axons following taxol treatment, and this result is in 
line with previous research demonstrating that acetylated tubulin is significantly increased 
after taxol in non-neuronal cultured cells (Piperno et al., 1987; Webster et al., 1990) and in a 
kidney injury model (Han et al., 2016). Thus, increased tubulin acetylation in the presence of 
taxol is a potential protective mechanism for taxol following excitotoxic insult. The exact 
mechanism by which taxol protects axons from degeneration following excitotoxin exposure 
is currently unknown, however, it has been reported that other microtubule PTMs are also 
increased after taxol treatment. Detyrosinated tubulin has been demonstrated to be increased 
after treatment with taxol in cultured cells (Gundersen et al., 1987). In line with this data, 
tyrosinated tubulin was significantly decreased after treatment with taxol in this thesis. 
Tyrosinated tubulin is mainly located at the distal end of the axon, and at high levels, is 
associated with microtubule instability and can cause motor proteins to disassociate from 
microtubules. Tyrosination tubulin levels were unchanged after excitotoxin exposure, 
suggesting that tyrosinated tubulin does not have a driving role in microtubule breakdown 
during axon degeneration. Tyrosinated tubulin also recruits plus-end tracking proteins 
(+TIPs) that contain a CAP-Gly domain (Hammond et al., 2008) and as tyrosinated tubulin 
was unchanged by kainic acid treatment in this thesis, it could suggest that there was also no 
change to +TIPs bound to microtubule plus-ends, thus there is no consequential rapid 
depolymerisation. This could suggest a different mechanism for microtubule breakdown, so 
instead of rapid microtubule depolymerisation, severing protein activity could be enhanced 
by the other major microtubule severing enzyme spastin. Another PTM, glutamylation, 
enhances spastin severing activity, however, glutamylation expression during axon 
degeneration is widely disputed (Lacroix et al., 2010; Valenstein and Roll-Mecak, 2016). 
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To determine if targeting microtubules via replacement of tau can prevent axons from 
degenerating, taxol can be used, as it has the same microtubule binding site as tau. Previous 
research has shown that treatment with taxol followed by kainic acid-induced excitotoxicity 
prevents axon degeneration in vitro (King et al., 2013). To determine whether other 
microtubule changes can drive degeneration of axons, MAPs were also investigated in this 
thesis. Driving MAP dephosphorylation via PP2A activation, which should increase MAP 
binding to microtubules, did not provide a protective effect on axons in this study, suggesting 
altered MAP phosphorylation is not a driving factor in axon degeneration. However, a 
limitation of this study was that the phosphorylation of MAPs was not confirmed and 
concentrations of sodium selenate followed previous literature. Despite this, levels of some 
MAPs, including tau and CRMP2 were altered following excitotoxicity. Since CRMP2 and 
tau are reported to stabilise microtubules (Hensley and Kursula, 2016; Lin et al., 2011; 
Mokhtar et al., 2013), it could be hypothesised that increased levels of these proteins are 
neuroprotective at early stages of degeneration. In this regard, it has been shown that cleavage 
of CRMP2 occurs in axon degeneration after injury (Taghian et al., 2012). However, the role 
of tau and CRMP2 in axon degeneration is controversial as loss of tau has been shown to be 
neuroprotective (DeVos and Hyman, 2017; Zhang et al., 2009) and over-expression of 
CRMP2 can result in microtubule disassembly, as reported in dopamine-induced neuronal 
apoptosis (Hou et al., 2008). Although the role of CRMP2 and tau in axon degeneration are 
unclear, in the current study, trichostatin A and taxol significantly increased CRMP2 
expression suggesting that increased tau and CRMP2 do not drive axon degeneration. Future 
studies will further investigate the cause of CRMP2 and tau alterations in kainic acid-induced 
axon degeneration and whether their role is protective or detrimental.  
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MAP1B levels were not altered following kainic acid-induced axon degeneration, although 
they were altered by treatment with trichostatin A. This suggests that MAP1B is not involved 
in this specific axon degeneration pathway. MAP1B regulates tyrosination of alpha-tubulin 
(Utreras et al., 2008), which was also unchanged. This suggests that tyrosinated microtubules, 
which are predominately located at the distal end of the axon, are not driving kainic acid-
induced axon degeneration.  
 
In summary, targeting microtubules via the PTM acetylation and the MAP tau, could prevent 
degeneration of axons, and may be useful therapeutic targets of neurodegenerative disease 
and injury. 
 
Could pathological alterations in AD be explained by chronic excitotoxicity? 
This thesis investigated the downstream effects of chronic excitotoxin exposure, a 
pathological process that has been implicated in AD (Hynd et al., 2004; Ong et al., 2013; 
Wang and Reddy, 2017). It is therefore of interest to examine whether alterations described 
in neurons in this thesis share any similarities with neuronal alterations in AD. In particular, 
one of the pathological alterations that occur in AD and other neurodegenerative diseases are 
aggregation of MAPs. The MAPs, tau and CRMP2 both undergo abnormal 
hyperphosphorylation prior to pathology (Soutar et al., 2009), resulting in aggregation 
(Watamura et al., 2016) and with likely downstream functional consequences such as the 
impairment of axonal transport (Mokhtar et al., 2018). Despite extensive research, there is 
still no consensus on the mechanisms by which tau and CRMP2 are altered in AD. This thesis 
demonstrated that excitotoxicity also has an effect on MAPs, and particularly on CRMP2 and 
tau. Although phosphorylation was not examined in this thesis, the results suggest that 
excitotoxicity could be driving pathological changes in AD. For example, previous studies 
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have shown that during glutamate excitotoxicity, CRMP2 is phosphorylated by 
calcium/calmodulin-dependent protein kinase II (CaMKII) and is associated with axonal 
varicosities, however, over-expression of CRMP2 increases axonal resistance to glutamate 
toxicity (Hou et al., 2009). This could suggest that excitotoxicity which occurs in AD (Hynd 
et al., 2004; Ong et al., 2013; Wang and Reddy, 2017), could lead to phosphorylation of 
CRMP2, in turn causing axon damage. In addition, CRMP2 interacts with NMDA receptors 
and regulates their function (Brustovetsky et al., 2014), indicating the relationship between 
CRMP2 and excitotoxicity.  
 
Tau is a key aggregating protein, which causes pathology in several neurodegenerative 
diseases, including AD (Iqbal et al., 2010). Tau hyperphosphorylation is a well-studied 
pathology in AD (Gong and Iqbal, 2008; Šimić et al., 2016; Wang et al., 2013). Tau 
phosphorylation at multiple sites in the brain has been shown to be dysregulated during kainic 
acid excitotoxicity in a mouse model (Liang et al., 2009). This may suggest that excitotoxicity 
via glutamate receptors or Ab-induced toxicity (Pallo et al., 2016) contributes to AD 
pathology by promoting abnormal phosphorylation of tau. The finding that tau is upregulated 
following excitotoxicity was an unexpected finding in this thesis. It is unclear whether tau is 
also upregulated in AD, however, recent research has highlighted novel roles for tau, 
including tau secretion, which may contribute to the pathological spread of tau pathology 
(Dubal, 2018). 
 
Another unexpected finding in this thesis was that MAP2, a dendritic protein was observed 
in the axonal compartment after kainic acid-induced excitotoxicity. To my knowledge, this is 
the first time MAP2 has been described in the axonal compartment, although other research 
has shown that MAP2 expression is decreased in the dendrites after excitotoxicity in rat 
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hippocampus (Arias et al., 1997). Previous research has demonstrated that tau mis-localises 
to the dendrites in AD (Hoover et al., 2010). Together these data may suggest that in 
excitotoxic conditions, there is a general mis-localisation of MAPs, perhaps due to the 
breakdown of the axon initial segment (Leterrier, 2018; Sohn et al., 2016). 
 
In summary, proteins associated with microtubules may be altered by excitotoxic mechanisms 
in AD, and contribute to pathology. Therefore, targeting MAPs may be a valid therapeutic 
approach for AD.   
 
Could we safely target microtubules in neurodegenerative disease? 
Microtubule-stabilising drugs have been proposed as a potential therapeutic target in AD due 
to the extensive tau pathology in the brains of AD patients. Although microtubule-stabilising 
drugs have been trialled in mutant tau models, the effects of microtubule stabilisation on the 
pathology associated with amyloidosis has not been investigated (Brunden et al., 2010; Zhang 
et al., 2012; Matsuoka et al., 2008; Barten et al., 2012). Thus, one of the aims of this study 
was to determine if the microtubule-stabilising drug epothilone D affects the deposition of 
plaques and associated pathology in the APP/PS1 mouse model of AD. 
 
Maintaining the structural stability of the cytoskeleton during axon degeneration has been 
identified as a key stage in which to delay and/or prevent axon degeneration. The finding in 
chapter 3 that phosphorylated neurofilament protein is significantly reduced after epothilone 
D treatment in APP/PS1 and wildtype mice, suggests a direct link between the microtubule 
and neurofilament cytoskeleton (Zhao et al., 1994), that should be taken into consideration. 
In larger diameter axons, neurofilaments dominate microtubules by 10-fold (Lee and 
Cleaveland, 1996), however, in small diameter axons, fewer neurofilaments are present, and 
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a higher density of microtubules are present (Friede and Samorajski, 1970). Neurofilament 
accumulations have been implicated in a number of neurodegenerative diseases, including 
AD and it is unclear whether reducing neurofilaments would be a protective strategy in 
disease. In this thesis, epothilone D-induced reduction of phosphorylated neurofilament did 
not alter dystrophic neurite pathology in 15-month old APP/PS1 mice. However, a limitation 
of the current study, was the effect of epothilone D on overall levels of neurofilament proteins 
was not assessed and should be addressed in future studies. Despite the effects on the 
cytoskeleton induced by epothilone D, there were no alterations to other AD pathological 
features, such as amyloid plaque deposition and synaptic density suggesting that use of this 
drug to stabilise axons would not cause other detrimental effects. Epothilones have already 
been successfully used as therapeutics for various types of cancer and have undergone clinical 
trials (Beer et al., 2007; Eng et al., 2004; Lee et al., 2007). More recently, epothilones have 
also had success in mouse models of neurodegenerative disease, particularly tauopathies 
(Brizuela et al., 2014; Brunden et al., 2010; Fournet et al., 2012; Ruschel et al., 2015; Yu et 
al., 2018; Zhang et al., 2012a).  
 
The current study identified a protective effect of the microtubule-stabilising drug trichostatin 
A on axons following kainic acid-induced excitotoxicity. This drug has previously been 
shown to be a successful therapeutic in several models of disease, including models of spinal 
muscular atrophy, arthritis and osteoclastogenesis (Avila and Burnett, 2007; Huber et al., 
2007; Liu et al., 2014; Moreira et al., 2003; Nasu et al., 2008; Rahman et al., 2003; Williams 
et al., 2011; Yoo and Ko, 2011). However, although in this thesis, trichostatin A was used to 
target HDAC6 by application to the axonal compartment, trichostatin A is not specific for 
HDAC6. For example, trichostatin A has been shown to alter DNA replication in human cells 
(Kemp et al., 2005), and is a clastogen in human lymphoblasts in vitro (Olaharski et al., 2006). 
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It has also been shown to induce apoptosis in a human lung carcinoma cell line, suggesting 
that it has anti-cancer activity (Choi, 2005) and has been suggested to be a promising therapy 
for AD (as reviewed by Xu et al., 2011). Trichostatin A was shown to have no effect on 
removing plaques in an AD mouse model, however it was effective at preventing the 
formation of new amyloid deposits, although the size of existing plaques increased (Yang et 
al., 2014). Inhibition of another HDAC, HDAC3 reverses AD-related pathology in vitro and 
in an AD mouse model and alleviates memory impairment (Janczura et al., 2018). 
Trichostatin A has also been shown to ameliorate endotoxin-induced neuroinflammation and 
cognitive dysfunction in a endotoxin-induced mouse model (Hsing et al., 2015). In this thesis, 
treatment with trichostatin A significantly decreased axonal tau back to vehicle control levels 
following kainic acid exposure. This may suggest that trichostatin A has a beneficial effect 
on tau, although future studies will need to investigate this further. Based on the results of 
this thesis, and previous research, HDAC6 inhibitors warrant further investigate in the context 
of AD. However, although numerous HDAC6 inhibitors are FDA-approved for human use 
(as reviewed by Suraweera et al., 2018), blood brain barrier penetration needs to be 
considered.  
 
The main limitations of this thesis include the use of cell culture models, and the use of an 
animal model of AD. Future studies should focus on confirming the cell culture results in 
vivo. Furthermore, the APP/PS1 mouse model of AD used in this thesis does not exhibit all 
AD pathology, in particular, there is no tau neurofibrillary tangle pathology present. 
Therefore, the results of the current study should be confirmed using a mouse model 
exhibiting neurofibrillary tau pathology. Other limitations of the APP/PS1 mouse model used 
include the over-expression of APP driven by the prion promoter, with expression likely far 
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higher than in familial AD. The mice also start developing pathology at a young age (3 
months), which is not in the context of ageing.  
 
In summary, research suggests that microtubules are able to be targeted safely as a therapeutic 
for neurodegenerative diseases and microtubule-targeting drugs have shown efficacious 
results in mouse models of neurodegenerative diseases. However, translation of these 
outcomes to humans has been challenging, with clinical trials being terminated at Phase II or 
Phase III. Increased understanding of the mechanisms of microtubule disruption that occur in 
neurodegenerative diseases, will identify more specific targets for intervention and improve 
the likelihood of successful treatment. 
 
Conclusions 
The studies undertaken in this thesis further our understanding of how microtubules are not 
only altered, but can also be targeted to prevent axon degeneration. Based on previous 
literature, the alterations of microtubules during axon degeneration were unclear, but the 
results presented in this thesis elucidated some of the unknown alterations. Future studies of 
axon degeneration will continue to investigate alterations to microtubules, specifically the 
role of phosphorylated tau, and if it is altered after treatment with trichostatin A or taxol. 
Furthermore, other microtubules PTMs such as detyrosination and glutamylation should be 
investigated, as their role in axon degeneration is currently unclear. The studies described in 
this thesis provide insight into the axonal changes that occur following kainic acid-induced 
excitotoxicity, provide a greater understanding of disease mechanisms in axon degeneration 
and highlights new potential therapeutic targets. 
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8 APPENDICES 
8.1 COMMON LABORATORY REAGENTS 
0.01 M Phosphate Buffered Saline (PBS) – 1.0 L 
850 mL MilliQ® water 
100 mL 90.0 gL-1 Sodium chloride 
40 mL 28.0 gL-1 Di-sodium hydrogen orthophosphate  
10 mL 31.2 gL-1 Sodium di-hydrogen orthophosphate (NaH2PO4.2H2O; Ajax, 
Australia) 
4% Paraformaldehyde – 1.0 L 
40 g granulated paraformaldehyde (PFA) 
500 mL MilliQ® water 
400 mL 28.0 gL-1 Na2HPO 
100 mL 31.2 gL-1 NaH2PO4.2H2O 
1.0 M NaOH & 1.0 M HCl to pH 
Heat MilliQ® to 80ºC, add granulated PFA and 5 drops of NaOH. Stir until PFA 
dissolved, add NaH2PO4.H2O and Na2HPO. Filter and pH to 7.4. 
Tissue Storage Solution – 500 mL 
500 mL 0.01 M PBS 
0.5 g sodium azide 
Cryoprotectant Solution (30% sucrose) – 500 mL 
500 mL 0.01 M PBS 
150 g sucrose 
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0.02% sodium azide 
Initial Plating Media – 500 mL 
500 mL Neurobasal medium 
2% v/v B27 supplement 
10% v/v fetal calf serum 
0.5 mM glutamine 
25 mM glutamate 
1% v/v antibiotic/antimycotic 
Subsequent Plating Media – 500 mL 
500 mL Neurobasal medium 
2% v/v B27 supplement 
0.5 mM glutamine 
1% v/v antibiotic/antimycotic 
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8.2 STATISTICAL ANALYSIS 
 
Table 8.1  Statistical analysis for chapter 3 
Figure 
Number 
Figure Name Panel n Statistics p-value 95% Confidence 
Interval for Mean 
Figure 3.1 The effect of 
epothilone D 
treatment on weight 
in APP/PS1 mice 
 
 
A 
 
9 per 
group 
Two-way ANOVA 0.0684   
        
Figure 3.2 The effect of 
epothilone D 
treatment on 
behaviour and 
cognition in 
APP/PS1 mice 
 
A 9 per 
group 
Two-way ANOVA 0.0937   
        
  
 
 
B 
 
9 per 
group 
Two-way ANOVA, 
Tukey’s post hoc test 
0.0370 -2.680 -0.07161 
  C 9 per 
group 
Two-way ANOVA, 
Tukey’s post hoc test 
0.0367 -1607 -43.18 
        
  D 9 per 
group 
Two-way ANOVA 0.6550   
        
  F 9 per 
group 
Two-way ANOVA 0.2846   
        
  G 9 per 
group 
Two-way ANOVA 0.3820   
        
Figure 3.3 The effect of 
epothilone D 
treatment on 
A 9 per 
group 
Two-way ANOVA 0.1137   
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Figure 
Number 
Figure Name Panel n Statistics p-value 95% Confidence 
Interval for Mean 
cognition in 
APP/PS1 mice 
 
        
  B 9 per 
group 
Two-way ANOVA 0.2367   
        
  C 9 per 
group 
Two-way ANOVA 0.9506   
        
  D 9 per 
group 
Two-way ANOVA 0.7370   
        
Figure 3.4 Axonal pathology in 
epothilone D treated 
15-month old 
APP/PS1 mice 
A 6-7 per 
group 
Unpaired t-test, two-
tailed 
0.7853   
        
  B 6-7 per 
group 
Unpaired t-test, two-
tailed 
0.6419   
        
  C 6-7 per 
group 
Unpaired t-test, two-
tailed 
0.5528   
        
Figure 3.5 Axonal pathology in 
epothilone D treated 
15-month old 
APP/PS1 mice 
A 3-4 per 
group 
Non-parametric 
Kruskal-Wallis test, 
Dunn’s multiple 
comparisons test 
0.0204   
        
  B 3-4 per 
group 
Non-parametric 
Kruskal-Wallis test, 
Dunn’s multiple 
comparisons test 
0.2654   
        
  C 3-4 per 
group 
Non-parametric 
Kruskal-Wallis test, 
Dunn’s multiple 
comparisons test 
0.4812   
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Figure 
Number 
Figure Name Panel n Statistics p-value 95% Confidence 
Interval for Mean 
        
Figure 3.6 Synapse pathology 
in epothilone D 
treated 15-month-
old APP/PS1 mice 
B 7-8 per 
group 
Unpaired t-test, two-
tailed 
0.6482   
  C 7-8 per 
group 
Unpaired t-test, two-
tailed 
0.2995   
        
  D 7-8 per 
group 
Unpaired t-test, two-
tailed 
0.7967   
        
  F 7-8 per 
group 
Unpaired t-test, two-
tailed 
0.9438   
        
  G 7-8 per 
group 
Unpaired t-test, two-
tailed 
0.5462   
        
  H 7-8 per 
group 
Unpaired t-test, two-
tailed 
0.7086   
        
Figure 3.7 Western blot 
analysis of synapses 
in epothilone D 
treated 15-month-
old APP/PS1 mice 
A 3-4 per 
group 
Non-parametric 
Kruskal-Wallis test, 
Dunn’s multiple 
comparisons test 
0.0176   
        
  B 3-4 per 
group 
Non-parametric 
Kruskal-Wallis test, 
Dunn’s multiple 
comparisons test 
0.1191   
        
  C 3-4 per 
group 
Non-parametric 
Kruskal-Wallis test, 
Dunn’s multiple 
comparisons test 
0.1322   
        
  D 3-4 per 
group 
Non-parametric 
Kruskal-Wallis test, 
0.6919   
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Figure 
Number 
Figure Name Panel n Statistics p-value 95% Confidence 
Interval for Mean 
Dunn’s multiple 
comparisons test 
        
Figure 3.8 The effect of 
epothilone D on 
amyloid pathology 
in 15-month-old 
APP/PS1 mice 
C 7-8 per 
group 
Unpaired t-test, two-
tailed 
0.7475   
  D 7-8 per 
group 
Unpaired t-test, two-
tailed 
0.5603   
        
  E 7-8 per 
group 
Unpaired t-test, two-
tailed 
0.8623   
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Table 8.2  Statistical analysis for chapter 4 
Figure 
Number 
Figure Name Panel n Statistics p-value Mean 
Difference 
95% Confidence 
Interval for 
Mean 
Figure 4.1 Axon degeneration 
and loss in 
microfluidic 
chambers after kainic 
acid treatment 
 
A 
 
2 coverslips 
from 5 
culture days 
per 
treatment 
 
One-way ANOVA, 
Tukey’s post hoc test 
0.0002 -6.744 
4.331 
7.721 
-10.90 
0.1766 
3.567 
-2.589 
8.486 
11.88 
  
 
 
B 
 
2 coverslips 
from 5 
culture days 
per 
treatment 
 
One-way ANOVA, 
Tukey’s post hoc test 
0.0003 -20.85 
-26.66 
-34.57 
-40.37 
-7.139 
-12.94 
Figure 4.2 Changes to 
microtubule post-
translational 
modifications after 
kainic acid treatment 
A 3 coverslips 
from 4 
culture days 
per 
treatment 
One-way ANOVA, 
Tukey’s post hoc test 
0.0005 41.25 
47.05 
14.66 
20.46 
67.84 
73.64 
         
  B 3 coverslips 
from 4 
culture days 
per 
treatment 
One-way ANOVA 0.6014    
         
  C Pooled from 
2-3 
chambers 
per 
treatment 
from 4 
culture days 
Unpaired t-test, two-
tailed 
0.0422 -19.53 -38.10 -0.9581 
         
  D Pooled from 
2-3 
chambers 
per 
Unpaired t-test, two-
tailed 
0.3913 4.244 -6.997 15.48 
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Figure 
Number 
Figure Name Panel n Statistics p-value Mean 
Difference 
95% Confidence 
Interval for 
Mean 
treatment 
from 4 
culture days 
         
  E Pooled from 
2-3 
chambers 
per 
treatment 
from 4 
culture days 
Unpaired t-test, two-
tailed 
0.0164 -49.95 -87.00 -12.90 
         
Figure 4.3 Effect of trichostatin 
A on microtubule 
acetylation following 
kainic acid treatment 
A 2-3 
coverslips 
from 5 
culture days 
per 
treatment 
Non-parametric 
Kruskal-Wallis test, 
Dunn’s multiple 
comparisons test 
0.0001 -30.00 
-21.86 
  
         
  B 2-3 
coverslips 
from 5 
culture days 
per 
treatment 
Non-parametric 
Kruskal-Wallis test, 
Dunn’s multiple 
comparisons test 
0.0005 18.72 
25.06 
  
         
  C 3 coverslips 
from 5 
culture days 
per 
treatment 
Non-parametric 
Kruskal-Wallis test, 
Dunn’s multiple 
comparisons test 
0.2401    
         
Figure 4.4 Effect of trichostatin 
A on microtubule 
acetylation following 
kainic acid treatment 
A 3 coverslips 
from 5 
culture days 
per 
treatment 
Two-way ANOVA, 
Tukey’s post hoc test 
0.0001 26.22 
-19.17 
-45.39 
-29.36 
16.04 
16.22 
-29.17 
-55.40 
-39.36 
6.030 
36.23 
-9.163 
-35.39 
-19.35 
26.04 
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Figure 
Number 
Figure Name Panel n Statistics p-value Mean 
Difference 
95% Confidence 
Interval for 
Mean 
         
  B Pooled from 
2-3 
chambers 
per 
treatment 
from 5 
culture days 
Two-way ANOVA, 
Tukey’s post hoc test 
0.0001 24.67 
-17.88 
-42.55 
-22.42 
20.13 
13.76 
-28.78 
-53.45 
-33.33 
9.222 
35.57 
-6.976 
-31.64 
-11.52 
31.03 
         
  C Pooled from 
2-3 
chambers 
per 
treatment 
from 5 
culture days 
Two-way ANOVA, 
Tukey’s post hoc test 
0.0001 39.43 
-45.49 
-84.92 
-32.34 
52.58 
23.71 
-61.21 
-100.6 
-48.06 
36.86 
55.15 
-29.77 
-69.20 
-16.62 
68.30 
         
Figure 4.5 Effect of trichostatin 
A on microtubule 
tyrosination 
following kainic acid 
treatment 
A 3 coverslips 
from 5 
culture days 
per 
treatment 
Two-way ANOVA 0.3252    
         
  B Pooled from 
2-3 
coverslips 
per 
treatment 
from 5 
culture days 
Two-way ANOVA 0.8608    
         
Figure 4.6 Axon degeneration 
and axon loss after 
kainic acid treatment 
in the presence of 
trichostatin A 
A 1-2 
coverslips 
from 4 
culture days 
per 
treatment 
Two-way ANOVA, 
Tukey’s post hoc test 
0.0002 -6.744 
4.331 
7.865 
-10.97 
0.1066 
3.640 
-2.519 
8.556 
12.09 
Chapter 8 - Appendices 
  270  
 
Figure 
Number 
Figure Name Panel n Statistics p-value Mean 
Difference 
95% Confidence 
Interval for 
Mean 
         
  B 1-2 
coverslips 
from 4 
culture days 
per 
treatment 
Two-way ANOVA, 
Tukey’s post hoc test 
<0.000
1 
-17.30 
12.46 
16.68 
-25.41 
4.349 
8.570 
-9.190 
20.57 
24.79 
         
Figure 4.7 The effect of taxol 
on microtubule post-
translational 
modifications 
A 3 coverslips 
from 5 
culture days 
per 
treatment 
Two-way ANOVA <0.000
1 
33.59 
-11.54 
-19.45 
-53.04 
24.20 
-20.94 
-28.85 
-62.44 
42.99 
-2.149 
-10.06 
-43.65 
         
  B 3 coverslips 
from 5 
culture days 
per 
treatment 
Two-way ANOVA, 
Tukey’s post hoc test 
<0.000
1 
17.39 
35.64 
12.02 
30.27 
18.25 
12.01 
30.26 
6.637 
24.88 
12.86 
22.78 
41.02 
17.40 
35.65 
23.63 
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Table 8.3    Statistical analysis of chapter 5 
Figure 
Number 
Figure Name Panel n Statistics p-value Mean 
Differences 
95% Confidence 
Interval for 
Mean 
Figure 5.1 The effect of 
kainic acid on 
microtubule-
associated proteins 
 
A Pooled from 
2-3 
coverslips 
per 
treatment 
from 4 
culture days 
One-way ANOVA, 
Tukey’s post hoc 
test 
0.0002 -79.86 
-102.9 
-144.0 
-157.6 
-15.75 
-48.25 
         
  
 
B 
 
Pooled from 
2-3 
coverslips 
per 
treatment 
from 4 
culture days 
Unpaired t-test, two-
tailed 
0.0043 24.56 11.11 38.02 
         
  C 3 coverslips 
from 4 
culture days 
per 
treatment 
Unpaired t-test, two-
tailed 
0.0036 36.39 17.09 55.70 
         
  D 3 coverslips 
from 4 
culture days 
per 
treatment 
Unpaired t-test, two-
tailed 
0.4826    
         
  E Pooled from 
2-3 
coverslips 
per 
treatment 
from 4 
culture days 
Unpaired t-test, two-
tailed 
0.0005 23.21 14.99 31.43 
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Figure 
Number 
Figure Name Panel n Statistics p-value Mean 
Differences 
95% Confidence 
Interval for 
Mean 
  F Pooled from 
2-3 
coverslips 
per 
treatment 
from 4 
culture days 
Unpaired t-test, two-
tailed 
0.8351    
         
Figure 5.2 Changes to MAP2 
after excitotoxin 
exposure 
A 2 coverslips 
per 
treatment 
from 4 
culture days 
One-way ANOVA, 
Tukey’s post hoc 
test 
0.0001 -3.112 
-2.422 
2.380 
1.690 
-4.442 
-3.752 
1.050 
0.3606 
-1.782 
-1.093 
3.710 
3.020 
         
         
Figure 5.3 Axon degeneration 
and loss after 
sodium selenate 
treatment after 
kainic acid 
treatment 
A 2 coverslips 
per 
treatment 
from 4 
culture days 
One-way ANOVA, 
Tukey’s post hoc 
test 
0.0115 -3.024 
-2.917 
-5.477 
-5.370 
-0.5707 
-0.4644 
         
  B 2 coverslips 
per 
treatment 
from 4 
culture days 
One-way ANOVA, 
Tukey’s post hoc 
test 
0.0004 -23.34 
-22.04 
-34.41 
-33.11 
-12.26 
-10.96 
         
Figure 5.4 Changes to 
microtubule-
associated proteins 
with trichostatin A 
treatment after 
kainic acid 
treatment 
A 3 coverslips 
from 5 
culture days 
per 
treatment 
Two-way ANOVA, 
Tukey’s post hoc 
test 
<0.0001 -22.41 
24.90 
23.62 
-26.65 
20.66 
19.38 
-18.17 
29.14 
27.86 
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Figure 
Number 
Figure Name Panel n Statistics p-value Mean 
Differences 
95% Confidence 
Interval for 
Mean 
  B Pooled from 
2-3 
coverslips 
per 
treatment 
from 5 
culture days 
Two-way ANOVA 0.0003 -23.70 
17.29 
14.67 
-34.78 
6.206 
3.592 
-12.62 
28.36 
25.75 
         
  C 3 coverslips 
from 5 
culture days 
per 
treatment 
Two-way ANOVA, 
Tukey’s post hoc 
test 
0.0009 -18.44 
-25.75 
-23.81 
-33.26 
-40.57 
-38.62 
-3.625 
-10.94 
-8.990 
         
  D 3 coverslips 
from 5 
culture days 
per 
treatment 
Two-way ANOVA 0.9695    
         
Figure 5.5 Changes to 
microtubule-
associated proteins 
with trichostatin A 
treatment after 
kainic acid 
treatment 
A Pooled from 
2-3 
coverslips 
per 
treatment 
from 5 
culture days 
Two-way ANOVA <0.0001 -17.74 
-20.71 
-39.10 
-21.36 
-18.39 
-29.81 
-32.78 
-51.17 
-33.43 
-30.46 
-5.672 
-8.642 
-27.03 
-9.290 
-6.320 
         
  B Pooled from 
2-3 
coverslips 
per 
treatment 
from 5 
culture days 
Two-way ANOVA, 
Tukey’s post hoc 
test 
<0.0001 -19.26 
-23.84 
-23.15 
-30.10 
-34.68 
-33.99 
-8.422 
-13.00 
-12.31 
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Figure 
Number 
Figure Name Panel n Statistics p-value Mean 
Differences 
95% Confidence 
Interval for 
Mean 
  C Pooled from 
2-3 
coverslips 
per 
treatment 
from 5 
culture days 
Two-way ANOVA, 
Tukey’s post hoc 
test 
<0.0001 -22.63 
-19.67 
-24.81 
-21.85 
-31.06 
-28.10 
-33.24 
-5.465 
-14.20 
-11.24 
-16.38 
-13.42 
         
  D Pooled from 
2-3 
coverslips 
per 
treatment 
from 5 
culture days 
Two-way ANOVA, 
Tukey’s post hoc 
test 
<0.0001 -105.7 
-93.88 
104.2 
11.84 
-92.39 
-114.4 
-102.6 
95.52 
3.128 
-101.1 
-97.01 
-85.17 
112.9 
20.55 
-83.68 
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8.3 PDF VERSION OF THE HDAC6 INHIBITOR TRICHOSTATIN A ACETYLATES 
MICROTUBULES AND PROTECTS AXONS FROM EXCITOTOXIN-INDUCED 
DEGENERATION IN A COMPARTMENTED CULTURE MODEL 
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The HDAC6 Inhibitor Trichostatin A
Acetylates Microtubules and
Protects Axons From
Excitotoxin-Induced Degeneration in
a Compartmented Culture Model
Kelsey Hanson*, Nan Tian, James C. Vickers and Anna E. King
Wicking Dementia Research and Education Centre, College of Health, University of Tasmania, Hobart, TAS, Australia
Axon degeneration has been implicated as a pathological process in several
neurodegenerative diseases and acquired forms of neural injury. We have previously
shown that stabilizing microtubules can protect axons against excitotoxin-induced
fragmentation, however, the alterations of microtubules following excitotoxicity that
results in axon degeneration are currently unknown. Hence, this study investigated
whether excitotoxicity affects the post-translational modifications of microtubules and
microtubule-associated proteins, and whether reversing these changes has the potential
to rescue axons from degeneration. To investigate microtubule alterations, primary
mouse cortical neurons at 10 days in vitro were treated with 10 or 25µM kainic
acid to induce excitotoxicity and axon degeneration. Post-translational modifications
of microtubules and associated proteins were examined at 6 h following kainic acid
exposure, relative to axon degeneration. While there were no changes to tyrosinated
tubulin or MAP1B, acetylated tubulin was significantly (p < 0.05) decreased by 40%
at 6 h post-treatment. To determine whether increasing microtubule acetylation prior
to kainic acid exposure could prevent axon fragmentation, we investigated the effect
of reducing microtubule deacetylation with the HDAC6 inhibitor, trichostatin A. We
found that trichostatin A prevented kainic acid-induced microtubule deacetylation and
significantly (p < 0.05) protected axons from fragmentation. These data suggest that
microtubule acetylation is a potential target for axonal protection where excitotoxicity
may play a role in neuronal degeneration.
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INTRODUCTION
Axon degeneration is a pathological process that occurs in several neurodegenerative diseases, and
acquired forms of brain injury, and can occur independently of cell death (Lingor et al., 2012).
The best described mechanisms of axon degeneration are axonal pruning, which occurs during
development and Wallerian degeneration, which occurs following axon severing (Coleman, 2005;
Coleman and Freeman, 2017). In contrast, the cellular process underlying axon degeneration in a
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range of neurodegenerative diseases and following brain injury
are less well understood and are unlikely to be linked to direct
axonal severing, but rather to a gradual series of biochemical
changes following specific disease-associated pathological insults.
One such pathological insult, excitotoxicity, is a result
of excessive stimulation by the excitatory neurotransmitter
glutamate, leading to, for example, increased intracellular
calcium and a cascade of harmful calcium-dependent events
(Dong et al., 2009). Excitotoxicmechanisms have been implicated
in Alzheimer’s disease, traumatic brain injury, stroke, and
amyotrophic lateral sclerosis, which all undergo some form of
axon degeneration (as reviewed by Gibson and Bromberg, 2012;
Lai et al., 2014; Siedler et al., 2014; Lewerenz and Maher, 2015).
Our previous studies in compartmentalized cultured neurons
have shown that excitotoxicity directed to the neuronal soma
results in fragmentation of the unexposed axon (Hosie et al.,
2012). This was significantly attenuated by treatment of the
axons with the microtubule stabilizing drug, taxol, implicating
microtubule disruption in the breakdown of the axon (King et al.,
2013).
Microtubules are highly dynamic polymers of alpha and beta
tubulin. Their ability to undergo rapid changes in polymerization
state (termed dynamic instability) is essential for their function
and is controlled by the binding of associate proteins (MAPs)
as well as by their post-translational modifications (PTMs)
(Horio and Murata, 2014). The microtubule disruption that
occurs following excitotoxin exposure and leads to axon
degeneration could result from depolymerization, potentially
relating to changes to PTM or from altered MAP binding.
However, microtubule PTMs and MAP binding are not
independent, and some MAP binding capacity to microtubules
can be influenced by microtubule PTMs (Howes et al., 2014).
PTMs of microtubules include glutamylation, tyrosination,
and acetylation. Acetylation, glutamylation and detyrosination
are associated with stable microtubules, whereas tyrosination
is associated with unstable and more dynamic areas of
microtubules (Uchida and Shumyatsky, 2015). Thus, microtubule
PTMs may be a potential target for therapeutic intervention.
In this regard, drugs targeting acetylation such as HDAC6
(histone deacetylase 6) inhibitors have been investigated for the
treatment of depression, cancer, stroke, environmental stress and
Huntington’s disease (Dompierre et al., 2007; Lazo-Gómez et al.,
2013; Simoes-Pires et al., 2013; Jochems et al., 2014; Brindisi et al.,
2016, 2018; Ceccacci and Minucci, 2016; Wang et al., 2016; Rao
et al., 2017).
In this study we have investigated the temporal changes to
microtubule PTMs and MAPs following an excitotoxic insult
with a view to modifying microtubule stability to prevent axon
degeneration. Furthermore, we also investigated the eﬀect of the
HDAC6 inhibitor, trichostatin A, on axon degeneration.
MATERIALS AND METHODS
Ethics and Mice
All experiments and procedures were approved by the University
of Tasmania Animal Ethics Committee (A12780 and A15121)
and were in accordance with the Australian Guidelines for the
Care and Use of Animals for Scientific Purposes. C57Bl/6 mice
were housed in optiMICE cages on a 12-h light/dark cycle with
free access to food and water.
Primary Cortical Cell Culture
Mouse cortical neuron cultures were prepared as previously
described (King et al., 2013). Cortical neurons were prepared
from embryonic day 15.5 (E15.5) C57Bl/6 mice. Females
were sacrificed using CO2 and embryos were removed and
decapitated. Heads were kept on ice during dissection to prevent
tissue degradation. Cortices were removed using a dissecting
microscope (Leica), dissociated from the meningeal layers and
transferred to 5ml Hanks Balanced Salt Solution (HBSS, Gibco).
Trypsin (0.0125%) was added for 4min at 37◦C, followed by
removal of HBSS and replaced with 1ml of initial plating media
[Neurobasal media (Gibco) containing 2% B27 supplement,
0.5mM glutamine, 25µM glutamate, 10% fetal calf serum and
1% antibiotic/antimiotic] and mechanically triturated with a
1ml pipette. Cell density was assessed using a trypan blue
exclusion assay and 200,000 cells were plated either into the soma
compartment of microfluidic chambers (450µm long, 10µm
wide, and 3µm high barrier grooves, Xona Microfluidics), which
allows fluidic isolation of cells from the axon (Taylor et al., 2006),
or directly into the wells of poly-L-lysine coated culture plates.
Cells were allowed to adhere to the coverslip (Livingstone) at
37◦C for 30min prior to adding initial plating media to the
chambers and were incubated at 37◦C overnight before initial
media was replacement with subsequent plating media with no
fetal calf serum and glutamate. Cells were grown to 10 days in
vitro (DIV) at 37◦C in 5% CO2.
Pharmacological Manipulation
Cells were treated with 0, 10, or 25µM of kainic acid (Sigma,
lot #SLBD1491V) in DMSO (Sigma, Lot # RNBF1056) at 10
DIV, a timepoint which corresponds to dense axonal growth in
the axon compartment of microfluidic chambers (Hosie et al.,
2012; Millet and Gillette, 2012). Cells in 12-well plates or the
soma compartment of microfluidic chambers were exposed to
kainic acid for 1, 6, and 18 h. For a set of experiments cells
were treated with trichostatin A, an inhibitor of the deacetylating
enzyme HDAC6, which promotes microtubule acetylation.
Cells at 10 DIV in 12-well plates or axonal compartment
of microfluidic chambers were treated with 10 or 100 nM
trichostatin A (Sigma, Lot # 026M4036V) for 2 h before 6 h
of kainic acid exposure prior to ELISA analysis for acetylated
tubulin. The health of cells following TSA treatment was
not significantly diﬀerent from vehicle control, as determined
using an alamarBlue assay (Supplementary Figure 1). For all
pharmacological manipulations vehicle controls were performed
and are reported. No significant diﬀerence was found in any
measure for vehicles to untreated cells.
Live Cell Imaging and Quantitation of
Axonal Degeneration
Microfluidic cultures were imaged on a Nikon TiE live cell
microscope, with chambers maintained at 37◦C. Imaging was
performed prior to treatment and 18 h following treatment.
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Axonal side of the microfluidic chambers were imaged using 40×
objective lens to measure axon fragmentation and degeneration.
A quantitative measure of axonal degeneration was obtained
from five random regions of interest (200 × 200µm) in the
axonal chamber, at least 40µm away from the microgrooves.
Identical regions were imaged before and after treatment. Axon
degeneration was calculated by counting degenerated axons.
A degeneration index (DI) was determined by the following
equation.
DI =
⎛
⎝
(
axons degenerated before
axons degenerated after
)
total number of axons
⎞
⎠× 100 (1)
The percentage fragmentation refers to the percentage of axons
the have fragmented after treatment, compared to the total
number of axons before treatment. In our experiments we also
analyzed 35, 50, and 100µM of kainic acid in the cell culture
using live imaging, however the axons were too degenerated to
be able to target therapeutically.
ELISA Analysis of Microtubule
Post-translational Modifications
Plating media was removed from cells plated in 12-well trays,
and cultures were rinsed with HBSS. Cells were harvested with
RIPA buﬀer with protease (CompleteTM Mini Protease Inhibitor
Cocktail tablets, Roche) and phosphatase inhibitors (Phosphatase
Inhibitor Cocktail, A.G. Scientific). Samples were centrifuged at
13,000 rpm for 1min and pellets were discarded. Samples were
diluted at 1:300 in 50 µl bicarbonate/carbonate coating buﬀer
(AbCam), added to 96-well plate and incubated overnight at 4◦C.
For the standard curve, protein samples were serially diluted at
1:100, 1:200, 1:400, and 1:800. A blank and no primary control
were included to correct for ELISA results. Plate was washed
with washing buﬀer (0.01M PBS with 0.05% tween-20) prior to
blocking with blocking buﬀer (0.01M PBS with 5% fetal bovine
serum) and incubated at 37◦C for 30min. Plates were washed
prior to incubation with detecting antibodies (acetylated tubulin
1:500 mouse, Sigma; tyrosinated tubulin 1:500 rabbit, Millipore;
tau 1:1,000 rabbit, DAKO; CRMP2 1:1,000 rabbit, Sigma; MAP1B
1:500 mouse, AbCam) diluted in blocking buﬀer for 1 h at room
temperature. Plates were washed and incubated with species-
specific HRP secondary antibody (DAKO) diluted in blocking
buﬀer at 1:2,000 and incubated at room temperature for 45min.
Plates were washed and incubated with room temperature
tetramethylbenzidine (TMB) substrate (Thermo Scientific, Lot #
SA2328991) for 15min. The reaction was stopped 0.1M H2SO4.
Plate was read using plate reader at 450 nm.
Western Blot Analysis of Microtubule
Post-translational Modifications
Plating media was removed from microfluidic chambers and
culture was rinsed with HBSS. Axons were harvested with
RIPA buﬀer with protease (CompleteTM Mini Protease Inhibitor
Cocktail tablets, Roche) and phosphatase inhibitors (Phosphatase
Inhibitor Cocktail, A.G. Scientific), with protein pooled from
2 to 4 chambers per treatment group. Denatured protein
samples (20 µg) were electrophoresed into Bolt R⃝ 4–12%
Bis-Tris gels (Invitrogen), transferred to PVDF membrane
(Bio-Rad) and incubated overnight with primary antibodies
acetylated tubulin (1:1,000 mouse, Sigma), tyrosinated tubulin
(1:1,000 rabbit,Millipore),MAP1B (1:1,000mouse, AbCam). The
corresponding anti-rabbit or anti-mouse horseradish peroxidase
conjugated secondary antibody (1:7,000, DAKO) was used as
previously described (King et al., 2018). GAPDH (1:5,000
mouse, Millipore) was used as a loading control. Bands were
visualized with enhanced chemiluminescence (ECL) solution-
Luminata ForteWestern horseradish peroxidase (HRP) substrate
(Millipore) and images acquired with a Chemi-Smart 5000
Imaging System (Vilber Lourmat) equipped with Chemi-Capt
5000 software. Band intensity was measured as the integrated
intensity using Fiji software. After standardizing to GAPDH,
each value was calculated as a percentage of control samples (See
Supplementary Figure 1).
Statistical Analysis
Values were reported as means ± standard error of the mean
(SEM), with diﬀerences considered significant at p < 0.05.
Diﬀerences for ELISA and axon degeneration counts were
evaluated using one-way ANOVA, with Tukey’s post-hoc test
for multiple comparisons between groups. For kainic acid live
imaging experiments two coverslips on five separate culture days
were analyzed. For trichostatin A live imaging experiments, 1–
2 coverslips from four separate culture days were analyzed. For
whole cell kainic acid ELISAs, three coverslips per treatment from
four separate culture days were used. For whole cell trichostatin A
ELISAs, three coverslips per treatment from five separate culture
days were used. For axon-only kainic acid ELISAs, cells were
pooled from 2 to 3 chambers per treatment from four separate
culture days. For axon-only trichostatin A ELISAs, cells were
pooled from 2 to 3 chambers per treatment from five separate
culture days. All statistical analysis and graphs were prepared in
GraphPad Prism (v6.1).
RESULTS
Model of Excitotoxin-Induced Axon
Degeneration
Microfluidic chambers allow compartmentalized separation of
axons from the somatodendritic compartment, which permits
treatment to be applied exclusive to either compartment of
the chamber. To establish an acute model of excitotoxin-
induced axon degeneration, mouse cortical neurons at 10
DIV were exposed to 10 and 25µM kainic acid in the
somatodendritic compartment for 18 h. Live imaging of axons
was performed immediately prior to and post-treatment to
determine a degeneration index. Axon loss was significantly
increased (p < 0.05) at 25µM kainic acid compared to control
(Figure 1A). Axonal degeneration at both 10 and 25µM kainic
acid was significantly increased (p < 0.05) compared to control
(Figure 1B).
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FIGURE 1 | Axon degeneration and loss in microfluidic chambers after kainic acid treatment. Live imaging of the axonal compartment of microfluidic chambers were
analyzed for (A) axon loss and (B) axon degeneration index after treatment with 10 or 25µM kainic acid. Axon loss was significantly increased (p < 0.05) following
25µM kainic acid treatment relative to control, whereas, 10µM kainic acid did not cause significant axon loss compared to control. The axon degeneration index was
significantly increased (p < 0.05) following either 10 or 25µM doses of kainic acid compared to control. Bar graph represents mean ± SEM *p < 0.05 relative to
control.
Microtubule Alterations After
Excitotoxin-Induced Axon Degeneration
We next determined whether there were changes in microtubule
PTMs and the microtubule-associated protein, tau, following
25µM kainic acid exposure at 1 and 6 h, and whether these
changes were related to downstream degeneration (Figure 2).
Neuronal cells grown on 12-well trays and cells grown in the
somatodendritic compartment of microfluidic chambers were
exposed to 25µM kainic acid for 6 h. ELISA analysis of neurons
demonstrated that, at 1 h after 25µM kainic acid treatment,
acetylated and tyrosinated tubulin levels were unchanged,
however the microtubule associated protein tau was significantly
(p < 0.05) increased, compared to control (Figures 2A–C).
At 6 h after 25µM kainic acid treatment in both neurons
and axons, acetylated tubulin levels were significantly (p <
0.05) decreased (Figure 2D). Tyrosinated tubulin levels were
unchanged (Figure 2E), whereas, tau levels were also significantly
(p < 0.05) increased (Figure 2F). Western blot analysis of
acetylated tubulin levels in axons confirmed these were also
significantly (p< 0.05) decreased (Figure 2G).
Since 25µM kainic acid treatment aﬀected levels of the
microtubule associated protein tau, we examined whether
other microtubule associated proteins were altered at 6 h post
treatment. Neuronal cells grown on 12-well trays and cells grown
in somatodendritic compartment of microfluidic chambers were
exposed to 25µM kainic acid for 6 h. CRMP2 and MAP1B
levels in neurons and axons were examined using ELISA. Like
tau, CRMP2 was significantly (p < 0.05) increased following
excitotoxicity (Figures 3A,C) and MAP1B was unchanged in
both neurons and axons (Figures 3B,D).
Trichostatin A and Microtubule Alterations
Since our data showed significantly reduced acetylated tubulin
levels in the axon after 25µM kainic acid treatment (Figure 2),
we hypothesized that promoting microtubule acetylation could
rescue these changes and prevent axon degeneration. To promote
microtubule acetylation, trichostatin A was used to inhibit the
de-acetylating enzyme HDAC6.
We first determined the concentrations of trichostatin A
required to promote acetylation in our primary mouse cortical
cultures. ELISA analysis demonstrated that acetylated tubulin
levels after 10 and 100 nM trichostatin A were significantly (p
< 0.05) increased compared to control at 2 h post-treatment
(Figure 4A).
We next determined whether HDAC6 inhibition with
trichostatin A could rescue acetylated tubulin following
excitotoxin exposure. Neuronal cells grown on 12-well trays and
the axonal compartment of microfluidic chambers were pre-
treated with low (10 nM) trichostatin A for 2 h prior to exposure
to 25µM kainic acid. ELISA analysis demonstrated that 10 nM
trichostatin A restored acetylated tubulin levels after kainic acid
exposure, as compared to control, in both neurons and axons
(Figures 4B,C). Western blot analysis also demonstrated that
10 nM trichostatin A restored acetylated tubulin levels after
excitotoxicity in axons (Figure 4D).
Since our results had shown that tau and CRMP2 levels were
increased by kainic acid, we examined the eﬀect of trichostatin
A on these MAPs. ELISA analysis of neurons demonstrated that
10 nM trichostatin A treatment restored tau to control levels in
the presence of kainic acid (Figure 5B). However, CRMP2 levels
remained significantly (p < 0.05) higher following kainic acid
in the presence of 10 nM trichostatin A (Figure 5D). As we had
previously shown, tyrosinated tubulin and MAP1B levels were
unaﬀected by kainic acid and these were also unchanged at 10 nM
trichostatin A treatment (Figures 5A,C). ELISA analysis of axons
also demonstrated that tau levels were restored after 10 nM
trichostatin A, and tyrosinated tubulin levels were unchanged
(Figures 5E,F).
Trichostatin A and Axon Degeneration
We next determined if the rescue of acetylation by trichostatin
A treatment following excitotoxin exposure was also protective
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FIGURE 2 | Changes to microtubules after kainic acid treatment. Changes to microtubule post-translational modifications and the microtubule-associated protein tau
were investigated in both whole cultured neurons and isolated axons after treatment with 25µM kainic acid. ELISA analysis of neurons at 1 and 6 h after 25µM kainic
acid treatment showed (A) a significant decrease (p < 0.05) in acetylated tubulin levels after 6 h and (B) a significant decrease (p < 0.05) in tau levels at both 1 and
6 h, relative to control. (C) Tyrosinated tubulin levels were unchanged compared to control. ELISA analysis of axons at 6 h post treatment with 25µM kainic acid
demonstrated (D) significantly decreased (p < 0.05) levels of acetylated tubulin, whereas (E) tau axonal levels were significantly increased (p < 0.05) at this timepoint
relative to control. Axonal levels of (F) tyrosinated tubulin were unchanged compared to control. To confirm the effect of 25µM kainic acid on acetylated tubulin in
axons Western blot analysis was performed (G) demonstrating a significant decrease (p < 0.05). Bar graph represents mean ± SEM *p < 0.05 relative to control.
against axonal degeneration (Figure 6). Neurons were grown in
microfluidic chambers and axons exposed to low (10 nM) and
high (100 nM) trichostatin A for 2 h prior to somatodendritic
treatment with 25µM kainic acid. Axon degeneration was
quantitated from images acquired before and 18 h after kainic
acid treatment. In the presence of 10 and 100 nM trichostatin A,
Frontiers in Neuroscience | www.frontiersin.org 5 November 2018 | Volume 12 | Article 872
Hanson et al. Trichostatin A Protects Axons From Degeneration
FIGURE 3 | Changes to microtubules associated proteins after kainic acid treatment. Microtubule-associated proteins, CRMP2 and MAP1B levels were analyzed in
neurons and axons after 25µM kainic acid treatment for 6 h. ELISA analysis demonstrated that CRMP2 levels in (A) neurons and (C) axons were significantly
increased (p < 0.05) relative to control. ELISA analysis of MAP1B levels in (B) neurons and (D) axons were unchanged compared to control after 25µM kainic acid
treatment. Bar graph represents mean ± SEM *p < 0.05 relative to control.
axon degeneration (Figure 6B) and axon loss (Figure 6A) were
significantly reduced (p < 0.05) after exposure to 25µM kainic
acid.
DISCUSSION
Understanding the mechanisms underlying the relationship
between microtubule alterations and axon degeneration can
potentially lead to a better understanding of neurodegenerative
changes linked to excitotoxicity. The current study
investigated whether excitotoxin-induced axon degeneration
caused alterations in the post-translational modifications
of microtubules and the expression of microtubule-
associated protein, tau, and whether inhibition of these
biochemical changes to these cytoskeletal proteins can protect
axons.
The main finding of this study was that, following excitotoxin
exposure, there were changes to both microtubule PTMs and to
the levels of MAPs expressed by neurons and that these changes
occurred within 6 h of treatment. The key change to PTMs was
the acetylation of tubulin which occurred by 6 h and was present
in both whole neuron analysis as well as within the axons. The
major enzyme involved in tubulin acetylation state in mammals
is alpha-tubulin acetyltransferase 1 (αTAT1; Coombes et al.,
2016). It is currently unclear whether loss of tubulin acetylation
in the current project results from increased deacetylation or
from decreased acetylation. Furthermore, downstream processes
following kainic acid exposure that result in loss of acetylation
are currently not known but will be the subject of future
investigations.
In the current study, treatment with trichostatin A prevented
decreases in acetylated tubulin levels after kainic acid exposure,
consequently reducing axonal fragmentation and axon loss,
suggesting that tubulin deacetylation is a key event in excitotoxin
induced axon degeneration. Trichostatin A is a HDAC6 inhibitor,
which has been investigated in motor neuron degeneration
(Yoo et al., 2011; Lazo-Gómez et al., 2013) and used to
treat retinal degenerative diseases (reviewed in Zhang et al.,
2015). The importance of acetylation in microtubule stability
has been widely reported (Howes et al., 2014; Portran et al.,
2017). It is known that acetylated tubulin protects microtubules
against mechanical aging and is also a marker of long-lived
microtubules (Portran et al., 2017). Increasing microtubule
acetylation using trichostatin A, has been shown to restore
axonal transport in rat cortical neurons, following exposure
to mutant leucine-rich repeat kinase (LRRK2) (Godena et al.,
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FIGURE 4 | Effect of trichostatin A on microtubule acetylation following kainic
acid treatment. Acetylated tubulin levels in whole cultured neurons were
(Continued)
FIGURE 4 | analyzed after 10 and 100 nM of trichostatin A treatment for 2 h.
(A) ELISA analysis of acetylated tubulin levels after 10 or 100 nM trichostatin A
demonstrated a significant increase (p < 0.05) compared to control. ELISA
analysis demonstrated that in (B) whole cultured neurons and (C) isolated
axons, 10 nM trichostatin A inhibited the effect of 25µM kainic acid on
acetylated tubulin levels, and the levels of acetylated tubulin levels in kainic
acid treated neurons which had been treated with trichostatin A were not
significantly different from control, despite the significant decrease (p < 0.05) in
acetylated tubulin in cells treated with kainic acid alone. (D) To confirm the
ELISA analysis of acetylated tubulin levels a Western blot was performed of
harvested isolated axons from neurons treated with 25µM kainic acid in the
presence of absence of axonal trichostatin A (10 nM). This confirmed that
trichostatin A rescued the decrease in acetylation resulting from kainic acid
treatment. Bar graph represents mean ± SEM *p < 0.05 relative to control.
TSA, trichostatin A; KA, kainic acid.
2014). The same study showed that in vivo, trichostatin A
treatment or knockdown of HDAC6 and Sir-related protein
(SIRT) 2 (Sirt2), rescued axonal transport in a Drosophila
model of mutant LRRK2. In cultured mouse cerebellar granule
cells, levels of acetylation were compared between Wallerian
degeneration slow (WldS) mice, which have a mutation
that slows Wallerian degeneration (Lunn et al., 1989) and
wildtype mice (Suzuki and Koike, 2007). The authors found
that base levels of acetylation were increased in WldS cells
compared to wildtype. Furthermore, the authors showed that
the deacetylating enzyme SIRT2 plays a key role in resistance of
WldS cells to axon degeneration, whereby they found decreased
SIRT2 in WldS granule cell cytoplasm. Additionally, SIRT2
knockdown enhanced microtubule acetylation and reduced axon
degeneration in wildtype granule cells. These findings also
highlight the importance of microtubule acetylation in axon
degeneration.
Our study also showed that tyrosinated tubulin is unchanged
following kainic acid exposure. In contrast to acetylation,
which is associated with long-lived microtubules, tyrosination
is present in highly dynamic microtubules at the proximal end
of the axon (Witte et al., 2008), and has been reported as a
destabilizing microtubule PTM (Kreis, 1987; Khawaja et al.,
1988). This suggests that destabilizing microtubules through
tyrosination is not the key factor in driving excitotoxin-
induced axon degeneration. However, in axon regeneration
studies, absence of tubulin tyrosine ligase, which promoted
tubulin tyrosination, has been shown to severely reduce
axon regeneration (Song et al., 2015), suggesting that tubulin
tyrosination may be more important for regeneration rather
than degeneration. However, PTMs have also been described
following developmental axon pruning, which can be modeled
in vitro by trophic factor withdrawal (reviewed in Saxena and
Caroni, 2007). Developmental axon pruning has been shown to
involve decreases in both acetylation and tyrosination, with an
accompanying increase in detyrosinated tubulin (Unsain et al.,
2018).
The microtubule-associated protein, tau, has been implicated
in neurodegenerative disease, particularly Alzheimer’s disease
(AD) and was therefore of interest in this study. In AD, tau
has been reported to dissociate from microtubules; thereby
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FIGURE 5 | Effect of trichostatin A on tyrosinated tubulin and microtubule-associated proteins following kainic acid treatment. ELISA analysis demonstrated that (A)
trichostatin A had no effect on neuronal tyrosinated tubulin levels following kainic acid treatment relative to control. (B) Trichostatin A rescued kainic acid-induced
increases in tau, with no significant difference in tau levels for kainic acid treated cells in the presence of trichostatin A. (C) MAP1B levels were unchanged compared
to control with any of the treatments. (D) CRMP2 levels were significantly increased (p < 0.05) relative to control by either treatment with kainic acid or trichostatin A or
by kainic acid in the presence of trichostatin A. Tyrosinated tubulin and tau levels were also analyzed in isolated axons after treatment of the neurons with 25µM kainic
acid in the presence or absence of axonal 10 nM trichostatin A. (E) Tyrosinated tubulin levels were not significantly different between treatment groups. (F) As
expected, tau levels were significantly increased (p < 0.05) after 25µM kainic acid treatment, compared to control and this effect was prevented by trichostatin A
treatment. Bar graph represents mean ± SEM *p < 0.05 relative to control. TSA; trichostatin A, KA; kainic acid.
Frontiers in Neuroscience | www.frontiersin.org 8 November 2018 | Volume 12 | Article 872
Hanson et al. Trichostatin A Protects Axons From Degeneration
FIGURE 6 | Axon degeneration and axon loss after kainic acid treatment in the presence of trichostatin A. Live images of the axonal compartments of microfluidic
chambers were analyzed for (A) axon loss and (B) axon degeneration after treatment of the neurons with 25µM kainic acid in the presence or absence of 10 or
100 nM axonal trichostatin A. Both axon loss and axon degeneration were significantly increased (p < 0.05) with 25µM kainic acid treatment, however, this effect was
rescued by treatment with either concentration of trichostatin A. In the presence of trichostatin A, axonal loss and degeneration were not significantly different from
controls. (C) Figure to show how trichostatin A and kainic acid treatment is administered to microfluidic chamber compartments. Representative images for (D)
control, (E) 25µM kainic acid, (F) 10 nM trichostatin A + 25µM kainic acid and (G) 100 nM trichostatin A + 25µM kainic acid. Bar graph represents mean ± SEM *p
< 0.05 relative to control. Scale bar = 50µm. TSA, trichostatin A; KA, kainic acid.
reducing microtubule stability (Sontag et al., 1996; Kadavath
et al., 2015). The dissociated tau then aggregates to form tau
neurofibrillary tangles; a major hallmark of Alzheimer’s disease.
However, the exact function of tau in binding to microtubules
is not clear. In this study, we showed that tau expression levels
were increased following excitotoxicity. Tau was shown to be
increased as early as 1 h after kainic acid treatment, suggesting
it could be a compensatory mechanism, potentially to increase
microtubule stability. The changes in tau prompted us to examine
expression levels of other MAPs and we demonstrated that like
tau, CRMP2 was increased following excitotoxin exposure. The
dysregulation and hyperphosphorylation of CRMP2 has been
observed in Alzheimer’s disease (Williamson et al., 2011; Hensley
and Kursula, 2016). Examining phosphorylation of these MAPs
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as well as how these proteins are altered by excitotoxic treatment,
will be of interest in future studies.
Alterations to microtubules have also been demonstrated in
other forms of axonal injury. For example, dynamic stretch
injury of neuronal cultured cells induced axon degeneration,
which was inhibited by taxol (Tang-Schomer et al., 2010).
This strengthens earlier research in this area, suggesting that
cytoskeletal changes begin as early as 5min post fluid percussive
injury (Pettus and Povlishock, 1996), indicating that changes to
microtubules could be one of the earliest events to occur after
initiating axonal injury and degeneration. Another study which
investigated alpha tubulin levels after optic nerve stretch injury
found decreased alpha tubulin levels between 0.5 and 4 h post-
injury, and a secondary decline after 72 h post-injury (Serbest
et al., 2007). This also suggests that microtubules may have an
initial role after injury and another role in a secondary event
post-injury.
CONCLUSION
Together these data indicate that alterations to microtubule
may be an early and modifiable event in several forms
of axon degeneration. The earliest change detected, after
1 h of kainic acid treatment, was a significant increase in
tau, which was followed by 6 h by a significant decrease in
acetylated tubulin and significant increase in CRMP2. These
MAPs and PTM are associated with dynamic instability
of the microtubules, however tyrosinated tubulin, and
MAP1B levels, which are also linked to microtubule
stability were unaﬀected. Together these results suggest
that microtubule alterations were specific to the insult.
Promotion of microtubule acetylation with trichostatin A
treatment, in some cases restored altered levels of PTMs and
MAPs to control levels. The current study demonstrates
that altering microtubule acetylation can help prevent
axon degeneration through excitotoxin exposure. Further
deciphering microtubule post-translational modifications and
their interaction with degenerating pathways will be important
in providing therapeutic treatment in several neurodegenerative
diseases.
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